var title_f11_38_11872="Rigby vaginal retractor";
var content_f11_38_11872=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F67616&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F67616&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Rigby vaginal retractor",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 160px; height: 449px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_38_11872=[""].join("\n");
var outline_f11_38_11872=null;
var title_f11_38_11873="Meningococcal polysaccharide vaccine: Patient drug information";
var content_f11_38_11873=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Meningococcal polysaccharide vaccine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38965?source=see_link\">",
"     see \"Meningococcal polysaccharide vaccine: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/24/16773?source=see_link\">",
"     see \"Meningococcal polysaccharide vaccine: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F192529\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Menomune&reg;-A/C/Y/W-135",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F12592967\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Menomune&reg;-A/C/Y/W-135",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt adi-os drugH1Div\" id=\"F10030556\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     CDC Information",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705779",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Vaccine Information Statements (VIS) are made by the staff of the Centers for Disease Control and Prevention (CDC). Each VIS gives information to properly inform the adult receiving the vaccine or, in the case of a minor, the child's parent or legal representative about the risks and benefits of each vaccine. Before a doctor vaccinates a child or an adult, the provider is required by the National Childhood Vaccine Injury Act to give a copy of the VIS. You can also get foreign language versions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705997",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <a href=\"file://www.immunize.org/vis/vis_meningococcal.asp\" target=\"_blank\">",
"        Vaccine Information Statements (VIS)",
"       </a>",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11807 Version 27.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-14.112.150.12-37D25D05A2-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_38_11873=[""].join("\n");
var outline_f11_38_11873=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192529\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12592967\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030556\">",
"      CDC Information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38965?source=related_link\">",
"      Meningococcal polysaccharide vaccine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/24/16773?source=related_link\">",
"      Meningococcal polysaccharide vaccine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_38_11874="Calculator: MELDNa score for end-stage liver disease (not appropriate for patients under the age of 12) (SI units)";
var content_f11_38_11874=[" <div id=\"topicText\">",
"  <div id=\"mc3k\">",
"   <form action=\"\" id=\"MELDNa_SI_form\" name=\"MELDNa_SI_form\" onkeydown=\"clrResults();\" onkeyup=\"MELDNa_SI_fx();\" onsubmit=\"return false;\">",
"    <table cellpadding=\"4\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"100%\">",
"     <tr>",
"      <td bgcolor=\"#eeeeee\" width=\"1%\">",
"       <br/>",
"      </td>",
"      <td align=\"left\" bgcolor=\"#eeeeee\">",
"       <span class=\"medCalcFontTitleBox\">",
"        Calculator: MELDNa score for end-stage liver disease (not appropriate for patients under the age of 12) (SI units)",
"       </span>",
"      </td>",
"     </tr>",
"    </table>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <center>",
"     <div id=\"calc_equation\">",
"      <table cellpadding=\"10\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\">",
"       <tr>",
"        <td align=\"left\" bgcolor=\"#6c9a9c\">",
"         <span class=\"medCalcFontFormuli\">",
"          MELDScore = 10 * ((0.957 * ln(Creatinine/88.4)) + (0.378 * ln(Bilirubin/17.1)) + (1.12 * ln(INR))) + 6.43",
"         </span>",
"        </td>",
"       </tr>",
"       <tr>",
"        <td align=\"left\" bgcolor=\"#6c9a9c\">",
"         <span class=\"medCalcFontFormuli\">",
"          MELDNaScore = MELDScore - SerumNa - (0.025 * MELDScore * (140 - SerumNa)) + 140",
"         </span>",
"        </td>",
"       </tr>",
"      </table>",
"      <br/>",
"      &nbsp;",
"      <br/>",
"     </div>",
"    </center>",
"    <div id=\"calc_main\">",
"     <center>",
"      <table cellpadding=\"6\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"95%\">",
"       <tr>",
"        <td align=\"right\" width=\"50%\">",
"         <center>",
"          <span class=\"medCalcFontIO\">",
"           Input:",
"          </span>",
"          <br/>",
"          &nbsp;",
"          <br/>",
"          <table cellpadding=\"3\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\">",
"           <tr>",
"            <td align=\"right\" width=\"42%\">",
"             <span class=\"medCalcFontOneBold\">",
"              Creatinine",
"             </span>",
"            </td>",
"            <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"             &nbsp;",
"             <input name=\"Creatinine_param\" onblur=\"MELDNa_SI_fx(); minMaxCheck();\" onchange=\"MELDNa_SI_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"            </td>",
"            <td align=\"left\" valign=\"top\" width=\"115\">",
"             <select class=\"medCalcFontSelect\" name=\"Creatinine_unit\" onchange=\"MELDNa_SI_fx();\" style=\"width:105px;\">",
"              <option selected=\"selected\" value=\"1|0|mcmol/L\">",
"               mcmol/L",
"              </option>",
"              <option value=\"1000|0|mmol/L\">",
"               mmol/L",
"              </option>",
"             </select>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"right\" width=\"42%\">",
"             <span class=\"medCalcFontOneBold\">",
"              Bilirubin",
"             </span>",
"            </td>",
"            <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"             &nbsp;",
"             <input name=\"Bilirubin_param\" onblur=\"MELDNa_SI_fx(); minMaxCheck();\" onchange=\"MELDNa_SI_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"            </td>",
"            <td align=\"left\" valign=\"top\" width=\"115\">",
"             <select class=\"medCalcFontSelect\" name=\"Bilirubin_unit\" onchange=\"MELDNa_SI_fx();\" style=\"width:105px;\">",
"              <option selected=\"selected\" value=\"1|0|mcmol/L\">",
"               mcmol/L",
"              </option>",
"              <option value=\"1000|0|mmol/L\">",
"               mmol/L",
"              </option>",
"             </select>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"right\" width=\"42%\">",
"             <span class=\"medCalcFontOneBold\">",
"              INR",
"             </span>",
"            </td>",
"            <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"             &nbsp;",
"             <input name=\"INR_param\" onblur=\"MELDNa_SI_fx(); minMaxCheck();\" onchange=\"MELDNa_SI_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"            </td>",
"            <td align=\"left\">",
"             &nbsp;",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"right\" width=\"42%\">",
"             <span class=\"medCalcFontOneBold\">",
"              Serum Na",
"             </span>",
"            </td>",
"            <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"             &nbsp;",
"             <input name=\"Serum_Na_param\" onblur=\"MELDNa_SI_fx(); minMaxCheck();\" onchange=\"MELDNa_SI_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"            </td>",
"            <td align=\"left\" valign=\"top\" width=\"115\">",
"             <select class=\"medCalcFontSelect\" name=\"Serum_Na_unit\" onchange=\"MELDNa_SI_fx();\" style=\"width:105px;\">",
"              <option value=\"0.001|0|mcmol/L\">",
"               mcmol/L",
"              </option>",
"              <option selected=\"selected\" value=\"1|0|mmol/L\">",
"               mmol/L",
"              </option>",
"             </select>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"right\">",
"             <span class=\"medCalcFontOneBold\">",
"              Hemodialysis twice in week prior",
"             </span>",
"            </td>",
"            <td align=\"left\" colspan=\"3\">",
"             <span class=\"medCalcFontOne\">",
"              <input name=\"Hemodialysis_twice_in_week_prior_radio\" onclick=\"Creatinine_param.value = '353.6'; Creatinine = 353.6; MELDNa_SI_fx();\" type=\"radio\" value=\"Yes\"/>",
"              Yes",
"             </span>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"left\">",
"             <br/>",
"            </td>",
"            <td align=\"left\" colspan=\"3\">",
"             <span class=\"medCalcFontOne\">",
"              <input checked=\"checked\" name=\"Hemodialysis_twice_in_week_prior_radio\" onclick=\"Creatinine_param.value = ''; MELD_Score_param.value = ''; MELDNa_Score_param.value = '';\" type=\"radio\" value=\"No\"/>",
"              No",
"             </span>",
"            </td>",
"           </tr>",
"          </table>",
"         </center>",
"        </td>",
"        <td align=\"left\" bgcolor=\"#eeeeee\">",
"         <center>",
"          <span class=\"medCalcFontIO\">",
"           Results:",
"          </span>",
"          <br/>",
"          &nbsp;",
"          <br/>",
"          <table bgcolor=\"#eeeeee\" cellspacing=\"4\" summary=\"MedCalc 3000 Table\">",
"           <tr>",
"            <td align=\"right\">",
"             <span class=\"medCalcFontOneBold\">",
"              MELD Score",
"             </span>",
"            </td>",
"            <td nowrap=\"nowrap\" valign=\"top\">",
"             &nbsp;",
"             <input name=\"MELD_Score_param\" onfocus=\"blur();\" size=\"6\" type=\"text\"/>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"right\">",
"             <span class=\"medCalcFontOneBold\">",
"              MELDNa Score",
"             </span>",
"            </td>",
"            <td nowrap=\"nowrap\" valign=\"top\">",
"             &nbsp;",
"             <input name=\"MELDNa_Score_param\" onfocus=\"blur();\" size=\"6\" type=\"text\"/>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td colspan=\"3\">",
"             &nbsp;",
"             <br/>",
"            </td>",
"           </tr>",
"          </table>",
"         </center>",
"         <br/>",
"         &nbsp;",
"         <br/>",
"         <center>",
"          <span class=\"medCalcFontOne\">",
"           <input name=\"reset\" type=\"reset\" value=\"Reset form\"/>",
"          </span>",
"         </center>",
"        </td>",
"       </tr>",
"      </table>",
"     </center>",
"    </div>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <div id=\"calc_hints\">",
"     <span class=\"medCalcFontOne\">",
"     </span>",
"    </div>",
"    <div id=\"calc_notes\">",
"     <span class=\"medCalcFontOneBold\">",
"      Notes",
"     </span>",
"     <ul class=\"medCalcFontOne\">",
"      <li>",
"       The Model of End-stage Liver Disease, or",
"       <b>",
"        MELD Score",
"       </b>",
"       is used to estimate relative disease severity and likely survival of patients awaiting liver transplantation.",
"      </li>",
"      <li>",
"       The MELDNa score system adds a",
"       <b>",
"        Serum Na",
"       </b>",
"       parameter, so the added risk of significant hyponatremia may be taken into account.",
"      </li>",
"      <li>",
"       Children under the age of 12 should be assessed by the",
"       <b>",
"        PELD Score",
"       </b>",
"       .",
"      </li>",
"      <li>",
"       If a patient has had 2 or more hemodialysis treatments or 24 hours of CVVHD in the week prior to the time of the scoring,",
"       <b>",
"        Creatinine",
"       </b>",
"       will be set to 353.6 mcmol/L, the maximum creatinine level allowed in the model.",
"      </li>",
"      <li>",
"       For patients with hepatocellular carcinoma, the PELD/MELD score is increased according to an algorithm established by UNOS (United Network for Organ Sharing.)",
"      </li>",
"      <li>",
"       Additional information about the",
"       <b>",
"        MELD",
"       </b>",
"       and",
"       <b>",
"        PELD",
"       </b>",
"       scores is at the UNOS website, file://optn.transplant.hrsa.gov/resources/",
"       <wbr>",
"       </wbr>",
"       professionalResources.asp?index=8",
"      </li>",
"      <li>",
"       Please see appropriate UpToDate topic reviews for further information.",
"      </li>",
"     </ul>",
"    </div>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <div id=\"calc_refs\">",
"     <span class=\"medCalcFontRef\">",
"      <b>",
"       References",
"      </b>",
"     </span>",
"     <ol>",
"      <li>",
"       <span class=\"medCalcFontRef\">",
"        Kim WR, Biggins SW, Kremers WK, Wiesner RH, et. al. Hyponatremia and mortality among patients on the liver-transplant  waiting list.",
"        <i>",
"         N Engl J Med",
"        </i>",
"        . 2008 Sep 4;359(10):1018-26.",
"       </span>",
"      </li>",
"     </ol>",
"    </div>",
"   </form>",
"  </div>",
" </div>",
" <div id=\"topicAgreement\">",
"  Use of UpToDate is subject to the",
"  <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"   Subscription and License Agreement",
"  </a>",
"  .",
" </div>",
" <div id=\"printDisclaimer\">",
"  Information on this page may not appear correctly if printed.",
" </div>",
" <div id=\"disclaimerCalculator\">",
"  <div class=\"medCalcFontTwo\">",
"   <p class=\"header\">",
"    Legal Notices and Disclaimer",
"   </p>",
"   <p>",
"    All information contained in and produced by the MedCalc 3000 system is provided",
"			for educational purposes only. This information should not be used for the diagnosis or treatment",
"			of any health problem or disease.",
"    <b>",
"     THIS INFORMATION IS NOT INTENDED TO REPLACE CLINICAL JUDGMENT OR",
"			GUIDE INDIVIDUAL PATIENT CARE IN ANY MANNER.",
"    </b>",
"    <a class=\"medCalcDisclaimerLink\" href=\"./med-calc-disclaimer\">",
"     Click here for",
"				full notice and disclaimer.",
"    </a>",
"   </p>",
"   <p class=\"copy\">",
"    MedCalc 3000 is Copyright &copy; 1998-2013 Foundation Internet Services",
"   </p>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_38_11874=[" ",
"",
"",
"function log(i){",
"return Math.log(i) * Math.LOG10E;   ",
"}",
"",
"function ln(i){",
"return Math.log(i);",
"}",
"",
"function sq(i){",
"return i * i;",
"}",
"",
"function sqr(i){",
"return Math.sqrt(i);",
"}",
"",
"",
"function power(x,y){",
"return Math.pow(x,y);",
"}",
"",
"function eTo(x){",
"return Math.exp(x);",
"}",
"",
"",
"function fixDP(r, dps) {",
"if (isNaN(r)) return \"NaN\";",
"var msign = '';",
"if (r < 0) msign = '-';",
"x = Math.abs(r);",
"if (x > Math.pow(10, 21)) return msign + x.toString();",
"var m = Math.round(x * Math.pow(10, dps)).toString();",
"if (dps == 0) return msign + m;",
"while (m.length <= dps) m = \"0\" + m;",
"return msign + m.substring(0, m.length - dps) + \".\" + m.substring(m.length - dps);",
"}",
"",
"var currenttimeout;",
"",
"",
"var calctxt = ''; ",
"var xmltxt = ''; ",
"var htmtxt = ''; ",
"",
"",
"",
"function MELDNa_SI_fx() {",
"",
"currenttimeout = self.setTimeout('minMaxCheck();', 3000);",
"",
"with(document.MELDNa_SI_form){",
"",
"",
"doCalc = true;",
"if (Creatinine_param.value.indexOf(',') >= 0){ Creatinine_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(Creatinine_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = Creatinine_unit.options[Creatinine_unit.selectedIndex].value.split('|');",
"Creatinine = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"if (Bilirubin_param.value.indexOf(',') >= 0){ Bilirubin_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(Bilirubin_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = Bilirubin_unit.options[Bilirubin_unit.selectedIndex].value.split('|');",
"Bilirubin = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"if (INR_param.value.indexOf(',') >= 0){ INR_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(INR_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"INR = param_value;",
"if (Serum_Na_param.value.indexOf(',') >= 0){ Serum_Na_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(Serum_Na_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = Serum_Na_unit.options[Serum_Na_unit.selectedIndex].value.split('|');",
"Serum_Na = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"dp = 0;",
"if (Hemodialysis_twice_in_week_prior_radio[0].checked){",
"Creatinine_param.value = '353.6'; Creatinine = 353.6;",
"for(i = 0; i < Creatinine_unit.options.length; i++){",
"if (Creatinine_unit.options[i].value == '1|0|mcmol/L') Creatinine_unit.selectedIndex = i;",
"}}",
"MELD_Score =  10 * ((0.957 * ln(Creatinine/88.4)) + (0.378 * ln(Bilirubin/17.1)) + (1.12 * ln(INR))) + 6.43;",
"",
"if (doCalc) MELD_Score_param.value = fixDP(MELD_Score, dp);",
"",
"",
"",
"MELDNa_Score =  MELD_Score - Serum_Na - (0.025 * MELD_Score * (140 - Serum_Na)) + 140;",
"",
"if (doCalc) MELDNa_Score_param.value = fixDP(MELDNa_Score, dp);",
"",
"",
"",
"",
"",
"}",
"",
"}",
"",
"function minMaxCheck(){",
"",
"if (currenttimeout) self.clearTimeout(currenttimeout);",
"",
"with(document.MELDNa_SI_form){",
"",
"if (Creatinine_param.value && Creatinine < 88.4) {",
"Creatinine = 0;",
"Creatinine_param.value = \"\";",
"clrResults();",
"doCalc = false;",
"alert(\"The minimum value for Creatinine is 88.4 mcmol/L.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"if (Creatinine_param.value && Creatinine > 353.6) {",
"Creatinine_param.value = \"\";",
"clrResults();",
"Creatinine = 0;",
"doCalc = false;",
"alert(\"The maximum value for Creatinine is 353.6 mcmol/L.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"if (Bilirubin_param.value && Bilirubin < 17) {",
"Bilirubin = 0;",
"Bilirubin_param.value = \"\";",
"clrResults();",
"doCalc = false;",
"alert(\"The minimum value for Bilirubin is 17 mcmol/L.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"if (INR_param.value && INR < 1) {",
"INR = 0;",
"INR_param.value = \"\";",
"clrResults();",
"doCalc = false;",
"alert(\"The minimum value for INR is 1 .\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"if (INR_param.value && INR > 100) {",
"INR_param.value = \"\";",
"clrResults();",
"INR = 0;",
"doCalc = false;",
"alert(\"The maximum value for INR is 100 .\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"if (Serum_Na_param.value && Serum_Na < 125) {",
"Serum_Na = 0;",
"Serum_Na_param.value = \"\";",
"clrResults();",
"doCalc = false;",
"alert(\"The minimum value for Serum Na is 125 mmol/L.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"if (Serum_Na_param.value && Serum_Na > 140) {",
"Serum_Na_param.value = \"\";",
"clrResults();",
"Serum_Na = 0;",
"doCalc = false;",
"alert(\"The maximum value for Serum Na is 140 mmol/L.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"",
"",
"}",
"",
"}",
"",
"",
"function clrResults(){",
"",
"if (currenttimeout) self.clearTimeout(currenttimeout);",
"",
"with(document.MELDNa_SI_form){",
"",
"MELD_Score_param.value = '';",
"MELDNa_Score_param.value = '';",
"",
"",
"}",
"",
"}",
"",
"",
"",
"",
"",
"",
"",
"",
"",
"",
"",
""].join("\n");
var outline_f11_38_11874=null;
var title_f11_38_11875="Patient information: Colostomy care (The Basics)";
var content_f11_38_11875=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"14\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/16719\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/27/29107\">",
"         Digestive system",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_figure\" href=\"UTD.htm?6/7/6256\">",
"          Colostomy",
"         </a>",
"         <li>",
"          <a class=\"graphic graphic_table\" href=\"UTD.htm?28/61/29661\">",
"           Amount of fiber in different foods",
"          </a>",
"          <li>",
"           <a class=\"graphic graphic_table\" href=\"UTD.htm?18/13/18653\">",
"            Foods that can affect bowel movements and gas",
"           </a>",
"          </li>",
"         </li>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?37/9/38034\">",
"         Patient information: Colectomy (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?19/27/19890\">",
"         Patient information: Colon and rectal cancer (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?20/59/21426\">",
"         Patient information: Constipation in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?9/56/10115\">",
"         Patient information: Crohn's disease in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?21/31/22002\">",
"         Patient information: Gas and bloating (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?34/51/35634\">",
"         Patient information: High-fiber diet (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?39/59/40882\">",
"         Patient information: Ileostomy care (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?41/17/42258\">",
"         Patient information: Ulcerative colitis in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?6/0/6148\">",
"         Patient information: Colon and rectal cancer (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?23/40/24196\">",
"         Patient information: Crohn's disease (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?8/39/8817\">",
"         Patient information: High-fiber diet (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?10/39/10869\">",
"         Patient information: Ulcerative colitis (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Colostomy care (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/colostomy-care-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H84445846\">",
"      <span class=\"h1\">",
"       What is a colostomy?",
"      </span>",
"      &nbsp;&mdash;&nbsp;A colostomy is an opening in the belly made by a doctor as a way for bowel movements to leave the body. To make a colostomy, your doctor will do a procedure to make a small opening in your belly. Then he or she will connect your large intestine to this opening (",
"      <a class=\"graphic graphic_figure graphicRef66110 \" href=\"UTD.htm?28/27/29107\">",
"       figure 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef57774 \" href=\"UTD.htm?6/7/6256\">",
"       figure 2",
"      </a>",
"      ).",
"     </p>",
"     <p>",
"      A colostomy is sometimes called a &ldquo;stoma,&rdquo; which is a medical word that means &ldquo;opening.&rdquo; After a colostomy is made, your bowel movements will come out through the stoma into a bag that is attached to your skin.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H84445896\">",
"      <span class=\"h1\">",
"       What will my bowel movements be like with a colostomy?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You will probably have about 4 to 8 bowel movements a day. Your bowel movements might be looser (not as solid) than they used to be.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H84445911\">",
"      <span class=\"h1\">",
"       How do I manage my colostomy?",
"      </span>",
"      &nbsp;&mdash;&nbsp;A special nurse (called an ostomy nurse) will teach you how to manage your colostomy. He or she will teach you:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        When and how to empty the bag that collects your bowel movements",
"       </li>",
"       <li>",
"        When and how to put on a new bag to collect your bowel movements",
"       </li>",
"       <li>",
"        How to check your stoma for problems",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      There are different types of colostomy bags that people can use. With some types of bags, you empty, clean, and reuse them. With other types, you throw them out after each use.",
"     </p>",
"     <p>",
"      Some people worry that their bag will leak, or that other people will be able to smell their bowel movements. But these things rarely happen. The bags are made so that they do not leak or smell.",
"     </p>",
"     <p>",
"      If you have a certain type of colostomy, you might be able to manage it with a process called &ldquo;irrigation.&rdquo; This is a way to make your bowel movements regular. It involves squirting water into your stoma on a regular basis to cause a bowel movement to happen.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H84445926\">",
"      <span class=\"h1\">",
"       What problems can happen with a colostomy?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Different problems can happen with a colostomy, either right away or years later. Let your doctor or nurse know if you have any of the following symptoms or problems:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Your stoma is swollen or larger than usual.",
"       </li>",
"       <li>",
"        Your stoma is smaller than usual.",
"       </li>",
"       <li>",
"        Your stoma leaks more than usual.",
"       </li>",
"       <li>",
"        You have a rash or sores around your stoma.",
"       </li>",
"       <li>",
"        You have diarrhea.",
"       </li>",
"       <li>",
"        You have sudden belly pain, cramps, or nausea.",
"       </li>",
"       <li>",
"        You are dehydrated. Dehydration is when the body loses too much water. Symptoms of dehydration include not making as much urine or having dark yellow urine, or feeling thirsty, tired, dizzy, or confused.",
"       </li>",
"       <li>",
"        You haven&rsquo;t had any gas or bowel movements for 4 to 6 hours (during the day). These symptoms could mean that your stoma is blocked.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H84445941\">",
"      <span class=\"h1\">",
"       Do I need to follow a special diet?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Probably not. But you should avoid getting constipated. (Constipation means trouble having bowel movements.) To avoid constipation, you can:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Eat foods that have a lot of fiber (",
"        <a class=\"graphic graphic_table graphicRef52349 \" href=\"UTD.htm?28/61/29661\">",
"         table 1",
"        </a>",
"        )",
"       </li>",
"       <li>",
"        Drink plenty of water and other fluids",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      The foods you eat can affect the odor of your bowel movements, and how solid or loose they are. Certain foods can also make you have more gas. The foods that can affect your bowel movements and gas are listed in the Table (",
"      <a class=\"graphic graphic_table graphicRef58115 \" href=\"UTD.htm?18/13/18653\">",
"       table 2",
"      </a>",
"      ).",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H84445996\">",
"      <span class=\"h1\">",
"       What will my life be like with a colostomy?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You should be able to live an active and normal life with your colostomy. But many people worry about the following things:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Clothes &ndash; You do not need to wear special clothes. Other people won&rsquo;t be able to see your bag under your clothes.",
"       </li>",
"       <li>",
"        Baths and showers &ndash; You can take a bath or shower with or without your bag on.",
"       </li>",
"       <li>",
"        Sports &ndash; You will probably be able to play most sports. You might want to wear a special belt to protect your bag and keep it in place. Doctors usually recommend that people with a colostomy not play certain contact sports (such as football) or lift weights.",
"       </li>",
"       <li>",
"        Swimming &ndash; You can swim with your bag on. Make sure to empty your bag before you swim.",
"       </li>",
"       <li>",
"        Sex &ndash; You can have sex. But you might want to wear a special wrap to protect (and hide) your bag during sex.",
"       </li>",
"       <li>",
"        Travel &ndash; When you travel, be sure to bring extra supplies to manage your colostomy. If you fly, take your supplies in your carry-on luggage.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      It is normal to feed sad, upset, or worried when you have a colostomy. If you have these feelings, try to get help. You can talk with a family member, friend, or counselor. You might also find it helpful to go to a support group for people with a colostomy.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H26018299\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?37/9/38034?source=see_link\">",
"       Patient information: Colectomy (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?19/27/19890?source=see_link\">",
"       Patient information: Colon and rectal cancer (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?9/56/10115?source=see_link\">",
"       Patient information: Crohn's disease in adults (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?41/17/42258?source=see_link\">",
"       Patient information: Ulcerative colitis in adults (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?21/31/22002?source=see_link\">",
"       Patient information: Gas and bloating (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?34/51/35634?source=see_link\">",
"       Patient information: High-fiber diet (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?20/59/21426?source=see_link\">",
"       Patient information: Constipation in adults (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?39/59/40882?source=see_link\">",
"       Patient information: Ileostomy care (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?6/0/6148?source=see_link\">",
"       Patient information: Colon and rectal cancer (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?10/39/10869?source=see_link\">",
"       Patient information: Ulcerative colitis (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?23/40/24196?source=see_link\">",
"       Patient information: Crohn's disease (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?8/39/8817?source=see_link\">",
"       Patient information: High-fiber diet (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?11/38/11875?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16719 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-221.179.173.170-4115C7D097-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_38_11875=[""].join("\n");
var outline_f11_38_11875=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H84445846\">",
"      What is a colostomy?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H84445896\">",
"      What will my bowel movements be like with a colostomy?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H84445911\">",
"      How do I manage my colostomy?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H84445926\">",
"      What problems can happen with a colostomy?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H84445941\">",
"      Do I need to follow a special diet?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H84445996\">",
"      What will my life be like with a colostomy?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26018299\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/16719\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/27/29107\">",
"      Digestive system",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_figure\" href=\"UTD.htm?6/7/6256\">",
"       Colostomy",
"      </a>",
"      <li>",
"       <a class=\"graphic graphic_table\" href=\"UTD.htm?28/61/29661\">",
"        Amount of fiber in different foods",
"       </a>",
"       <li>",
"        <a class=\"graphic graphic_table\" href=\"UTD.htm?18/13/18653\">",
"         Foods that can affect bowel movements and gas",
"        </a>",
"       </li>",
"      </li>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?37/9/38034?source=related_link\">",
"      Patient information: Colectomy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?6/0/6148?source=related_link\">",
"      Patient information: Colon and rectal cancer (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?19/27/19890?source=related_link\">",
"      Patient information: Colon and rectal cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?20/59/21426?source=related_link\">",
"      Patient information: Constipation in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?23/40/24196?source=related_link\">",
"      Patient information: Crohn's disease (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?9/56/10115?source=related_link\">",
"      Patient information: Crohn's disease in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?21/31/22002?source=related_link\">",
"      Patient information: Gas and bloating (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?8/39/8817?source=related_link\">",
"      Patient information: High-fiber diet (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?34/51/35634?source=related_link\">",
"      Patient information: High-fiber diet (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?39/59/40882?source=related_link\">",
"      Patient information: Ileostomy care (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?10/39/10869?source=related_link\">",
"      Patient information: Ulcerative colitis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?41/17/42258?source=related_link\">",
"      Patient information: Ulcerative colitis in adults (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_38_11876="Magnesium L-aspartate hydrochloride: Patient drug information";
var content_f11_38_11876=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Magnesium L-aspartate hydrochloride: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/12/30916?source=see_link\">",
"     see \"Magnesium L-aspartate hydrochloride: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/7/28788?source=see_link\">",
"     see \"Magnesium L-aspartate hydrochloride: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F190750\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Maginex&trade; DS [OTC];",
"     </li>",
"     <li>",
"      Maginex&trade; [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10013744\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop and treat low magnesium levels.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691572",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to help growth and good health.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10013743\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702435",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to magnesium L-aspartate hydrochloride or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10013748\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697312",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have myasthenia gravis, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697314",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have nerve disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697716",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Try to space other drugs from this one by 2 hours. This drug stops many drugs from getting into the body.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10013749\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10013751\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10013746\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695907",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug with food.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swallow tablet whole. Do not chew, break, or crush.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695388",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Mix granules with half a cup of water or juice.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10013747\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10013752\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10013753\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11217 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-180.241.123.62-6A9128D992-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_38_11876=[""].join("\n");
var outline_f11_38_11876=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190750\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013744\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013743\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013748\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013749\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013751\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013746\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013747\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013752\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013753\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?30/12/30916?source=related_link\">",
"      Magnesium L-aspartate hydrochloride: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/7/28788?source=related_link\">",
"      Magnesium L-aspartate hydrochloride: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_38_11877="Minoxidil (systemic): Drug information";
var content_f11_38_11877=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Minoxidil (systemic): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?24/26/24996?source=see_link\">",
"    see \"Minoxidil (systemic): Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/55/21364?source=see_link\">",
"    see \"Minoxidil (systemic): Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F8774839\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F8774868\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Loniten&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F8774874\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Vasodilator, Direct-Acting",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F8774967\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Hypertension:",
"     </b>",
"     Oral: Initial: 5 mg once daily, increase gradually every 3 days (maximum: 100 mg/day); usual dosage range (JNC 7): 2.5-80 mg/day in 1-2 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Dosage adjustment is needed when added to concomitant therapy.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F8774966\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/55/21364?source=see_link\">",
"      see \"Minoxidil (systemic): Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Hypertension:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Children &lt;12 years:",
"     </i>",
"     Initial: 0.1-0.2 mg/kg once daily; maximum: 5 mg/day; increase gradually every 3 days; usual dosage range: 0.25-1 mg/kg/day in 1-2 divided doses; maximum: 50 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Children &ge;12 years:",
"     </i>",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F8774968\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypertension: Initial: 2.5 mg once daily; increase gradually.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F8774969\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Patient with renal failure and/or receiving dialysis may require dosage reduction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Supplemental dose is not necessary after hemo- or peritoneal dialysis.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F8774977\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 2.5 mg, 10 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F8774869\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F8774881\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Management of severe hypertension (usually in combination with a diuretic and beta-blocker)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F8774841\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:0em;margin-left:2em;text-align:justify;\">",
"       Loniten&reg; may be confused with Lipitor&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Minoxidil may be confused with metolazone, midodrine, Minipress&reg;, Minocin&reg;, Monopril&reg;, Noxafil&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Noxidil [Thailand] may be confused with Noxafil brand name for posaconazole [U.S. and multiple international markets]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F8774911\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     Frequency not always reported.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: ECG changes (T-wave changes 60%), peripheral edema (7%), pericardial effusion with tamponade (3%), pericardial effusion without tamponade (3%), angina pectoris, heart failure, pericarditis, rebound hypertension (in children after a gradual withdrawal), sodium and water retention, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Hypertrichosis (common; 80%), bullous eruption (rare), rash, Stevens-Johnson syndrome (rare)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Breast tenderness (rare; &lt;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Nausea, vomiting, weight gain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Leukopenia (rare), thrombocytopenia (rare), transient decreased erythrocyte count (hemodilution), transient decreased hematocrit/hemoglobin (hemodilution)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Increased alkaline phosphatase",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Transient increase in serum BUN and creatinine",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Pulmonary edema",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F8774907\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to minoxidil or any component of the formulation; pheochromocytoma",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F8774908\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Fluid retention: May cause salt and water retention; administer with a diuretic, preferably a loop diuretic (eg, furosemide) to prevent fluid retention and subsequent local and generalized edema. Use with extreme caution in patients with heart failure.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pericardial effusion/tamponade:",
"     <b>",
"      [U.S. Boxed Warning]: May cause pericarditis and pericardial effusion that may progress to tamponade;",
"     </b>",
"     patients with renal impairment not on dialysis may be at higher risk. Use with caution in patients with heart failure. Observe patients closely.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Rapid blood pressure control: Rapid control of blood pressure in patients with severe hypertension can lead to syncope, CVA, MI, and/or ischemia of other special sense organs (eg, vision).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sinus tachycardia:",
"     <b>",
"      [U.S. Boxed Warning]: May increase oxygen demand and exacerbate angina pectoris;",
"     </b>",
"     concomitant use with a beta-blocker (if no contraindication exists) may help reduce the effect. Use with caution in patients with ischemic heart disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Acute myocardial infarct (MI): Avoid use for a month after acute MI. Use with extreme caution; ensure patient is receiving a beta blocker prior to initiation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Heart failure: Compared to placebo minoxidil increased the frequency of clinical events, including increased need for diuretics, angina, ventricular arrhythmias, worsening heart failure and death (Franciosa, 1984).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with significant renal impairment; renal failure and dialysis patients may require a smaller dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in the elderly; initiate at the low end of the dosage range and monitor closely.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use:",
"     <b>",
"      [U.S. Boxed Warning]: Maximum therapeutic doses of a diuretic and two antihypertensives should be used before this drug is ever added. Should be given with a diuretic to minimize fluid gain and a beta-blocker (if no contraindications) to prevent tachycardia. Anyone with malignant hypertension should be hospitalized with close medical supervision to ensure blood pressure is reducing and to prevent too rapid of a reduction in blood pressure.",
"     </b>",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299718\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F8774914\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfuzosin: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amifostine: Antihypertensives may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, antihypertensive medications should be withheld for 24 hours prior to amifostine administration. If antihypertensive therapy can not be withheld, amifostine should not be administered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: May enhance the hypotensive effect of other Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): May enhance the adverse/toxic effect of Minoxidil (Systemic). Severe hypertrichosis has been reported.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diazoxide: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypotensive Properties): May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RiTUXimab: Antihypertensives may enhance the hypotensive effect of RiTUXimab.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F8774919\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Herb/Nutraceutical: Bayberry, blue cohosh, cayenne, ephedra, ginger, ginseng (American), kola, licorice may diminish the antihypertensive effects of minoxidil. Black cohosh, California poppy, coleus, golden seal, hawthorn, mistletoe, periwinkle, quinine, shepherd's purse may enhance the hypotensive effects of minoxidil.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F8774882\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F8774883\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were observed in some animal studies.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F8774905\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F8774906\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk has been reported in one case report of a woman receiving 10 mg/day orally.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F8774979\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Minoxidil Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2.5 mg (100): $58.78",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (100): $129.14",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F8774970\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blood pressure, standing and sitting/supine; fluid and electrolyte balance and body weight should be monitored. Any tests that are abnormal at the time of initiation (including, renal function tests, ECG, echocardiogram, chest x-ray) should be repeated initially every 1-3 months then every 6-12 months once stable.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F12707702\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Guayaten (VE);",
"     </li>",
"     <li>",
"      Loniten (AT, AU, BR, CH, GB, GR, IE, IT, NO, TH, TW);",
"     </li>",
"     <li>",
"      Lonnoten (NL);",
"     </li>",
"     <li>",
"      Lonolox (DE);",
"     </li>",
"     <li>",
"      Lonoten (FR);",
"     </li>",
"     <li>",
"      Manoxidil (TH);",
"     </li>",
"     <li>",
"      Vaxdil (CO)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F8774941\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Produces vasodilation by directly relaxing arteriolar smooth muscle, with little effect on veins; effects may be mediated by cyclic AMP; stimulation of hair growth is secondary to vasodilation, increased cutaneous blood flow and stimulation of resting hair follicles",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F8774942\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Hypotensive: ~30 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Peak effect: 2-8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: 2-5 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: None",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: 88%, primarily via glucuronidation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: 90%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Adults: 3.5-4.2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (12% as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Chobanian AV, Bakris GL, Black HR, et al, &ldquo;The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2003, 289 (19):2560-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/38/11877/abstract-text/12748199/pubmed\" id=\"12748199\" target=\"_blank\">",
"        12748199",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Franciosa JA, Jordan RA, Wilen MM, et al, &ldquo;Minoxidil in Patients With Chronic Left Heart Failure: Contrasting Hemodynamic and Clinical Effects in a Controlled Trial,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 1984, 70(1):63-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/38/11877/abstract-text/6373050/pubmed\" id=\"6373050\" target=\"_blank\">",
"        6373050",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents &ldquo;Fourth Report on High Blood Pressure in Children and Adolescents,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2004, 114(2 Suppl): 555-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/38/11877/abstract-text/15286277/pubmed\" id=\"15286277\" target=\"_blank\">",
"        15286277",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9598 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-14.112.150.18-37D25D05A2-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_38_11877=[""].join("\n");
var outline_f11_38_11877=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8774839\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8774868\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8774874\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8774967\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8774966\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8774968\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8774969\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8774977\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8774869\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8774881\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8774841\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8774911\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8774907\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8774908\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299718\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8774914\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8774919\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8774882\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8774883\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8774905\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8774906\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8774979\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8774970\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12707702\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8774941\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8774942\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9598\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9598|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?24/26/24996?source=related_link\">",
"      Minoxidil (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/55/21364?source=related_link\">",
"      Minoxidil (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?26/47/27379?source=related_link\">",
"      Minoxidil (topical): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?32/58/33699?source=related_link\">",
"      Minoxidil (topical): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_38_11878="Pathology aortic intramural hematoma";
var content_f11_38_11878=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F64205&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F64205&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 555px\">",
"   <div class=\"ttl\">",
"    Pathology aortic intramural hematoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 535px; height: 174px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Autopsy specimen from a patient with an intramural hematoma of the ascending aorta. Left panel: Transverse section through the aorta shows the surrounding the aortic intima (*); the intima itself is intact. Right panel: Longitudinal section through the aorta.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From Maraj, R, Rekpattanapipat, P, Jacobs, LE, et al. Am J Cardiol 2000; 86:664, with permission from Excerpta Medica, Inc.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.elsevier.com/locate/jacc\">",
"      file://www.elsevier.com/locate/jacc",
"     </a>",
"     <br/>",
"     <a href=\" file://www.sciencedirect.com\">",
"      file://www.sciencedirect.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_38_11878=[""].join("\n");
var outline_f11_38_11878=null;
var title_f11_38_11879="Ovarian cancer";
var content_f11_38_11879=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F64039%7EOBGYN%2F52787&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F64039%7EOBGYN%2F52787&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Ovarian cancer",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 321px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Transvaginal ultrasound image of the left ovary showing ovarian cancer. The left ovarian mass is primarily solid as indicated by the long arrow. A small cystic portion is demonstrated by the short arrow.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Thomas D Shipp, MD. Copyright &copy; Thomas D Shipp, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Ovarian cancer",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 431px; height: 355px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Transvaginal ultrasound image of the right ovary showing ovarian cancer. The right ovarian mass has both solid and cystic components as indicated by the arrow and arrowhead, respectively.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Thomas D Shipp, MD. Copyright &copy; Thomas D Shipp, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_38_11879=[""].join("\n");
var outline_f11_38_11879=null;
var title_f11_38_11880="Copper deficiency myeloneuropathy";
var content_f11_38_11880=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Copper deficiency myeloneuropathy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/38/11880/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/38/11880/contributors\">",
"     Neeraj Kumar, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/38/11880/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/38/11880/contributors\">",
"     Michael J Aminoff, MD, DSc",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/38/11880/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/38/11880/contributors\">",
"     Janet L Wilterdink, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?11/38/11880/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 19, 2011.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1290238\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Copper deficiency-associated myelopathy has been well described in various animal species, in particular ruminants, in which it is called swayback or enzootic ataxia. Acquired copper deficiency has only recently been recognized to cause a myelopathy in humans [",
"    <a class=\"abstract\" href=\"UTD.htm?11/38/11880/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The neurologic manifestations of copper deficiency are usually, but not always, accompanied by the typical hematologic derangements of anemia and leukopenia.",
"   </p>",
"   <p>",
"    This topic discusses the neurologic manifestations of acquired copper deficiency. The physiologic and biochemical functions of dietary copper and the dietary requirements of copper are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/19/39226?source=see_link&amp;anchor=H9#H9\">",
"     \"Overview of dietary trace minerals\", section on 'Copper'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A brief overview of Menkes disease, a congenital x-linked disorder of severe copper deficiency, is also discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/19/39226?source=see_link&amp;anchor=H16#H16\">",
"     \"Overview of dietary trace minerals\", section on 'Menkes disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37833037\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The age range of reported cases of copper deficiency myeloneuropathy is 30 to 82 years [",
"    <a class=\"abstract\" href=\"UTD.htm?11/38/11880/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. More cases in women than men are reported.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37833129\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mechanism underlying neurologic damage in individuals with copper deficiency is uncertain. Copper is a component of enzymes that have a critical role in the structure and function of the nervous system [",
"    <a class=\"abstract\" href=\"UTD.htm?11/38/11880/abstract/5-10\">",
"     5-10",
"    </a>",
"    ]. It permits electron transfer in key enzymatic pathways. These include cytochrome-c-oxidase for electron transport and oxidative phosphorylation,",
"    <span class=\"nowrap\">",
"     copper/zinc",
"    </span>",
"    superoxide dismutase for antioxidant defense, tyrosinase for melanin synthesis, dopamine beta-hydroxylase for catecholamine biosynthesis, lysyl oxidase for crosslinking of collagen and elastin, peptidylglycine alpha-amidating monooxygenase for neuropeptide and peptide hormone processing, monoamine oxidase for serotonin synthesis, and ceruloplasmin for brain iron homeostasis.",
"   </p>",
"   <p>",
"    There are limited pathologic studies in individuals with acquired copper deficiency. A few reports of nerve biopsies in patients confirm the presence of axonal degeneration [",
"    <a class=\"abstract\" href=\"UTD.htm?11/38/11880/abstract/1,11-14\">",
"     1,11-14",
"    </a>",
"    ]. A single postmortem examination in one patient revealed significant degeneration in the dorsal and lateral columns of the spinal cord [",
"    <a class=\"abstract\" href=\"UTD.htm?11/38/11880/abstract/15\">",
"     15",
"    </a>",
"    ]. In animals, neuronal loss in the cerebellum and spinal tracts with extensive demyelination is reported [",
"    <a class=\"abstract\" href=\"UTD.htm?11/38/11880/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37833569\">",
"    <span class=\"h1\">",
"     CAUSES OF ACQUIRED COPPER DEFICIENCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although rare, acquired copper deficiency has been well documented in humans [",
"    <a class=\"abstract\" href=\"UTD.htm?11/38/11880/abstract/5,16\">",
"     5,16",
"    </a>",
"    ]. The co-existence of multiple causes of copper deficiency increases the risk of a clinically significant deficiency state:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Gastric surgery is the most common cause of acquired copper deficiency, underlying about half of reported cases [",
"      <a class=\"abstract\" href=\"UTD.htm?11/38/11880/abstract/1,3,11,17-29\">",
"       1,3,11,17-29",
"      </a>",
"      ]. Typically neurologic manifestations are delayed by years following gastric surgery.",
"     </li>",
"     <li>",
"      Excessive zinc ingestion is another cause of copper deficiency [",
"      <a class=\"abstract\" href=\"UTD.htm?11/38/11880/abstract/28-34\">",
"       28-34",
"      </a>",
"      ]. Copper and zinc are competitively absorbed from the gastrointestinal tract. In addition to overuse of zinc supplements [",
"      <a class=\"abstract\" href=\"UTD.htm?11/38/11880/abstract/35\">",
"       35",
"      </a>",
"      ], ingestion of denture cream [",
"      <a class=\"abstract\" href=\"UTD.htm?11/38/11880/abstract/15,31-33,36\">",
"       15,31-33,36",
"      </a>",
"      ] and parenteral zinc overloading during chronic hemodialysis [",
"      <a class=\"abstract\" href=\"UTD.htm?11/38/11880/abstract/37\">",
"       37",
"      </a>",
"      ] have also been linked to copper deficiency myelopathy.",
"     </li>",
"     <li>",
"      Dietary copper deficiency is rare, but has been described in premature infants receiving milk formulas without adequate copper supplementation [",
"      <a class=\"abstract\" href=\"UTD.htm?11/38/11880/abstract/5,38\">",
"       5,38",
"      </a>",
"      ]. Copper deficiency may also be a complication of prolonged total parenteral nutrition, in particular when copper supplementation is withheld due to cholestasis or other reason [",
"      <a class=\"abstract\" href=\"UTD.htm?11/38/11880/abstract/7,29,39\">",
"       7,29,39",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Enteropathies associated with malabsorption, such as cystic fibrosis, celiac disease, and inflammatory bowel disease may be associated with copper deficiency [",
"      <a class=\"abstract\" href=\"UTD.htm?11/38/11880/abstract/1,5,16,29,40,41\">",
"       1,5,16,29,40,41",
"      </a>",
"      ]. In some cases the neurologic manifestations have occurred in the absence of gastrointestinal symptoms [",
"      <a class=\"abstract\" href=\"UTD.htm?11/38/11880/abstract/40,42,43\">",
"       40,42,43",
"      </a>",
"      ]. Bacterial overgrowth has also been implicated as a cause of copper deficiency in a patient with a prior history of gastric surgery [",
"      <a class=\"abstract\" href=\"UTD.htm?11/38/11880/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Over-treatment of Wilson disease with zinc and chelators has only rarely been reported to cause copper deficiency-related neurologic manifestations [",
"      <a class=\"abstract\" href=\"UTD.htm?11/38/11880/abstract/44-46\">",
"       44-46",
"      </a>",
"      ]. Other copper-chelators, tetrathiomolybdate, have been associated with copper deficiency [",
"      <a class=\"abstract\" href=\"UTD.htm?11/38/11880/abstract/47\">",
"       47",
"      </a>",
"      ]. The antiparasitic agent, clioquinol, is a copper chelator and was linked to many cases of myelo-optico-neuropathy (a syndrome similar to copper deficiency myeloneuropathy) in Japan in the 1960s [",
"      <a class=\"abstract\" href=\"UTD.htm?11/38/11880/abstract/48-50\">",
"       48-50",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In some cases, the cause of copper deficiency is not evident even after extensive investigation [",
"    <a class=\"abstract\" href=\"UTD.htm?11/38/11880/abstract/1,3,4,13,26,51\">",
"     1,3,4,13,26,51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These and other risk factors for copper deficiency are discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/19/39226?source=see_link&amp;anchor=H15#H15\">",
"     \"Overview of dietary trace minerals\", section on 'Risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H61087700\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37834722\">",
"    <span class=\"h2\">",
"     Neurological",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common neurologic manifestation of acquired copper deficiency is that of a myelopathy or myeloneuropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?11/38/11880/abstract/1,2,4,17,18,30,33,40,42,52\">",
"     1,2,4,17,18,30,33,40,42,52",
"    </a>",
"    ]. Patients typically present with a subacute gait disorder with prominent sensory ataxia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    spasticity. Examination reveals long tract signs with spasticity in the legs and Babinski response, along with impaired vibration and position sense and a positive Romberg sign. Bladder dysfunction is relatively uncommon, but can occur [",
"    <a class=\"abstract\" href=\"UTD.htm?11/38/11880/abstract/2,4,27\">",
"     2,4,27",
"    </a>",
"    ]. This pattern of neurologic deficits reflects involvement of the dorsal columns of the spinal cord and is similar to that seen in patients with subacute combined degeneration secondary to vitamin B",
"    <sub>",
"     12",
"    </sub>",
"    deficiency. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/44/5832?source=see_link&amp;anchor=H16#H16\">",
"     \"Anatomy and localization of spinal cord disorders\", section on 'Dorsal (posterior) cord syndrome'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/42/32426?source=see_link&amp;anchor=H20#H20\">",
"     \"Disorders affecting the spinal cord\", section on 'Subacute combined degeneration'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Symptoms and signs suggesting an associated peripheral neuropathy are common [",
"    <a class=\"abstract\" href=\"UTD.htm?11/38/11880/abstract/33\">",
"     33",
"    </a>",
"    ]. The neuropathy may take different forms. A complaint of lower limb paresthesias is present in nearly all patients, and most demonstrate a stocking distribution of impaired sensation to pain and temperature [",
"    <a class=\"abstract\" href=\"UTD.htm?11/38/11880/abstract/1,2,18\">",
"     1,2,18",
"    </a>",
"    ]. Superimposed neuropathy may lead to suppressed reflexes in the legs, although many patients have brisk reflexes instead, reflecting the myelopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?11/38/11880/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. A common finding is brisk knee jerks with depressed or absent ankle jerks. Less common peripheral nerve manifestations include a wrist or foot drop [",
"    <a class=\"abstract\" href=\"UTD.htm?11/38/11880/abstract/1\">",
"     1",
"    </a>",
"    ], asymmetric sensory symptoms of the face and trunk as well as limbs, suggesting a sensory ganglionopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?11/38/11880/abstract/13\">",
"     13",
"    </a>",
"    ], and a progressive, asymmetric weakness with electrodiagnostic evidence of denervation suggesting lower motor neuron disease [",
"    <a class=\"abstract\" href=\"UTD.htm?11/38/11880/abstract/12,32\">",
"     12,32",
"    </a>",
"    ]. In most cases, the associated neuropathy develops along with the myelopathy; however, in some cases, these develop before the myelopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?11/38/11880/abstract/11\">",
"     11",
"    </a>",
"    ] or in the absence of a myelopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?11/38/11880/abstract/25,26,31,44,53\">",
"     25,26,31,44,53",
"    </a>",
"    ]. Not all of the cases of reported isolated neuropathy in this setting were confirmed by careful neurologic examination; the association between copper deficiency and an isolated neuropathy requires further study. &nbsp;",
"   </p>",
"   <p>",
"    Optic nerve involvement of varying severity has been reported as part of this syndrome in a number of patients, although not in most [",
"    <a class=\"abstract\" href=\"UTD.htm?11/38/11880/abstract/21,25,27,54\">",
"     21,25,27,54",
"    </a>",
"    ]. Affected patients typically have bilateral vision loss, without optic disc edema, at times with an abrupt presentation.",
"   </p>",
"   <p>",
"    Rare neurologic symptoms associated with copper deficiency in isolated case reports include myopathy (along with myelopathy) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/38/11880/abstract/43\">",
"     43",
"    </a>",
"    ], myelo-optico-neuropathy with hyposmia and hypogeusia [",
"    <a class=\"abstract\" href=\"UTD.htm?11/38/11880/abstract/21\">",
"     21",
"    </a>",
"    ], and cognitive impairment [",
"    <a class=\"abstract\" href=\"UTD.htm?11/38/11880/abstract/32\">",
"     32",
"    </a>",
"    ]. However, the precise significance of these reported associations is unclear and needs further confirmation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37834729\">",
"    <span class=\"h2\">",
"     Hematological",
"    </span>",
"    &nbsp;&mdash;&nbsp;The hematological hallmark of copper deficiency is anemia and leukopenia; these are present in most, but not all patients with associated neurologic deficits [",
"    <a class=\"abstract\" href=\"UTD.htm?11/38/11880/abstract/1-3,14,26,28-30,33,55,56\">",
"     1-3,14,26,28-30,33,55,56",
"    </a>",
"    ]. The anemia may be microcytic, macrocytic, or normocytic. Thrombocytopenia and pancytopenia are relatively rare. Typical bone marrow findings include a left shift in granulocytic and erythroid maturation with cytoplasmic vacuolization in erythroid and myeloid precursors and the presence of ringed sideroblasts or hemosiderin containing plasma cells [",
"    <a class=\"abstract\" href=\"UTD.htm?11/38/11880/abstract/26,29,31\">",
"     26,29,31",
"    </a>",
"    ]. Erythroid hyperplasia with decreased myeloid to erythroid ratio and dyserythropoiesis including megaloblastic changes may be seen. In some cases, patients with copper deficiency were initially given a diagnosis of sideroblastic anemia, myelodysplastic syndrome, or aplastic anemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H61087758\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;One case series and a case report describe hepatic iron overload",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cirrhosis in five patients with copper deficiency myeloneuropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?11/38/11880/abstract/28,57\">",
"     28,57",
"    </a>",
"    ]. The authors speculated that this was caused by the secondary deficiency of ceruloplasmin, which is responsible for oxidizing iron for binding to transferrin, which facilitates iron mobilization. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37835686\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other causes of myelopathy, particularly syndromes affecting the dorsal spinal cord, should be considered in the differential diagnosis of this clinical presentation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/44/5832?source=see_link\">",
"     \"Anatomy and localization of spinal cord disorders\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/42/32426?source=see_link\">",
"     \"Disorders affecting the spinal cord\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In particular, the subacute combined degeneration resulting from vitamin B",
"    <sub>",
"     12",
"    </sub>",
"    deficiency can have a very similar neurologic presentation. Some diagnoses of copper deficiency myeloneuropathy were made only after vitamin B",
"    <sub>",
"     12",
"    </sub>",
"    supplementation failed to halt neurologic progression [",
"    <a class=\"abstract\" href=\"UTD.htm?11/38/11880/abstract/1,3,18,24,31,54\">",
"     1,3,18,24,31,54",
"    </a>",
"    ]. Copper and vitamin B",
"    <sub>",
"     12",
"    </sub>",
"    deficiency may also coexist, particularly in patients with a history of gastric surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?11/38/11880/abstract/1-3,31,58\">",
"     1-3,31,58",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/42/32426?source=see_link&amp;anchor=H20#H20\">",
"     \"Disorders affecting the spinal cord\", section on 'Subacute combined degeneration'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/32/11786?source=see_link&amp;anchor=H2126412#H2126412\">",
"     \"Etiology and clinical manifestations of vitamin B12 and folate deficiency\", section on 'Neurologic changes'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/29/11732?source=see_link\">",
"     Nitrous oxide",
"    </a>",
"    abuse can also lead to subacute combined degeneration, by inactivation of vitamin B",
"    <sub>",
"     12",
"    </sub>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?11/38/11880/abstract/59-61\">",
"     59-61",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/61/33753?source=see_link&amp;anchor=H11#H11\">",
"     \"Inhalant abuse in children and adolescents\", section on 'Nitrous oxide'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other causes of a dorsal cord syndrome include multiple sclerosis (more typically the primary progressive form), tabes dorsalis, Friedreich ataxia, vascular malformations, epidural and intradural extramedullary tumors, cervical spondylotic myelopathy, and atlantoaxial subluxation [",
"    <a class=\"abstract\" href=\"UTD.htm?11/38/11880/abstract/62\">",
"     62",
"    </a>",
"    ]. Adrenomyeloneuropathy and hereditary spastic paraplegia should also be considered in some cases. These entities are described in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/42/32426?source=see_link\">",
"     \"Disorders affecting the spinal cord\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/18/27944?source=see_link\">",
"     \"Cervical spondylotic myelopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37836419\">",
"    <span class=\"h1\">",
"     DIAGNOSIS AND EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of copper deficiency myeloneuropathy is made in patients with the characteristic clinical syndrome and laboratory indicators of copper deficiency.",
"   </p>",
"   <p>",
"    Patients who present with a myelopathy should also have imaging studies (usually magnetic resonance imaging) of the spinal cord to exclude other conditions. Vitamin B",
"    <sub>",
"     12",
"    </sub>",
"    levels should be checked to exclude the alternative or comorbid diagnosis of vitamin B",
"    <sub>",
"     12",
"    </sub>",
"    deficiency.",
"   </p>",
"   <p>",
"    While not essential in the evaluation of copper deficiency myeloneuropathy, some patients will have electrophysiology studies or a lumbar puncture.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37836493\">",
"    <span class=\"h2\">",
"     Laboratory studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laboratory indicators of copper deficiency include a decrease in serum copper or ceruloplasmin levels (more than 90 percent of circulating copper is bound to ceruloplasmin). Measurement of 24-hour urinary copper excretion is a less sensitive marker for copper deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?11/38/11880/abstract/29,63\">",
"     29,63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    All described cases of copper deficiency myeloneuropathy have had low serum copper levels [",
"    <a class=\"abstract\" href=\"UTD.htm?11/38/11880/abstract/2,3,14,52\">",
"     2,3,14,52",
"    </a>",
"    ]. However, in marginal copper deficiency, serum copper levels may be normal [",
"    <a class=\"abstract\" href=\"UTD.htm?11/38/11880/abstract/7,64\">",
"     7,64",
"    </a>",
"    ]. Ceruloplasmin is an acute phase reactant and will be elevated in the presence of inflammatory conditions and also at times in pregnancy, oral contraceptive use, liver disease, malignancy, hematologic disease, myocardial infarction, infections, smoking, diabetes, and uremia. It is possible that in these settings, levels of serum copper and ceruloplasmin may be normal, even while stores of copper are low, and a copper deficiency could be masked. Copper levels may also be low in the absence of true copper deficiency in patients with Wilson&rsquo;s disease or in heterozygous carriers of the Wilson disease gene [",
"    <a class=\"abstract\" href=\"UTD.htm?11/38/11880/abstract/65\">",
"     65",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/48/14088?source=see_link\">",
"     \"Tests used in the diagnosis of Wilson disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When excessive zinc ingestion is suspected or when the cause of copper deficiency is unknown, serum zinc and 24-hour urinary zinc excretion levels should be obtained. A significant elevation in these should prompt an investigation for an exogenous source of zinc. However, zinc levels have been reported to be modestly elevated in patients with copper deficiency myeloneuropathy in the absence of known excessive zinc ingestion [",
"    <a class=\"abstract\" href=\"UTD.htm?11/38/11880/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Vitamin B",
"    <sub>",
"     12",
"    </sub>",
"    levels should be checked as vitamin B",
"    <sub>",
"     12",
"    </sub>",
"    deficiency may co-exist with copper deficiency, particularly in cases of prior gastric surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?11/38/11880/abstract/3\">",
"     3",
"    </a>",
"    ]. Measurement of methylmalonic acid and homocysteine, which are elevated in vitamin B",
"    <sub>",
"     12",
"    </sub>",
"    deficiency increases the sensitivity of laboratory testing, and should be performed in high risk patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/0/5130?source=see_link&amp;anchor=H9#H9\">",
"     \"Diagnosis and treatment of vitamin B12 and folate deficiency\", section on 'Cobalamin levels'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/0/5130?source=see_link&amp;anchor=H10#H10\">",
"     \"Diagnosis and treatment of vitamin B12 and folate deficiency\", section on 'Methylmalonic acid and homocysteine'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37836770\">",
"    <span class=\"h2\">",
"     Neuroimaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Imaging of the spinal cord, usually with magnetic resonance imaging (MRI) should be undertaken as part of the initial evaluation in all patients with a myelopathy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/44/5832?source=see_link&amp;anchor=H24#H24\">",
"     \"Anatomy and localization of spinal cord disorders\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    MRI of the spine may be normal [",
"    <a class=\"abstract\" href=\"UTD.htm?11/38/11880/abstract/1-3,11,14,21,33,42,43,66,67\">",
"     1-3,11,14,21,33,42,43,66,67",
"    </a>",
"    ], but many patients have increased T2 signal involving the dorsal column in either the cervical or thoracic cord, or both [",
"    <a class=\"abstract\" href=\"UTD.htm?11/38/11880/abstract/1-3,13,14,17,33,52,56,68,69\">",
"     1-3,13,14,17,33,52,56,68,69",
"    </a>",
"    ]. The signal change may also involve the central cord or lateral column [",
"    <a class=\"abstract\" href=\"UTD.htm?11/38/11880/abstract/68\">",
"     68",
"    </a>",
"    ], and also may extend into the brainstem [",
"    <a class=\"abstract\" href=\"UTD.htm?11/38/11880/abstract/70\">",
"     70",
"    </a>",
"    ]. Contrast enhancement is typically absent. These findings are similar to those reported in patients with vitamin B",
"    <sub>",
"     12",
"    </sub>",
"    deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?11/38/11880/abstract/3\">",
"     3",
"    </a>",
"    ]. After treatment, the signal abnormality may resolve [",
"    <a class=\"abstract\" href=\"UTD.htm?11/38/11880/abstract/3,69\">",
"     3,69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In some patients who have had brain MRI, nonspecific areas of increased signal involving the subcortical white matter have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?11/38/11880/abstract/1,2,32,42\">",
"     1,2,32,42",
"    </a>",
"    ]. In some cases, the subcortical white matter changes appear confluent or cluster in the periventricular region and suggest demyelination [",
"    <a class=\"abstract\" href=\"UTD.htm?11/38/11880/abstract/1,21,33,66,67\">",
"     1,21,33,66,67",
"    </a>",
"    ]. The significance of these changes and their association with copper deficiency is uncertain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37837319\">",
"    <span class=\"h2\">",
"     Electrophysiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nerve conduction studies and other electrophysiological tests are not essential in the diagnosis or evaluation of patients with copper deficiency myeloneuropathy, but may be ordered in the initial evaluation of a patient&rsquo;s complaints.",
"   </p>",
"   <p>",
"    In patients with copper deficiency myeloneuropathy, nerve conduction studies typically reveal an axonal sensorimotor polyneuropathy of varying severity [",
"    <a class=\"abstract\" href=\"UTD.htm?11/38/11880/abstract/1,2,11,13,14,21,26,30,35,42-44,52\">",
"     1,2,11,13,14,21,26,30,35,42-44,52",
"    </a>",
"    ]. Myopathic potentials are rarely seen on electromyography [",
"    <a class=\"abstract\" href=\"UTD.htm?11/38/11880/abstract/2,68\">",
"     2,68",
"    </a>",
"    ]. Rare patients with copper deficiency myeloneuropathy have prominent reduction in motor action potentials along with denervation suggesting lower motor neuron disease [",
"    <a class=\"abstract\" href=\"UTD.htm?11/38/11880/abstract/12,32\">",
"     12,32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Evoked potential studies may provide electrophysiologic evidence of posterior column dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?11/38/11880/abstract/2,14\">",
"     2,14",
"    </a>",
"    ]. In one series of 20 patients with copper deficiency myeloneuropathy, somatosensory evoked potentials were abnormal in all [",
"    <a class=\"abstract\" href=\"UTD.htm?11/38/11880/abstract/1-3,13,14,21,42\">",
"     1-3,13,14,21,42",
"    </a>",
"    ]. Visual evoked potentials may also be prolonged in patients with copper deficiency myeloneuropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?11/38/11880/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37837693\">",
"    <span class=\"h2\">",
"     Cerebrospinal fluid analysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lumbar puncture and cerebrospinal fluid (CSF) analysis are not routinely indicated. When performed, a slight, nonspecific elevation in the CSF protein may be seen in this disorder, but no other abnormalities are generally reported [",
"    <a class=\"abstract\" href=\"UTD.htm?11/38/11880/abstract/1,13,21,32,33,35,37,44\">",
"     1,13,21,32,33,35,37,44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37837827\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;There have been no studies that address the most appropriate dose, duration, route, and form of copper supplementation, and many regimens have been used successfully. Commonly used copper salts include copper gluconate, copper sulphate, and copper chloride. For oral replacement, we typically use elemental copper.",
"   </p>",
"   <p>",
"    Because of the need for long term replacement, parenteral therapy is not preferred and is not required in most patients. Some clinicians have employed initial parenteral administration followed by oral administration [",
"    <a class=\"abstract\" href=\"UTD.htm?11/38/11880/abstract/27\">",
"     27",
"    </a>",
"    ]. Copper supplements may not be adequately absorbed when administered through a jejunostomy tube necessitating parenteral therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?11/38/11880/abstract/71\">",
"     71",
"    </a>",
"    ]. Other situations in which parenteral therapy may be preferred or required include severely depleted patients or significant malabsorption.",
"   </p>",
"   <p>",
"    The standard dose is 2 mg of elemental copper per day. The same dose of elemental copper may be given intravenously; a commonly used regimen is 2 mg of elemental copper administered intravenously (over two hours) daily for five days and periodically thereafter. Subcutaneous and intramuscular supplementation have also been employed. Some patients require higher doses. In our practice, we give 8 mg of elemental copper each day orally for a week, 6 mg for the second week, 4 mg for the third week, and 2 mg thereafter. Periodic assessment of serum copper is essential to determine adequacy of replacement and to decide on the most appropriate long term administration strategy.",
"   </p>",
"   <p>",
"    In those patients in whom excess zinc ingestion is the likely cause, stopping zinc supplementation may suffice and no additional copper supplementation may be required. However, copper supplementation is generally started at least initially in addition to stopping zinc supplementation [",
"    <a class=\"abstract\" href=\"UTD.htm?11/38/11880/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Copper deficiency in gastrointestinal disease may be accompanied by deficiencies of zinc, vitamin B",
"    <sub>",
"     12",
"    </sub>",
"    , vitamin D, vitamin E, and iron [",
"    <a class=\"abstract\" href=\"UTD.htm?11/38/11880/abstract/41\">",
"     41",
"    </a>",
"    ]; these should be supplemented as well when appropriate. However, iron therapy in a patient with anemia of indeterminate cause may decrease copper absorption.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37838016\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Copper supplementation generally prevents further neurologic deterioration, but improvement of neurologic signs and symptoms is variable, often subjective, and limited to sensory symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?11/38/11880/abstract/1-4,21,22,24,30,31,33,35,40,52,56,69\">",
"     1-4,21,22,24,30,31,33,35,40,52,56,69",
"    </a>",
"    ]. Most patients have residual deficits [",
"    <a class=\"abstract\" href=\"UTD.htm?11/38/11880/abstract/2,11,12,17,27\">",
"     2,11,12,17,27",
"    </a>",
"    ]. However, there are reports of substantive improvement in the neurologic deficits, along with abnormalities of nerve conduction studies, evoked potential studies, and MRI signal change with normalization of serum copper [",
"    <a class=\"abstract\" href=\"UTD.htm?11/38/11880/abstract/1-3,42\">",
"     1-3,42",
"    </a>",
"    ]. The duration and severity of symptoms prior to supplementation may influence prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?11/38/11880/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast, response of the hematological parameters (including bone marrow findings) is prompt and often complete [",
"    <a class=\"abstract\" href=\"UTD.htm?11/38/11880/abstract/1,2,4,14,26,31,33,55\">",
"     1,2,4,14,26,31,33,55",
"    </a>",
"    ]. Hematological recovery may be accompanied by reticulocytosis.",
"   </p>",
"   <p>",
"    The natural history of this disorder is not well known, but it is likely that symptoms will continue to progress in the absence of treatment. In one exceptional case of copper deficiency myeloneuropathy related to excessive zinc ingestion that was not diagnosed for several months, neurologic disability progressed to include diaphragmatic weakness and ultimately, fatal aspiration [",
"    <a class=\"abstract\" href=\"UTD.htm?11/38/11880/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37838520\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acquired copper deficiency has been recently recognized to cause a myeloneuropathy in humans.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Gastric surgery is the most common cause of acquired copper deficiency. Other causes include excessive zinc ingestion, dietary copper deficiency, malabsorption syndromes, and chelation therapy in Wilson disease. (See",
"      <a class=\"local\" href=\"#H37833569\">",
"       'Causes of acquired copper deficiency'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most common neurologic manifestation of acquired copper deficiency is that of a myeloneuropathy. Patients typically present with a subacute onset of a gait disturbance. (See",
"      <a class=\"local\" href=\"#H37834722\">",
"       'Neurological'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The hematological hallmark of copper deficiency is anemia and leukopenia; these are present in most, but not all patients with associated neurologic deficits. (See",
"      <a class=\"local\" href=\"#H37834729\">",
"       'Hematological'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The subacute combined degeneration resulting from vitamin B",
"      <sub>",
"       12",
"      </sub>",
"      deficiency has a very similar neurologic presentation and may be comorbid with copper deficiency myeloneuropathy. Other causes of a dorsal spinal cord syndrome should be considered in the differential diagnosis. (See",
"      <a class=\"local\" href=\"#H37835686\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of copper deficiency myeloneuropathy is made in a patient with the characteristic clinical syndrome and laboratory indicators of copper deficiency. (See",
"      <a class=\"local\" href=\"#H37836419\">",
"       'Diagnosis and evaluation'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Testing in patients with this clinical syndrome should include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Magnetic resonance imaging of the spine",
"     </li>",
"     <li>",
"      Serum copper and ceruloplasmin levels",
"     </li>",
"     <li>",
"      Vitamin B",
"      <sub>",
"       12",
"      </sub>",
"      levels along with methylmalonic acid and homocysteine levels in patients with a history of gastric surgery",
"     </li>",
"     <li>",
"      Zinc levels when excessive zinc ingestion is suspected or when the cause of copper deficiency is unknown",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Many different regimens of copper replacement have been used with success. (See",
"      <a class=\"local\" href=\"#H37837827\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For most patients with copper deficiency myeloneuropathy, we use 8 mg of elemental copper each day orally for a week, 6 mg for the second week, 4 mg for the third week, and 2 mg thereafter",
"     </li>",
"     <li>",
"      Parenteral administration may be required in some patients",
"     </li>",
"     <li>",
"      Periodic assessment of serum copper is essential to determine adequacy of replacement and to decide on the most appropriate long term administration strategy",
"     </li>",
"     <li>",
"      Zinc supplementation should be stopped",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Copper supplementation generally prevents further neurologic deterioration, but improvement of neurologic signs and symptoms is variable, and most patients have some residual deficits. (See",
"      <a class=\"local\" href=\"#H37838016\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11880/abstract/1\">",
"      Kumar N, Gross JB Jr, Ahlskog JE. Copper deficiency myelopathy produces a clinical picture like subacute combined degeneration. Neurology 2004; 63:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11880/abstract/2\">",
"      Kumar N. Copper deficiency myelopathy (human swayback). Mayo Clin Proc 2006; 81:1371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11880/abstract/3\">",
"      Kumar N, Ahlskog JE, Klein CJ, Port JD. Imaging features of copper deficiency myelopathy: a study of 25 cases. Neuroradiology 2006; 48:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11880/abstract/4\">",
"      Jaiser SR, Winston GP. Copper deficiency myelopathy. J Neurol 2010; 257:869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11880/abstract/5\">",
"      Williams DM. Copper deficiency in humans. Semin Hematol 1983; 20:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11880/abstract/6\">",
"      Linder MC, Hazegh-Azam M. Copper biochemistry and molecular biology. Am J Clin Nutr 1996; 63:797S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11880/abstract/7\">",
"      Shike M. Copper in parenteral nutrition. Gastroenterology 2009; 137:S13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11880/abstract/8\">",
"      Zatta P, Frank A. Copper deficiency and neurological disorders in man and animals. Brain Res Rev 2007; 54:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11880/abstract/9\">",
"      Mercer JF, Llanos RM. Molecular and cellular aspects of copper transport in developing mammals. J Nutr 2003; 133:1481S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11880/abstract/10\">",
"      Babich PS, Tsymbalenko NV, Klotchenko SA, et al. Effect of a deficiency of ceruloplasmin copper in blood plasma on copper metabolism in the brain. Bull Exp Biol Med 2009; 148:592.",
"     </a>",
"    </li>",
"    <li>",
"     Everett, CM, Matharu, M, Gawler, J. Neuropathy progressing to myeloneuropathy 20 years after partial gastrectomy. Neurology 2006; 66:1451.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11880/abstract/12\">",
"      Weihl CC, Lopate G. Motor neuron disease associated with copper deficiency. Muscle Nerve 2006; 34:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11880/abstract/13\">",
"      Zara G, Grassivaro F, Brocadello F, et al. Case of sensory ataxic ganglionopathy-myelopathy in copper deficiency. J Neurol Sci 2009; 277:184.",
"     </a>",
"    </li>",
"    <li>",
"     Goodman, BP, Bosch, EP, Ross, MA, et al. Clinical and Electrodiagnostic Findings in Copper Deficiency Myeloneuropathy. J Neurol Neurosurg Psychiatry 2009:524.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11880/abstract/15\">",
"      Afrin LB. Fatal copper deficiency from excessive use of zinc-based denture adhesive. Am J Med Sci 2010; 340:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11880/abstract/16\">",
"      Danks DM. Copper deficiency in humans. Annu Rev Nutr 1988; 8:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11880/abstract/17\">",
"      Schleper B, Stuerenburg HJ. Copper deficiency-associated myelopathy in a 46-year-old woman. J Neurol 2001; 248:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11880/abstract/18\">",
"      Kumar N, McEvoy KM, Ahlskog JE. Myelopathy due to copper deficiency following gastrointestinal surgery. Arch Neurol 2003; 60:1782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11880/abstract/19\">",
"      Kumar N, Ahlskog JE, Gross JB Jr. Acquired hypocupremia after gastric surgery. Clin Gastroenterol Hepatol 2004; 2:1074.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11880/abstract/20\">",
"      Juhasz-Pocsine K, Rudnicki SA, Archer RL, Harik SI. Neurologic complications of gastric bypass surgery for morbid obesity. Neurology 2007; 68:1843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11880/abstract/21\">",
"      Spinazzi M, De Lazzari F, Tavolato B, et al. Myelo-optico-neuropathy in copper deficiency occurring after partial gastrectomy. Do small bowel bacterial overgrowth syndrome and occult zinc ingestion tip the balance? J Neurol 2007; 254:1012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11880/abstract/22\">",
"      Winston GP, Jaiser SR. Copper deficiency: an unusual case of myelopathy with neuropathy. Ann Clin Biochem 2008; 45:616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11880/abstract/23\">",
"      Prodan CI, Bottomley SS, Vincent AS, et al. Copper deficiency after gastric surgery: a reason for caution. Am J Med Sci 2009; 337:256.",
"     </a>",
"    </li>",
"    <li>",
"     Griffith, DP, Liff, DA, Ziegler, TR, et al. Acquired copper deficiency: a potentially serious and preventable complication following gastric bypass surgery. Obesity 2009; 17:827.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11880/abstract/25\">",
"      Gregg XT, Reddy V, Prchal JT. Copper deficiency masquerading as myelodysplastic syndrome. Blood 2002; 100:1493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11880/abstract/26\">",
"      Huff JD, Keung YK, Thakuri M, et al. Copper deficiency causes reversible myelodysplasia. Am J Hematol 2007; 82:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11880/abstract/27\">",
"      Naismith RT, Shepherd JB, Weihl CC, et al. Acute and bilateral blindness due to optic neuropathy associated with copper deficiency. Arch Neurol 2009; 66:1025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11880/abstract/28\">",
"      Thackeray EW, Sanderson SO, Fox JC, Kumar N. Hepatic iron overload or cirrhosis may occur in acquired copper deficiency and is likely mediated by hypoceruloplasminemia. J Clin Gastroenterol 2011; 45:153.",
"     </a>",
"    </li>",
"    <li>",
"     Halfdanarson, T, Kumar, N, Li, C-Y, et al. Hematological manifestations of copper deficiency. European journal of Hematology 2008; 80(6):523.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11880/abstract/30\">",
"      Kumar N, Gross JB Jr, Ahlskog JE. Myelopathy due to copper deficiency. Neurology 2003; 61:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11880/abstract/31\">",
"      Willis MS, Monaghan SA, Miller ML, et al. Zinc-induced copper deficiency: a report of three cases initially recognized on bone marrow examination. Am J Clin Pathol 2005; 123:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11880/abstract/32\">",
"      Nations SP, Boyer PJ, Love LA, et al. Denture cream: an unusual source of excess zinc, leading to hypocupremia and neurologic disease. Neurology 2008; 71:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11880/abstract/33\">",
"      Hedera P, Peltier A, Fink JK, et al. Myelopolyneuropathy and pancytopenia due to copper deficiency and high zinc levels of unknown origin II. The denture cream is a primary source of excessive zinc. Neurotoxicology 2009; 30:996.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11880/abstract/34\">",
"      Plum LM, Rink L, Haase H. The essential toxin: impact of zinc on human health. Int J Environ Res Public Health 2010; 7:1342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11880/abstract/35\">",
"      Rowin J, Lewis SL. Copper deficiency myeloneuropathy and pancytopenia secondary to overuse of zinc supplementation. J Neurol Neurosurg Psychiatry 2005; 76:750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11880/abstract/36\">",
"      Khaleeli Z, Healy DG, Briddon A, et al. Copper deficiency as a treatable cause of poor balance. BMJ 2010; 340:c508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11880/abstract/37\">",
"      Yaldizli O, Johansson U, Gizewski ER, Maschke M. Copper deficiency myelopathy induced by repetitive parenteral zinc supplementation during chronic hemodialysis. J Neurol 2006; 253:1507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11880/abstract/38\">",
"      Wapnir RA. Copper absorption and bioavailability. Am J Clin Nutr 1998; 67:1054S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11880/abstract/39\">",
"      Fuhrman MP, Herrmann V, Masidonski P, Eby C. Pancytopenia after removal of copper from total parenteral nutrition. JPEN J Parenter Enteral Nutr 2000; 24:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11880/abstract/40\">",
"      Halfdanarson TR, Kumar N, Hogan WJ, Murray JA. Copper deficiency in celiac disease. J Clin Gastroenterol 2009; 43:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11880/abstract/41\">",
"      Henri-Bhargava A, Melmed C, Glikstein R, Schipper HM. Neurologic impairment due to vitamin E and copper deficiencies in celiac disease. Neurology 2008; 71:860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11880/abstract/42\">",
"      Goodman BP, Mistry DH, Pasha SF, Bosch PE. Copper deficiency myeloneuropathy due to occult celiac disease. Neurologist 2009; 15:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11880/abstract/43\">",
"      Kumar N, Low PA. Myeloneuropathy and anemia due to copper malabsorption. J Neurol 2004; 251:747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11880/abstract/44\">",
"      Foubert-Samier A, Kazadi A, Rouanet M, et al. Axonal sensory motor neuropathy in copper-deficient Wilson's disease. Muscle Nerve 2009; 40:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11880/abstract/45\">",
"      da Silva-J&uacute;nior FP, Machado AA, Lucato LT, et al. Copper deficiency myeloneuropathy in a patient with Wilson disease. Neurology 2011; 76:1673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11880/abstract/46\">",
"      Horvath J, Beris P, Giostra E, et al. Zinc-induced copper deficiency in Wilson disease. J Neurol Neurosurg Psychiatry 2010; 81:1410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11880/abstract/47\">",
"      Lang TF, Glynne-Jones R, Blake S, et al. Iatrogenic copper deficiency following information and drugs obtained over the Internet. Ann Clin Biochem 2004; 41:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11880/abstract/48\">",
"      Konagaya M, Matsumoto A, Takase S, et al. Clinical analysis of longstanding subacute myelo-optico-neuropathy: sequelae of clioquinol at 32 years after its ban. J Neurol Sci 2004; 218:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11880/abstract/49\">",
"      Kumar N, Knopman D. SMON, clioquinol, and copper. Postgrad Med J 2005; 81:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11880/abstract/50\">",
"      Schaumburg H, Herskovitz S. Copper deficiency myeloneuropathy: a clue to clioquinol-induced subacute myelo-optic neuropathy? Neurology 2008; 71:622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11880/abstract/51\">",
"      Bach JP, Kumar N, Depboylu C, et al. Copper deficiency associated with severe neurological disorder--a genetic work-up of possible mutations in copper transport proteins. J Neurol Sci 2010; 291:95.",
"     </a>",
"    </li>",
"    <li>",
"     Kelkar, P, Shereen, C, Muley, S. Response to oral supplementation in copper deficiency myeloneuropathy. Journal of Clinical Neuromuscular Disease 2008; 10:1.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11880/abstract/53\">",
"      Harless W, Crowell E, Abraham J. Anemia and neutropenia associated with copper deficiency of unclear etiology. Am J Hematol 2006; 81:546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11880/abstract/54\">",
"      Pineles SL, Wilson CA, Balcer LJ, et al. Combined optic neuropathy and myelopathy secondary to copper deficiency. Surv Ophthalmol 2010; 55:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11880/abstract/55\">",
"      Kumar N, Elliott MA, Hoyer JD, et al. \"Myelodysplasia,\" myeloneuropathy, and copper deficiency. Mayo Clin Proc 2005; 80:943.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11880/abstract/56\">",
"      Greenberg SA, Briemberg HR. A neurological and hematological syndrome associated with zinc excess and copper deficiency. J Neurol 2004; 251:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11880/abstract/57\">",
"      Videt-Gibou D, Belliard S, Bardou-Jacquet E, et al. Iron excess treatable by copper supplementation in acquired aceruloplasminemia: a new form of secondary human iron overload? Blood 2009; 114:2360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11880/abstract/58\">",
"      Prodan CI, Bottomley SS, Vincent AS, et al. Hypocupremia associated with prior vitamin B12 deficiency. Am J Hematol 2007; 82:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11880/abstract/59\">",
"      Diamond AL, Diamond R, Freedman SM, Thomas FP. \"Whippets\"-induced cobalamin deficiency manifesting as cervical myelopathy. J Neuroimaging 2004; 14:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11880/abstract/60\">",
"      Doran M, Rassam SS, Jones LM, Underhill S. Toxicity after intermittent inhalation of nitrous oxide for analgesia. BMJ 2004; 328:1364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11880/abstract/61\">",
"      Ng J, Frith R. Nanging. Lancet 2002; 360:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11880/abstract/62\">",
"      Kumar N. Pearls: myelopathy. Semin Neurol 2010; 30:38.",
"     </a>",
"    </li>",
"    <li>",
"     Turnlund JR. Copper. In: Modern nutrition in health and disease, 10th, Shils ME, Shike M, Ross AC, et al (Eds), Lippincott Williams and Wilkins, Baltimore 2006. p.286.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11880/abstract/64\">",
"      Milne DB. Assessment of copper nutritional status. Clin Chem 1994; 40:1479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11880/abstract/65\">",
"      Kumar N, Butz JA, Burritt MF. Clinical significance of the laboratory determination of low serum copper in adults. Clin Chem Lab Med 2007; 45:1402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11880/abstract/66\">",
"      Prodan CI, Holland NR. CNS demyelination from zinc toxicity? Neurology 2000; 54:1705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11880/abstract/67\">",
"      Prodan CI, Holland NR, Wisdom PJ, et al. CNS demyelination associated with copper deficiency and hyperzincemia. Neurology 2002; 59:1453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11880/abstract/68\">",
"      Ferrara JM, Skeen MB, Edwards NJ, et al. Subacute combined degeneration due to copper deficiency. J Neuroimaging 2007; 17:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11880/abstract/69\">",
"      Goodman BP, Chong BW, Patel AC, et al. Copper deficiency myeloneuropathy resembling B12 deficiency: partial resolution of MR imaging findings with copper supplementation. AJNR Am J Neuroradiol 2006; 27:2112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11880/abstract/70\">",
"      Kumar G, Goyal MK, Lucchese S, Dhand U. Copper deficiency myelopathy can also involve the brain stem. AJNR Am J Neuroradiol 2011; 32:E14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11880/abstract/71\">",
"      Jayakumar S, Micallef-Eynaud PD, Lyon TD, et al. Acquired copper deficiency following prolonged jejunostomy feeds. Ann Clin Biochem 2005; 42:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11880/abstract/72\">",
"      Prodan CI, Rabadi M, Vincent AS, Cowan LD. Copper supplementation improves functional activities of daily living in adults with copper deficiency. J Clin Neuromuscul Dis 2011; 12:122.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16517 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-F9050627AA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_38_11880=[""].join("\n");
var outline_f11_38_11880=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H37838520\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1290238\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H37833037\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H37833129\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H37833569\">",
"      CAUSES OF ACQUIRED COPPER DEFICIENCY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H61087700\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37834722\">",
"      Neurological",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37834729\">",
"      Hematological",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H61087758\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H37835686\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H37836419\">",
"      DIAGNOSIS AND EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37836493\">",
"      Laboratory studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37836770\">",
"      Neuroimaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37837319\">",
"      Electrophysiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37837693\">",
"      Cerebrospinal fluid analysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H37837827\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H37838016\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H37838520\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/44/5832?source=related_link\">",
"      Anatomy and localization of spinal cord disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/18/27944?source=related_link\">",
"      Cervical spondylotic myelopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/0/5130?source=related_link\">",
"      Diagnosis and treatment of vitamin B12 and folate deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/42/32426?source=related_link\">",
"      Disorders affecting the spinal cord",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/32/11786?source=related_link\">",
"      Etiology and clinical manifestations of vitamin B12 and folate deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/61/33753?source=related_link\">",
"      Inhalant abuse in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/19/39226?source=related_link\">",
"      Overview of dietary trace minerals",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/48/14088?source=related_link\">",
"      Tests used in the diagnosis of Wilson disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_38_11881="Desmoid tumors: Systemic therapy";
var content_f11_38_11881=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Desmoid tumors: Systemic therapy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/38/11881/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/38/11881/contributors\">",
"     Vinod Ravi, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/38/11881/contributors\">",
"     Shreyaskumar R Patel, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/38/11881/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/38/11881/contributors\">",
"     Thomas F DeLaney, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/38/11881/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/38/11881/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?11/38/11881/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 22, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Desmoid tumors (also called aggressive fibromatosis, deep musculoaponeurotic fibromatosis, and fibrosarcoma grade I of the desmoid type) are locally aggressive tumors with no known potential for metastasis or dedifferentiation. However, tumor invasion into vital structures",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    organs can result in substantial morbidity and may be fatal, especially in the case of intraabdominal desmoids arising in patients with familial adenomatous polyposis (FAP). Desmoid tumors are responsible for 9 to 11 percent of deaths among patients with FAP. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/11/30906?source=see_link&amp;anchor=H3#H3\">",
"     \"Desmoid tumors: Epidemiology, risk factors, molecular pathogenesis, clinical presentation, diagnosis, and local therapy\", section on 'Gardner's syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because desmoid tumors lack the ability to metastasize, local control using surgery and radiation has traditionally been the mainstay of therapy for these tumors. However, there is a significant risk of local recurrence, even after complete surgical resection. Increasingly, a multidisciplinary approach to management is being used, particularly among patients with an intraabdominal desmoid. Multimodality therapy can result in effective disease control in up to 96 percent of such patients with both FAP-associated and sporadic desmoid tumors, even when the disease occurs at a difficult location such as the intestinal mesentery [",
"    <a class=\"abstract\" href=\"UTD.htm?11/38/11881/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic review will discuss systemic therapy for desmoid tumors. Epidemiology, risk factors, molecular pathogenesis, clinical presentation, and local treatment options for desmoids are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/11/30906?source=see_link\">",
"     \"Desmoid tumors: Epidemiology, risk factors, molecular pathogenesis, clinical presentation, diagnosis, and local therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENERAL ASPECTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Desmoid tumors lack the ability to metastasize, and therefore local control using surgery and radiation has traditionally been the mainstay of therapy for these tumors. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/11/30906?source=see_link&amp;anchor=H17#H17\">",
"     \"Desmoid tumors: Epidemiology, risk factors, molecular pathogenesis, clinical presentation, diagnosis, and local therapy\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are no evidence-based or widely accepted guidelines for management of unresectable desmoids. At our institution [",
"    <a class=\"abstract\" href=\"UTD.htm?11/38/11881/abstract/1\">",
"     1",
"    </a>",
"    ] and others [",
"    <a class=\"abstract\" href=\"UTD.htm?11/38/11881/abstract/2\">",
"     2",
"    </a>",
"    ], systemic therapy is increasingly being integrated into a multidisciplinary approach for selected patients with unresectable or intraabdominal desmoids for which local therapy options may cause unacceptable morbidity. Early and aggressive systemic therapy in well-selected patients has the potential to prevent complications that might adversely affect survival.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Common indications for systemic therapy are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Unresectable desmoids",
"     </li>",
"     <li>",
"      Multiple locoregional recurrences despite adequate local therapy",
"     </li>",
"     <li>",
"      Symptomatic disease for which local therapy options are radical or morbid",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Intraabdominal/mesenteric",
"      </span>",
"      desmoid tumors in patients with FAP",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Management of desmoid tumors in FAP patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with familial adenomatous polyposis (FAP) are a unique group with a high likelihood of developing desmoid tumors. The development of desmoid tumors in patients with FAP was first described by Gardner in 1951 and is now designated Gardner's syndrome (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef54879 \" href=\"UTD.htm?1/23/1392\">",
"     image 1",
"    </a>",
"    ). Between 10 and 20 percent of patients with FAP develop desmoid tumors, and the risk of developing a desmoid in a patient with FAP is 852 times that of the general population. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/11/30906?source=see_link&amp;anchor=H3#H3\">",
"     \"Desmoid tumors: Epidemiology, risk factors, molecular pathogenesis, clinical presentation, diagnosis, and local therapy\", section on 'Gardner's syndrome'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/11/7352?source=see_link\">",
"     \"Gardner syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although extremity desmoids can also occur, most of these patients develop abdominal tumors, one-half of which are intraabdominal. Ninety-five percent of the desmoid tumors that arise in patients with FAP are infiltrative with poorly defined margins and multiple tumor masses that are connected by tumor projections interspersed with mesenteric fat; only 5 percent have localized disease that is characterized as a solitary lesion with well-circumscribed borders [",
"    <a class=\"abstract\" href=\"UTD.htm?11/38/11881/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because of the infiltrative pattern with encasement of the mesenteric vasculature, complete (R0) resection is seldom possible without life-altering loss of intestinal function. In one series, 57 percent of FAP patients undergoing surgery for a desmoid tumor of the intestinal mesentery required resection of multiple intestinal segments (compared to 23 percent of patients with sporadic desmoid tumors), and 38 percent required multiple procedures (compared to 16 percent of patients with sporadic tumors) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/38/11881/abstract/2\">",
"     2",
"    </a>",
"    ]. Furthermore, surgery may provoke the development of desmoid tumors in patients with FAP [",
"    <a class=\"abstract\" href=\"UTD.htm?11/38/11881/abstract/3\">",
"     3",
"    </a>",
"    ]. In one series, the median interval to the development of a desmoid tumor after surgery in FAP patients is 2.3 years [",
"    <a class=\"abstract\" href=\"UTD.htm?11/38/11881/abstract/3\">",
"     3",
"    </a>",
"    ]. Finally, recurrences tend to be more frequent and aggressive with each surgical intervention and some studies suggest a decreased response to systemic therapy after multiple surgical procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?11/38/11881/abstract/4\">",
"     4",
"    </a>",
"    ]. Retrospective evaluation of outcomes in 62 patents with FAP and intraabdominal desmoids tumors showed that conservative management and surgery produced comparable outcomes (10-year rate of progression-free survival [PFS] 49 versus 33 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/38/11881/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These observations have led many clinicians (including our group), the American Society of Colon and Rectal Surgeons, and a joint task force of the American Society of Clinical",
"    <span class=\"nowrap\">",
"     Oncology/Society",
"    </span>",
"    of Surgical Oncology to advocate conservative management rather than initial resection for patients with Gardner's syndrome and intraabdominal desmoid tumors that are large, slow-growing, involve the mesentery, or encase vessels",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    organs [",
"    <a class=\"abstract\" href=\"UTD.htm?11/38/11881/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. We prefer to use non-cytotoxic systemic therapy initially, in the absence of significant symptoms or rapidly progressive disease. However, this is a controversial area, and some clinicians consider that surgery is still a standard approach for potentially resectable intraabdominal tumors in patients with FAP. This topic is addressed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/11/30906?source=see_link&amp;anchor=H958380#H958380\">",
"     \"Desmoid tumors: Epidemiology, risk factors, molecular pathogenesis, clinical presentation, diagnosis, and local therapy\", section on 'Issues specific to intraabdominal desmoids'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Choice of agent",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic therapy may be broadly classified into cytotoxic chemotherapy and less toxic targeted therapies such as hormonal therapy, nonsteroidal anti-inflammatory drugs (NSAIDs), and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    . The choice of agent depends on the urgency of the clinical situation. Aggressive systemic therapeutic options such as combination chemotherapy should be reserved for patients with an impending threat to life or function, while other patients who qualify for systemic therapy should be managed by less toxic approaches such as hormonal therapy, antiinflammatory therapy, or imatinib. An algorithmic approach to treatment based upon an assessment of the urgency of treatment is presented in the figure (",
"    <a class=\"graphic graphic_algorithm graphicRef67503 \" href=\"UTD.htm?0/5/91\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Response evaluation during systemic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Desmoid tumors are typically slow growing. Response to systemic therapy can be slow to manifest and may take six to eight months or more [",
"    <a class=\"abstract\" href=\"UTD.htm?11/38/11881/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. In some situations, the response may be delayed past the point of completion of the treatment regimen [",
"    <a class=\"abstract\" href=\"UTD.htm?11/38/11881/abstract/4\">",
"     4",
"    </a>",
"    ]. Patients who exhibit a delayed response may even experience an initial increase in tumor size, followed by an objective decrease in size [",
"    <a class=\"abstract\" href=\"UTD.htm?11/38/11881/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Duration of therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    At our institution, patients with desmoid tumors who are receiving systemic therapy are imaged every two to three cycles (or every two to three months for continuously dosed agents or weekly treatment regimens). The persistence of disease that is stable or minimally increased in size should not be considered a treatment failure during initial treatment. Symptomatic or functional improvement should be regarded as a reason to continue therapy when changes in the dimensions of the tumor are minimal or absent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     NON-CYTOTOXIC APPROACHES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Hormonal therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A potential role for female hormones in the pathogenesis of desmoid tumors is suggested by the finding that desmoids are more common in females than in males and the occurrence of abdominal wall desmoids during pregnancy and their resolution with the cessation of hormonal influences. These observations prompted investigation of anti-estrogenic therapies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/11/30906?source=see_link&amp;anchor=H2#H2\">",
"     \"Desmoid tumors: Epidemiology, risk factors, molecular pathogenesis, clinical presentation, diagnosis, and local therapy\", section on 'Epidemiology and risk factors'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/11/30906?source=see_link&amp;anchor=H4#H4\">",
"     \"Desmoid tumors: Epidemiology, risk factors, molecular pathogenesis, clinical presentation, diagnosis, and local therapy\", section on 'Pregnancy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/11/30906?source=see_link&amp;anchor=H5#H5\">",
"     \"Desmoid tumors: Epidemiology, risk factors, molecular pathogenesis, clinical presentation, diagnosis, and local therapy\", section on 'Antecedent trauma'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The efficacy of hormone therapy for management of unresectable symptomatic desmoid tumors was first described in 1983 [",
"    <a class=\"abstract\" href=\"UTD.htm?11/38/11881/abstract/10\">",
"     10",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     Tamoxifen",
"    </a>",
"    was used to treat a patient with Gardner's syndrome who had metastatic adenocarcinoma of the colon and multiple large painful desmoid lesions; within a week the patient's pain had disappeared and subsequently the size of the desmoid tumors decreased. Since this case report, there have been several such case reports and small studies that have confirmed the activity of hormone therapy against desmoid tumors.",
"   </p>",
"   <p>",
"    The exact mechanism of action of hormonal agents such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    remains largely unknown. Desmoid tumors are known to express estrogen receptors [",
"    <a class=\"abstract\" href=\"UTD.htm?11/38/11881/abstract/11\">",
"     11",
"    </a>",
"    ], particularly ER-beta [",
"    <a class=\"abstract\" href=\"UTD.htm?11/38/11881/abstract/12\">",
"     12",
"    </a>",
"    ], and this may account for the clinical activity of tamoxifen observed in this disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/2/7210?source=see_link&amp;anchor=H4#H4\">",
"     \"Mechanisms of action of selective estrogen receptor modulators\", section on 'Estrogen receptor beta: a second ER isoform'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Alternatively, it has been postulated that the latency of action of hormonal agents (and other therapies such as radiation or chemotherapy) may be reflective of deprivation of a growth signal or cytokine [",
"    <a class=\"abstract\" href=\"UTD.htm?11/38/11881/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Efficacy of tamoxifen and other SERMs",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     Tamoxifen",
"    </a>",
"    , a selective estrogen receptor modulator (SERM), is the most commonly used agent for the systemic therapy of desmoid tumors. Most of the data on tamoxifen are derived from isolated case reports [",
"    <a class=\"abstract\" href=\"UTD.htm?11/38/11881/abstract/4,14,15\">",
"     4,14,15",
"    </a>",
"    ] and small series [",
"    <a class=\"abstract\" href=\"UTD.htm?11/38/11881/abstract/16\">",
"     16",
"    </a>",
"    ]. In general, objective responses occur in 15 to 20 percent of patients, with an additional 25 to 30 percent achieving symptomatic improvement and disease stabilization; thus, the clinical benefit rate is approximately 50 percent.",
"   </p>",
"   <p>",
"    In one of the largest reports investigating benefit from",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    or another SERM,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/30/30181?source=see_link\">",
"     toremifene",
"    </a>",
"    , clinical benefit (stable disease, and partial or complete responses) was observed in 65 percent of 20 patients with progressive desmoid tumors (",
"    <a class=\"graphic graphic_table graphicRef81891 \" href=\"UTD.htm?27/31/28156\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/38/11881/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a second series, reported at the 2011 meeting of the American Society of Clinical Oncology (ASCO), 6 of 27 patients with sporadic desmoids who were treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/30/30181?source=see_link\">",
"     toremifene",
"    </a>",
"    had a partial response and 19 others had stable disease [",
"    <a class=\"abstract\" href=\"UTD.htm?11/38/11881/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Limited data are also available on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/15/6390?source=see_link\">",
"     raloxifene",
"    </a>",
"    . In one report, 13 patients with FAP and a progressive intraabdominal desmoid tumor received raloxifene (120 mg daily); all 13 responded, eight with a complete response [",
"    <a class=\"abstract\" href=\"UTD.htm?11/38/11881/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Other hormonal therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other therapies that have been used for hormonal manipulation of desmoid tumors include megestrol (one patient treated with 500 mg daily had a partial response that was sustained for 10 months) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/38/11881/abstract/20\">",
"     20",
"    </a>",
"    ], progesterone&nbsp;(",
"    <a class=\"graphic graphic_table graphicRef81891 \" href=\"UTD.htm?27/31/28156\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/38/11881/abstract/21\">",
"     21",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/22/9574?source=see_link\">",
"     goserelin",
"    </a>",
"    (which in combination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    resulted in a partial response for 17 months in one patient) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/38/11881/abstract/22\">",
"     22",
"    </a>",
"    ], and testolactone (an aromatase inhibitor) (",
"    <a class=\"graphic graphic_table graphicRef81891 \" href=\"UTD.htm?27/31/28156\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/38/11881/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Antiinflammatory agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first report of a nonsteroidal antiinflammatory agent (NSAID) producing regression in a desmoid tumor was in 1980, and since then, several small studies have confirmed the efficacy of NSAIDs in desmoid tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?11/38/11881/abstract/8,23-25\">",
"     8,23-25",
"    </a>",
"    ]&nbsp;(",
"    <a class=\"graphic graphic_table graphicRef58255 \" href=\"UTD.htm?37/17/38171\">",
"     table 2",
"    </a>",
"    ). In the largest of these series, 12 of 14 patients (86 percent) treated at Cleveland Clinic with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/17/44312?source=see_link\">",
"     sulindac",
"    </a>",
"    (median dose 300",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    had clinical benefit (an objective response or stable disease) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/38/11881/abstract/8\">",
"     8",
"    </a>",
"    ]. An important point is that these response data come from small subsets of the larger populations reported in these papers and should be therefore interpreted with caution. Durability of response was also not reported in these studies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Combined hormone plus antiinflammatory therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Combinations of NSAIDs with hormonal therapy have been investigated, and the available data suggest a higher response rate than with monotherapy using either NSAIDs or hormonal agents (",
"    <a class=\"graphic graphic_table graphicRef68431 \" href=\"UTD.htm?4/27/4540\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/38/11881/abstract/4,8,23,26,27\">",
"     4,8,23,26,27",
"    </a>",
"    ]. The largest trial that examined this concept separately investigated sporadic (n=8) and FAP associated (n=17) desmoids [",
"    <a class=\"abstract\" href=\"UTD.htm?11/38/11881/abstract/4\">",
"     4",
"    </a>",
"    ]. Patients received",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/17/44312?source=see_link\">",
"     sulindac",
"    </a>",
"    (300 mg daily) combined with either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    (doses ranging from 20 to 120 mg daily) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/15/6390?source=see_link\">",
"     raloxifene",
"    </a>",
"    . Results were as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Eleven patients (65 percent) with FAP-associated desmoid tumors had clinical benefit (stable disease or an objective response). There was a lower rate of response in patients with FAP who had prior surgery for a desmoid tumor than in those who had not undergone surgery, but the number of patients in this subset was small (n=4, with one partial response, and three progressive disease).",
"     </li>",
"     <li>",
"      Of the eight patients with sporadic desmoid tumors, five (63 percent) had stable disease, one (13 percent) had a complete response, and one (13 percent) remained disease free on adjuvant therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/15/6390?source=see_link\">",
"       raloxifene",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/17/44312?source=see_link\">",
"       sulindac",
"      </a>",
"      after surgical resection. There was only one patient with progressive disease as the best response.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, at least 65 percent of patients with FAP-associated desmoids and 75 percent of patients with sporadic desmoid tumors derived some clinical benefit from combination therapy in this study [",
"    <a class=\"abstract\" href=\"UTD.htm?11/38/11881/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Imatinib",
"    </span>",
"    &nbsp;&mdash;&nbsp;Accumulating data supports clinical benefit of the tyrosine kinase (TK) inhibitor",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    (Gleevec&reg;) in patients with desmoid tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?11/38/11881/abstract/28-31\">",
"     28-31",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a large multi-institutional phase II trial of 51 patients (45 evaluable), patients were dosed based on body surface area (BSA), with patients &ge;1.5 m",
"      <sup>",
"       2",
"      </sup>",
"      receiving 300 mg twice daily, patients 1 to 1.49 m",
"      <sup>",
"       2",
"      </sup>",
"      receiving 200 mg twice daily, and those &lt;1 m",
"      <sup>",
"       2",
"      </sup>",
"      receiving 100 mg twice daily [",
"      <a class=\"abstract\" href=\"UTD.htm?11/38/11881/abstract/32\">",
"       32",
"      </a>",
"      ]. Forty-three (84 percent) reached the primary endpoint defining clinical benefit (a complete or partial response within 16 weeks, or stable disease lasting at least 16 weeks). Three patients had an objective partial response. The progression-free survival rate at 3 years was 58 percent, and five patients remained progression-free after 4+ years of treatment.",
"     </li>",
"     <li>",
"      In a smaller multi-institutional trial of 19 patients with aggressive fibromatosis treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      800 mg daily, there were three partial responses (16 percent) and four patients with stable disease lasting at least one year; the overall disease control rate was 37 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?11/38/11881/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Benefit for",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      was also shown in a French Sarcoma Group trial in which 40 patients failing local treatment (and with documented evidence of progressive disease) received imatinib 400 mg per day (increased to 800",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      in the event of progression) [",
"      <a class=\"abstract\" href=\"UTD.htm?11/38/11881/abstract/33\">",
"       33",
"      </a>",
"      ]. Of 35 evaluable patients at three months, there was one complete and three partial responses, 28 had stable disease, and three patients progressed. The non-progression rate at 6, 9, and 12 months were 80, 69, and 67 percent, respectively. Among patients who developed progressive disease while receiving 400 mg daily, dose escalation resulted in stabilization of disease for a median time of 12 months (range 2 to 30 months), but eventually resulted in progression in 8 out of 10 patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The mechanism whereby",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    provides benefit remains unclear as tissue analysis has not uniformly demonstrated activating mutations in receptor tyrosine kinases such as c-kit or platelet-derived growth factor receptor-alpha (PDGFRA) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/38/11881/abstract/30\">",
"     30",
"    </a>",
"    ]. However, at least some data support the presence of PDGFRA and PDGFR-beta (PDGFRB) activation that appears to be sustained by an",
"    <span class=\"nowrap\">",
"     autocrine/paracrine",
"    </span>",
"    loop [",
"    <a class=\"abstract\" href=\"UTD.htm?11/38/11881/abstract/34\">",
"     34",
"    </a>",
"    ]. This provides a potential rationale for the use of tyrosine kinase inhibitors for the systemic treatment of desmoids.",
"   </p>",
"   <p>",
"    Thus,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    appears to be an active agent for the systemic therapy of desmoid tumors. Imatinib should be considered prior to cytotoxic therapy in patients in whom hormonal approaches fail. For most patients imatinib is less toxic than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    -based chemotherapy, and the lower potential response rate with imatinib might be counterbalanced by toxicity concerns when considering the choice of imatinib versus anthracycline-based chemotherapy, especially in younger patients with this diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H319056927\">",
"    <span class=\"h2\">",
"     Sorafenib",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/45/9944?source=see_link\">",
"     Sorafenib",
"    </a>",
"    is a multitargeted TK inhibitor that inhibits the vascular endothelial growth factor (VEGF) receptor TK, among others. Activity against desmoid tumors was suggested in a review of 26 patients who received sorafenib 400 mg daily, 11 as first-line systemic therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?11/38/11881/abstract/35\">",
"     35",
"    </a>",
"    ]. Twenty-three patients had documented radiographic disease progression prior to enrollment and two had achieved maximal benefit from chemotherapy. There were six partial responders (25 percent), and 17 had stable disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Interferon",
"    </span>",
"    &nbsp;&mdash;&nbsp;No large studies have investigated the role of IFN-a in desmoid tumors, and its role in therapy remains unclear because of the absence of efficacy data and the availability of other agents that have a more favorable adverse effect profile.",
"   </p>",
"   <p>",
"    In the largest series, 13 patients were treated with IFN-a (3.5 million international units administered three times a week), alone or in combination with tretinoin (30 mg orally daily); 9 of 13 patients were treated adjuvantly and 4 of 13 patients had therapy to stabilize progressive disease [",
"    <a class=\"abstract\" href=\"UTD.htm?11/38/11881/abstract/36\">",
"     36",
"    </a>",
"    ]. All four patients with progressive disease at treatment initiation experienced disease stabilization for periods ranging from 31 to 37 months; three had received a combination of IFN-a and tretinoin. Among the nine patients who were treated in the adjuvant setting, two developed recurrent disease.",
"   </p>",
"   <p>",
"    Other single patient case reports have documented responses to IFN-a that range from complete response to stable disease [",
"    <a class=\"abstract\" href=\"UTD.htm?11/38/11881/abstract/37-40\">",
"     37-40",
"    </a>",
"    ]. These data need to be interpreted with caution, as the number of cases is small. Also, newer results suggesting that IFN type I signaling upregulates the number of precursor cells thereby contributing to tumor formation and maintenance have raised questions about the therapeutic role of IFN-alfa in this disease [",
"    <a class=\"abstract\" href=\"UTD.htm?11/38/11881/abstract/41\">",
"     41",
"    </a>",
"    ]. We do not use IFN to treat desmoid tumors at our institution.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     CYTOTOXIC CHEMOTHERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;As a general rule, benign and slow-growing neoplastic processes are generally regarded as unresponsive to cytotoxic chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?11/38/11881/abstract/13\">",
"     13",
"    </a>",
"    ]. However, this rule does not apply to desmoid tumors; chemotherapy is effective against these slowly growing nonmetastasizing tumors. Chemotherapy is primarily used in the following clinical situations in which the benefits of therapy clearly outweigh the risks:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Unresectable tumor that meets ALL the following criteria: slowly progressive but symptomatic disease, failed prior radiation therapy, failed prior systemic non-cytotoxic therapy (hormonal",
"      <span class=\"nowrap\">",
"       therapy/NSAIDS)",
"      </span>",
"     </li>",
"     <li>",
"      Rapidly progressive, unresectable disease",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Given that several less toxic options are available for upfront use, cytotoxic chemotherapy has typically been used late in the course of treatment for desmoid tumors, after all other therapeutic options have been exhausted. Despite being used predominantly as a \"last resort\" treatment in patients with advanced disease, cytotoxic chemotherapy has been associated with good response rates (ranging from 17 to 100 percent in various studies, median 50 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/38/11881/abstract/14\">",
"     14",
"    </a>",
"    ]. Patients receiving chemotherapy can derive functional and symptomatic benefits, such as a decrease in pain, as early as four weeks into treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?11/38/11881/abstract/13,42\">",
"     13,42",
"    </a>",
"    ], and such symptomatic improvement may long precede any decrease in tumor size.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Monotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The published experience with monotherapy for desmoid tumors is limited and summarized in the table (",
"    <a class=\"graphic graphic_table graphicRef62085 \" href=\"UTD.htm?34/36/35404\">",
"     table 4",
"    </a>",
"    ). Anthracyclines are the most commonly reported agents used, including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?11/38/11881/abstract/43,44\">",
"     43,44",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/13/10458?source=see_link\">",
"     liposomal doxorubicin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?11/38/11881/abstract/2,44-47\">",
"     2,44-47",
"    </a>",
"    ] and esorubicin (an older agent that is not available in the United States) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/38/11881/abstract/48\">",
"     48",
"    </a>",
"    ]. Monotherapy appears to be fairly effective in controlling desmoid tumors, with response rates that exceed 75 percent in some series [",
"    <a class=\"abstract\" href=\"UTD.htm?11/38/11881/abstract/2,46\">",
"     2,46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Combination chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In well-selected patients with rapidly progressive desmoid tumors for which other local and systemic therapy options have failed, combination chemotherapy can effectively achieve disease control.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     Doxorubicin",
"    </a>",
"    -based combinations are most often used, and associated response rates range from 40 to 100 percent. Non-doxorubicin based regimens use either combinations of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/3/4152?source=see_link\">",
"     vinblastine",
"    </a>",
"    (VBL) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    (MTX) on a weekly schedule, or other combinations of vinca alkaloids plus an alkylating agent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Doxorubicin-containing combinations",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     Doxorubicin",
"    </a>",
"    -containing regimens have a higher response rate than monotherapy or non-anthracycline-containing regimens against desmoid tumors but also more toxic [",
"    <a class=\"abstract\" href=\"UTD.htm?11/38/11881/abstract/49-55\">",
"     49-55",
"    </a>",
"    ]. Doxorubicin plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/49/4887?source=see_link\">",
"     dacarbazine",
"    </a>",
"    (DTIC) represents the most commonly used cytotoxic chemotherapy combination for desmoid tumors at our institution. Phase II trials with this combination are lacking, but results from the largest retrospective studies are outlined in the table (",
"    <a class=\"graphic graphic_table graphicRef71589 \" href=\"UTD.htm?28/59/29628\">",
"     table 5",
"    </a>",
"    ). Almost all patients in these studies have derived clinical benefit, and most have responded with an objective complete or partial response, which has been sustained. In some cases, the clinical \"response\" has been sufficient to allow later surgical resection.",
"   </p>",
"   <p>",
"    In the largest published series, 11 patients received",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    (60 to 90",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/49/4887?source=see_link\">",
"     dacarbazine",
"    </a>",
"    (750 to 1000",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    infused continuously over a 72-hour period) for a median of five cycles [",
"    <a class=\"abstract\" href=\"UTD.htm?11/38/11881/abstract/50\">",
"     50",
"    </a>",
"    ]. Six of nine evaluable patients had an objective response (two complete, four partial). One complete responder died, two were lost to follow-up, and the remainder remained alive and progression-free with follow-up ranging from 28 to 235 months post diagnosis. Cardiac toxicity, myelosuppression, mucositis, and nausea are the most common side effects experienced with this regimen. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Duration of therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Methotrexate plus a vinca alkaloid",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several studies, including two phase II trials (one in adults and one in children), have demonstrated the activity of this combination with clinical benefit rates that range from 70 to 100 percent (",
"    <a class=\"graphic graphic_table graphicRef81000 \" href=\"UTD.htm?25/24/25997\">",
"     table 6",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/38/11881/abstract/9,42,47,56-60\">",
"     9,42,47,56-60",
"    </a>",
"    ]. The two prospective phase II trials are described in detail:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the adult phase II trial, MTX was administered at a dose of 30",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      and VBL was administered at a dose of 6",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      (total dose rounded to 50 mg of MTX and 10 mg of VBL); both were given IV weekly for a median interval of one year [",
"      <a class=\"abstract\" href=\"UTD.htm?11/38/11881/abstract/56\">",
"       56",
"      </a>",
"      ]. Of the 30 patients, 21 (70 percent) had durable clinical benefit (including stable disease, partial and complete responses that did not progress on or off chemotherapy, with a median follow-up of 62 months). Nine patients progressed at a median 10 months after stopping therapy. Neutropenia was the predominant toxicity.",
"     </li>",
"     <li>",
"      In the pediatric phase II trial, a lower rate of durable responses (30 percent) was seen, and they lasted a median of 43 months [",
"      <a class=\"abstract\" href=\"UTD.htm?11/38/11881/abstract/57\">",
"       57",
"      </a>",
"      ]. In this trial, 38 percent of patients progressed while receiving chemotherapy (compared to none in the adult trial), the majority of whom progressed at or before the first MRI scheduled at 12 weeks. Responses to treatment for desmoid tumors may take several months to evolve, and this slow response time may be responsible for the greater proportion of patients with \"early progression\" in the pediatric trial than in the adult trial.",
"      <br/>",
"      <br/>",
"      The median duration of therapy for all patients was 40 weeks (range 10 to 52). The best response was a complete response in one patient, partial response in four (objective response rate 19 percent), minor response in three, and stable disease in 10. Treatment was complicated by neutropenia in 22 patients, which was grade 4 in five. In contrast, only two patients developed grade 1 sensory neuropathy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For patients who develop neurotoxicity during therapy, a combination of MTX and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/59/953?source=see_link\">",
"     vinorelbine",
"    </a>",
"    may be considered. In one small report, vinorelbine, used at a dose of 20",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    weekly, in combination with MTX (50 mg weekly), induced either a PR or CR in 60 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?11/38/11881/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     DURATION OF THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;For both cytotoxic and non-cytotoxic agents, the duration of therapy should be based upon toxicity and response. As noted above, responses are typically delayed in desmoid tumors, and this complicates the use of radiographic imaging during therapy to guide the optimal duration of therapy. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Response evaluation during systemic therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    There are no data addressing the optimal duration of treatment, and there is no consensus on this issue. Although non-cytotoxic agents are often continued indefinitely in the absence of toxicity, treatment breaks can be incorporated into the treatment plan, particularly if there are side effects. For cytotoxic therapy, dose limiting toxicities tend to develop over time and the duration of therapy will depend on the regimen:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"       Doxorubicin",
"      </a>",
"      -based regimens are limited by cumulative cardiac toxicity and myelosuppression. In responding patients, we limit treatment to six to eight cycles of therapy with close monitoring.",
"     </li>",
"     <li>",
"      The weekly",
"      <span class=\"nowrap\">",
"       <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"        methotrexate",
"       </a>",
"       /",
"       <a class=\"drug drug_general\" href=\"UTD.htm?4/3/4152?source=see_link\">",
"        vinblastine",
"       </a>",
"      </span>",
"      combination is less toxic and typically administered for one year.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     TREATMENT OF RECURRENT/RELAPSED DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who develop a tumor recurrence or disease progression after an effective therapy has been discontinued can be retreated with the same or an alternative regimen depending on several factors such as the progression-free interval, the toxicity associated with the previous regimen, and the patient's candidacy for surgical",
"    <span class=\"nowrap\">",
"     resection/radiation",
"    </span>",
"    therapy. Retreatment with the same systemic therapy regimen may produce responses that are similar to the original response [",
"    <a class=\"abstract\" href=\"UTD.htm?11/38/11881/abstract/9\">",
"     9",
"    </a>",
"    ], but treatment-related toxicity and alternative strategies must be considered in the decision making.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5th to 6th grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10th to 12th grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?16/26/16802?source=see_link\">",
"       \"Patient information: Soft tissue sarcoma (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Desmoid tumors (also called aggressive fibromatosis) are benign, slowly growing fibroblastic neoplasms with no metastatic potential but a propensity for local recurrence, even after complete surgical resection. Despite being histologically benign, they are locally infiltrative and can cause death through invasion and destruction of adjacent vital structures and organs. (See",
"    <a class=\"local\" href=\"#H1\">",
"     'Introduction'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Indications for systemic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because desmoid tumors lack metastatic potential, they are primarily managed by local therapies such as surgery and radiation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/11/30906?source=see_link&amp;anchor=H17#H17\">",
"     \"Desmoid tumors: Epidemiology, risk factors, molecular pathogenesis, clinical presentation, diagnosis, and local therapy\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A multidisciplinary approach, with the incorporation of systemic therapy, is recommended for patients who have unresectable tumors, or a tumor for which resection is not possible without unacceptable morbidity (eg, an",
"    <span class=\"nowrap\">",
"     intraabdominal/mesenteric",
"    </span>",
"    tumor in a patient with FAP). Systemic therapy is also indicated for patients with multiple locoregional recurrences despite adequate local therapy. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Indications'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Choice of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic therapy may be broadly classified into cytotoxic chemotherapy and less toxic therapies such as hormonal therapy, nonsteroidal anti-inflammatory drugs (NSAIDs), and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    . The choice of therapy depends on the urgency of the clinical situation. Our general approach to systemic therapy is outlined in the figure (",
"    <a class=\"graphic graphic_algorithm graphicRef67503 \" href=\"UTD.htm?0/5/91\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For most patients who require systemic therapy who do not have an impending threat to life or function, we suggest noncytotoxic therapy rather than cytotoxic chemotherapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The choice of hormonal therapy or an NSAID should be based upon physician and patient preference. We generally start with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      20 mg daily.",
"      <br/>",
"      <br/>",
"      Responses in patients treated with non-cytotoxic agents can take months to manifest, and the therapy should be continued until progression, especially when there is symptomatic improvement. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Duration of therapy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'Response evaluation during systemic therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      rather than cytotoxic therapy in patients in whom hormonal approaches fail, as long as there is no urgency to induce a response (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Another option in this setting is an NSAID alone or the combined use of hormone therapy plus an NSAID. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Imatinib'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H12\">",
"       'Combined hormone plus antiinflammatory therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In clinical situations where there is an urgency to induce a response, we suggest cytotoxic chemotherapy rather than non-cytotoxic therapies (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The choice of the chemotherapy regimen should be based upon the clinical situation and the ability of the patient to tolerate the adverse effects associated with each regimen. Although response rates are higher with combination",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      -based chemotherapy (eg, doxorubicin plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/49/4887?source=see_link\">",
"       dacarbazine",
"      </a>",
"      ) as compared to anthracycline monotherapy or weekly low-dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      plus a vinca alkaloid, toxicity is also worse, and it is not clear that progression-free survival is better. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Combination chemotherapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11881/abstract/1\">",
"      Lev D, Kotilingam D, Wei C, et al. Optimizing treatment of desmoid tumors. J Clin Oncol 2007; 25:1785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11881/abstract/2\">",
"      Bertagnolli MM, Morgan JA, Fletcher CD, et al. Multimodality treatment of mesenteric desmoid tumours. Eur J Cancer 2008; 44:2404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11881/abstract/3\">",
"      J&auml;rvinen HJ. Desmoid disease as a part of familial adenomatous polyposis coli. Acta Chir Scand 1987; 153:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11881/abstract/4\">",
"      Hansmann A, Adolph C, Vogel T, et al. High-dose tamoxifen and sulindac as first-line treatment for desmoid tumors. Cancer 2004; 100:612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11881/abstract/5\">",
"      Nieuwenhuis MH, Mathus-Vliegen EM, Baeten CG, et al. Evaluation of management of desmoid tumours associated with familial adenomatous polyposis in Dutch patients. Br J Cancer 2011; 104:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11881/abstract/6\">",
"      Guillem JG, Wood WC, Moley JF, et al. ASCO/SSO review of current role of risk-reducing surgery in common hereditary cancer syndromes. J Clin Oncol 2006; 24:4642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11881/abstract/7\">",
"      Church J, Simmang C, Standards Task Force, et al. Practice parameters for the treatment of patients with dominantly inherited colorectal cancer (familial adenomatous polyposis and hereditary nonpolyposis colorectal cancer). Dis Colon Rectum 2003; 46:1001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11881/abstract/8\">",
"      Tsukada K, Church JM, Jagelman DG, et al. Noncytotoxic drug therapy for intra-abdominal desmoid tumor in patients with familial adenomatous polyposis. Dis Colon Rectum 1992; 35:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11881/abstract/9\">",
"      Reich S, Overberg-Schmidt US, B&uuml;hrer C, Henze G. Low-dose chemotherapy with vinblastine and methotrexate in childhood desmoid tumors. J Clin Oncol 1999; 17:1086.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11881/abstract/10\">",
"      Kinzbrunner B, Ritter S, Domingo J, Rosenthal CJ. Remission of rapidly growing desmoid tumors after tamoxifen therapy. Cancer 1983; 52:2201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11881/abstract/11\">",
"      Lim CL, Walker MJ, Mehta RR, Das Gupta TK. Estrogen and antiestrogen binding sites in desmoid tumors. Eur J Cancer Clin Oncol 1986; 22:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11881/abstract/12\">",
"      Deyrup AT, Tretiakova M, Montag AG. Estrogen receptor-beta expression in extraabdominal fibromatoses: an analysis of 40 cases. Cancer 2006; 106:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11881/abstract/13\">",
"      Patel SR, Benjamin RS. Desmoid tumors respond to chemotherapy: defying the dogma in oncology. J Clin Oncol 2006; 24:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11881/abstract/14\">",
"      Janinis J, Patriki M, Vini L, et al. The pharmacological treatment of aggressive fibromatosis: a systematic review. Ann Oncol 2003; 14:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11881/abstract/15\">",
"      Sportiello DJ, Hoogerland DL. A recurrent pelvic desmoid tumor successfully treated with tamoxifen. Cancer 1991; 67:1443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11881/abstract/16\">",
"      Rock MG, Pritchard DJ, Reiman HM, et al. Extra-abdominal desmoid tumors. J Bone Joint Surg Am 1984; 66:1369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11881/abstract/17\">",
"      Brooks MD, Ebbs SR, Colletta AA, Baum M. Desmoid tumours treated with triphenylethylenes. Eur J Cancer 1992; 28A:1014.",
"     </a>",
"    </li>",
"    <li>",
"     Fiore M, et al. Activity of toremifene in sporadic desmoid-type fibromatosis (abstract 10033). J Clin Oncol 2011; 29:613s. Abstractg available online at file://www.asco.org/ASCOv2/Meetings/Abstracts?&amp;vmview=abst_detail_view&amp;confID=102&amp;abstractID=75888 (Accessed on June 30, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11881/abstract/19\">",
"      Tonelli F, Ficari F, Valanzano R, Brandi ML. Treatment of desmoids and mesenteric fibromatosis in familial adenomatous polyposis with raloxifene. Tumori 2003; 89:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11881/abstract/20\">",
"      Wilcken N, Tattersall MH. Endocrine therapy for desmoid tumors. Cancer 1991; 68:1384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11881/abstract/21\">",
"      Lanari A. Effect of progesterone on desmoid tumors (aggressive fibromatosis). N Engl J Med 1983; 309:1523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11881/abstract/22\">",
"      Bauernhofer T, St&ouml;ger H, Schmid M, et al. Sequential treatment of recurrent mesenteric desmoid tumor. Cancer 1996; 77:1061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11881/abstract/23\">",
"      Waddell WR, Kirsch WM. Testolactone, sulindac, warfarin, and vitamin K1 for unresectable desmoid tumors. Am J Surg 1991; 161:416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11881/abstract/24\">",
"      Klein WA, Miller HH, Anderson M, DeCosse JJ. The use of indomethacin, sulindac, and tamoxifen for the treatment of desmoid tumors associated with familial polyposis. Cancer 1987; 60:2863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11881/abstract/25\">",
"      Dominguez-Malagon HR, Alfeiran-Ruiz A, Chavarria-Xicotencatl P, Duran-Hernandez MS. Clinical and cellular effects of colchicine in fibromatosis. Cancer 1992; 69:2478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11881/abstract/26\">",
"      Izes JK, Zinman LN, Larsen CR. Regression of large pelvic desmoid tumor by tamoxifen and sulindac. Urology 1996; 47:756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11881/abstract/27\">",
"      Lackner H, Urban C, Kerbl R, et al. Noncytotoxic drug therapy in children with unresectable desmoid tumors. Cancer 1997; 80:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11881/abstract/28\">",
"      Mace J, Sybil Biermann J, Sondak V, et al. Response of extraabdominal desmoid tumors to therapy with imatinib mesylate. Cancer 2002; 95:2373.",
"     </a>",
"    </li>",
"    <li>",
"     Chugh R, Maki RG, Thomas DG, et al. A SARC phase II multicenter trial of imatinib mesylate (IM) in patients with aggressive fibromatosis (abstract). J Clin Oncol 2006; 24:523s. (Abstract available online at www.asco.org/portal/site/ASCO/menuitem.34d60f5624ba07fd506fe310ee37a01d/?vgnextoid=76f8201eb61a7010VgnVCM100000ed730ad1RCRD, accessed July 20, 2006).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11881/abstract/30\">",
"      Heinrich MC, McArthur GA, Demetri GD, et al. Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor). J Clin Oncol 2006; 24:1195.",
"     </a>",
"    </li>",
"    <li>",
"     Dufresne A, Penel N, Salas S, et al. Updated outcome with long-term follow-up of imatinib for the treatment of progressive or recurrenct aggressive fibromatosis (Desmoid tumor): a FNCLCC French Sarcoma Group phase II trial (abstract #10518). J Clin Oncol 2009; 27:540s. (Abstract available online at www.asco.org/ASCOv2/Meetings/Abstracts?&amp;vmview=abst_detail_view&amp;confID=65&amp;abstractID=32664, accessed June 29, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11881/abstract/32\">",
"      Chugh R, Wathen JK, Patel SR, et al. Efficacy of imatinib in aggressive fibromatosis: Results of a phase II multicenter Sarcoma Alliance for Research through Collaboration (SARC) trial. Clin Cancer Res 2010; 16:4884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11881/abstract/33\">",
"      Penel N, Le Cesne A, Bui BN, et al. Imatinib for progressive and recurrent aggressive fibromatosis (desmoid tumors): an FNCLCC/French Sarcoma Group phase II trial with a long-term follow-up. Ann Oncol 2011; 22:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11881/abstract/34\">",
"      Signoroni S, Frattini M, Negri T, et al. Cyclooxygenase-2 and platelet-derived growth factor receptors as potential targets in treating aggressive fibromatosis. Clin Cancer Res 2007; 13:5034.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11881/abstract/35\">",
"      Gounder MM, Lefkowitz RA, Keohan ML, et al. Activity of Sorafenib against desmoid tumor/deep fibromatosis. Clin Cancer Res 2011; 17:4082.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11881/abstract/36\">",
"      Leithner A, Schnack B, Katterschafka T, et al. Treatment of extra-abdominal desmoid tumors with interferon-alpha with or without tretinoin. J Surg Oncol 2000; 73:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11881/abstract/37\">",
"      Raguse JD, Gath HJ, Oettle H, Bier J. Interferon-induced remission of rapidly growing aggressive fibromatosis in the temporal fossa. Int J Oral Maxillofac Surg 2004; 33:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11881/abstract/38\">",
"      Fernberg JO, Brosj&ouml; O, Larsson O, et al. Interferon-induced remission in aggressive fibromatosis of the lower extremity. Acta Oncol 1999; 38:971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11881/abstract/39\">",
"      Acker JC, Bossen EH, Halperin EC. The management of desmoid tumors. Int J Radiat Oncol Biol Phys 1993; 26:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11881/abstract/40\">",
"      Geurs F, Kok TC. Regression of a great abdominal desmoid tumor by interferon alpha. J Clin Gastroenterol 1993; 16:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11881/abstract/41\">",
"      Tjandra SS, Hsu C, Goh YI, et al. IFN-{beta} signaling positively regulates tumorigenesis in aggressive fibromatosis, potentially by modulating mesenchymal progenitors. Cancer Res 2007; 67:7124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11881/abstract/42\">",
"      Weiss AJ, Lackman RD. Low-dose chemotherapy of desmoid tumors. Cancer 1989; 64:1192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11881/abstract/43\">",
"      Seiter K, Kemeny N. Successful treatment of a desmoid tumor with doxorubicin. Cancer 1993; 71:2242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11881/abstract/44\">",
"      de Camargo VP, Keohan ML, D'Adamo DR, et al. Clinical outcomes of systemic therapy for patients with deep fibromatosis (desmoid tumor). Cancer 2010; 116:2258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11881/abstract/45\">",
"      Wehl G, Rossler J, Otten JE, et al. Response of progressive fibromatosis to therapy with liposomal doxorubicin. Onkologie 2004; 27:552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11881/abstract/46\">",
"      Constantinidou A, Jones RL, Scurr M, et al. Pegylated liposomal doxorubicin, an effective, well-tolerated treatment for refractory aggressive fibromatosis. Eur J Cancer 2009; 45:2930.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11881/abstract/47\">",
"      Constantinidou A, Jones RL, Scurr M, et al. Advanced aggressive fibromatosis: Effective palliation with chemotherapy. Acta Oncol 2011; 50:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11881/abstract/48\">",
"      Giaccone G, Donadio M, Calciati A. Phase II study of esorubicin in the treatment of patients with advanced sarcoma. Oncology 1989; 46:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11881/abstract/49\">",
"      Lynch HT, Fitzgibbons R Jr, Chong S, et al. Use of doxorubicin and dacarbazine for the management of unresectable intra-abdominal desmoid tumors in Gardner's syndrome. Dis Colon Rectum 1994; 37:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11881/abstract/50\">",
"      Patel SR, Evans HL, Benjamin RS. Combination chemotherapy in adult desmoid tumors. Cancer 1993; 72:3244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11881/abstract/51\">",
"      Okuno SH, Edmonson JH. Combination chemotherapy for desmoid tumors. Cancer 2003; 97:1134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11881/abstract/52\">",
"      Schnitzler M, Cohen Z, Blackstein M, et al. Chemotherapy for desmoid tumors in association with familial adenomatous polyposis. Dis Colon Rectum 1997; 40:798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11881/abstract/53\">",
"      Goepfert H, Cangir A, Ayala AG, Eftekhari F. Chemotherapy of locally aggressive head and neck tumors in the pediatric age group. Desmoid fibromatosis and nasopharyngeal angiofibroma. Am J Surg 1982; 144:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11881/abstract/54\">",
"      Gega M, Yanagi H, Yoshikawa R, et al. Successful chemotherapeutic modality of doxorubicin plus dacarbazine for the treatment of desmoid tumors in association with familial adenomatous polyposis. J Clin Oncol 2006; 24:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11881/abstract/55\">",
"      Garbay D, Le Cesne A, Penel N, et al. Chemotherapy in patients with desmoid tumors: a study from the French Sarcoma Group (FSG). Ann Oncol 2012; 23:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11881/abstract/56\">",
"      Azzarelli A, Gronchi A, Bertulli R, et al. Low-dose chemotherapy with methotrexate and vinblastine for patients with advanced aggressive fibromatosis. Cancer 2001; 92:1259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11881/abstract/57\">",
"      Skapek SX, Ferguson WS, Granowetter L, et al. Vinblastine and methotrexate for desmoid fibromatosis in children: results of a Pediatric Oncology Group Phase II Trial. J Clin Oncol 2007; 25:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11881/abstract/58\">",
"      Raney B, Evans A, Granowetter L, et al. Nonsurgical management of children with recurrent or unresectable fibromatosis. Pediatrics 1987; 79:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11881/abstract/59\">",
"      Skapek SX, Hawk BJ, Hoffer FA, et al. Combination chemotherapy using vinblastine and methotrexate for the treatment of progressive desmoid tumor in children. J Clin Oncol 1998; 16:3021.",
"     </a>",
"    </li>",
"    <li>",
"     Dileo P, Sala P, Piovesan C, et al. Efficacy of methotrexate + vinblastine in intra-abdominal desmoid (mesenteric aggressive fibromatosis): retrospective analysis of 29 patients from a single institution (abstract). J Clin Oncol 2008; 26;569s. (Abstract available online at www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&amp;vmview=abst_detail_view&amp;confID=55&amp;abstractID=31984, accessed on August 28, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11881/abstract/61\">",
"      Weiss AJ, Horowitz S, Lackman RD, Lackmen RD. Therapy of desmoid tumors and fibromatosis using vinorelbine. Am J Clin Oncol 1999; 22:193.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7749 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-6A12EA632A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_38_11881=[""].join("\n");
var outline_f11_38_11881=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENERAL ASPECTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Indications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Management of desmoid tumors in FAP patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Choice of agent",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Response evaluation during systemic therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      NON-CYTOTOXIC APPROACHES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Hormonal therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Efficacy of tamoxifen and other SERMs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Other hormonal therapies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Antiinflammatory agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Combined hormone plus antiinflammatory therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Imatinib",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H319056927\">",
"      Sorafenib",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Interferon",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      CYTOTOXIC CHEMOTHERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Monotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Combination chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Doxorubicin-containing combinations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Methotrexate plus a vinca alkaloid",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      DURATION OF THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      TREATMENT OF RECURRENT/RELAPSED DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Indications for systemic therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Choice of therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/7749\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/7749|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?0/5/91\" title=\"algorithm 1\">",
"      Algorithm Syst Rx desmoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/7749|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?1/23/1392\" title=\"diagnostic image 1\">",
"      Intraabdominal desmoid tumor in familial polyposis CT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/7749|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?27/31/28156\" title=\"table 1\">",
"      Hormone therapy for desmoids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?37/17/38171\" title=\"table 2\">",
"      NSAIDs desmoid Rx",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/27/4540\" title=\"table 3\">",
"      Hormone therapy plus NSAIDs for desmoids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?34/36/35404\" title=\"table 4\">",
"      Single agent chemo desmoids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?28/59/29628\" title=\"table 5\">",
"      Dox combos desmoids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?25/24/25997\" title=\"table 6\">",
"      Combination chemotherapy desmoids",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/11/30906?source=related_link\">",
"      Desmoid tumors: Epidemiology, risk factors, molecular pathogenesis, clinical presentation, diagnosis, and local therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/11/7352?source=related_link\">",
"      Gardner syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/2/7210?source=related_link\">",
"      Mechanisms of action of selective estrogen receptor modulators",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?16/26/16802?source=related_link\">",
"      Patient information: Soft tissue sarcoma (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_38_11882="Adjuvant and neoadjuvant treatment of gastric cancer";
var content_f11_38_11882=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Adjuvant and neoadjuvant treatment of gastric cancer",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/38/11882/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/38/11882/contributors\">",
"     Craig Earle, MD, MSc, FRCPC",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/38/11882/contributors\">",
"     Harvey Mamon, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/38/11882/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/38/11882/contributors\">",
"     Richard M Goldberg, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/38/11882/contributors\">",
"     Christopher G Willett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/38/11882/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/38/11882/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?11/38/11882/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 19, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of gastric cancer has been declining steadily since the 1930s, yet it remains a major cause of cancer death in the United States (US) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/38/11882/abstract/1\">",
"     1",
"    </a>",
"    ]. The high mortality rate reflects the prevalence of advanced disease at presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?11/38/11882/abstract/2\">",
"     2",
"    </a>",
"    ]. In population-based series of Western populations, the five-year survival rate for patients with completely resected stage I gastric cancer is approximately 70 to 75 percent, while it drops to 35 percent or less for stage II disease and beyond (",
"    <a class=\"graphic graphic_table graphicRef57916 \" href=\"UTD.htm?11/6/11374\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/38/11882/abstract/2\">",
"     2",
"    </a>",
"    ]. These sobering results have spawned efforts to improve the treatment results for this group of patients using adjuvant (postoperative) or neoadjuvant (preoperative) therapies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/15/33018?source=see_link&amp;anchor=H19#H19\">",
"     \"Invasive gastric cancer: Surgery and prognosis\", section on 'Prognosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The positive impact of such therapies on survival in patients with resected gastric cancer has become clearer over time, although there is no consensus as to the best approach. In many parts of the world, chemotherapy alone (either following surgery or combined preoperative and postoperative administration as in the multinational MAGIC trial [",
"    <a class=\"abstract\" href=\"UTD.htm?11/38/11882/abstract/3\">",
"     3",
"    </a>",
"    ]) is the preferred treatment strategy. On the other hand, a large American Intergroup trial (INT0116) demonstrating a significant survival benefit for chemoradiotherapy after complete resection resulted in the adoption of this strategy in the United States (US) despite concerns that inadequate surgical staging (particularly the extent of lymphadenectomy) may have led to an overestimation of benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?11/38/11882/abstract/4\">",
"     4",
"    </a>",
"    ]. The issues surrounding extent of lymph node dissection in gastric cancer are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/15/33018?source=see_link&amp;anchor=H12#H12\">",
"     \"Invasive gastric cancer: Surgery and prognosis\", section on 'Extent of lymph node dissection'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Another controversial issue is the management of cancers arising at the esophagogastric junction (EGJ). Classification and management of these tumors has evolved over time. In the latest edition of the TNM staging manual, tumors arising at the EGJ or in the cardia of the stomach (",
"    <a class=\"graphic graphic_figure graphicRef56689 \" href=\"UTD.htm?40/59/41907\">",
"     figure 1",
"    </a>",
"    ) within 5 cm of the EGJ that extend into the EGJ or esophagus (the so-called Siewert III EGJ tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?11/38/11882/abstract/5\">",
"     5",
"    </a>",
"    ]) are staged and treated as esophageal (",
"    <a class=\"graphic graphic_table graphicRef52078 \" href=\"UTD.htm?4/24/4494\">",
"     table 2",
"    </a>",
"    ) rather than stomach cancers [",
"    <a class=\"abstract\" href=\"UTD.htm?11/38/11882/abstract/6\">",
"     6",
"    </a>",
"    ]. However, tumors that arise beyond 5 cm of the EGJ or are within 5 cm of the EGJ but without extension to the esophagus or EGJ are still classified and treated as gastric cancers. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/45/7898?source=see_link&amp;anchor=H6#H6\">",
"     \"Diagnosis and staging of esophageal cancer\", section on 'TNM staging criteria'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/36/11850?source=see_link&amp;anchor=H12#H12\">",
"     \"Clinical features, diagnosis, and staging of gastric cancer\", section on 'TNM staging criteria'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic review will focus on adjuvant and neoadjuvant therapies for non-cardia gastric cancer. The epidemiology, staging, and surgical treatment of gastric cancers, and multimodality approaches for treatment of esophageal and EGJ tumors are covered elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/35/4661?source=see_link\">",
"     \"Epidemiology of gastric cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/36/11850?source=see_link\">",
"     \"Clinical features, diagnosis, and staging of gastric cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/15/33018?source=see_link\">",
"     \"Invasive gastric cancer: Surgery and prognosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/31/39418?source=see_link\">",
"     \"Radiation therapy, chemoradiotherapy, neoadjuvant approaches, and postoperative adjuvant therapy for localized cancers of the esophagus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/51/39738?source=see_link\">",
"     \"Multimodality approaches to potentially resectable esophagogastric junction and gastric cardia adenocarcinomas\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ADJUVANT CHEMORADIOTHERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interest in adjuvant radiation therapy (RT) stems from the observation that over 80 percent of patients who die from gastric cancer experience a local recurrence at some point [",
"    <a class=\"abstract\" href=\"UTD.htm?11/38/11882/abstract/7\">",
"     7",
"    </a>",
"    ]. Although the available data on whether there is a survival benefit from either postoperative or intraoperative RT in patients with resected gastric cancer are mixed [",
"    <a class=\"abstract\" href=\"UTD.htm?11/38/11882/abstract/8-11\">",
"     8-11",
"    </a>",
"    ], three randomized trials of postoperative combined chemoradiotherapy have shown a significant survival benefit compared to surgery alone after complete resection of gastric cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?11/38/11882/abstract/4,12,13\">",
"     4,12,13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Intergroup 0116",
"    </span>",
"    &nbsp;&mdash;&nbsp;The largest and most recent trial, US Intergroup INT0116, provides the most compelling data in support of adjuvant chemoradiotherapy following complete surgical resection, particularly since it used contemporary RT techniques and concurrently administered fluoropyrimidine radiosensitization [",
"    <a class=\"abstract\" href=\"UTD.htm?11/38/11882/abstract/4\">",
"     4",
"    </a>",
"    ]. Following potentially curative resection of gastric or EGJ cancer (T1-4, N0-1), 556 patients were randomly assigned to observation alone or adjuvant combined chemoradiotherapy. Treatment consisted of one cycle of FU (425",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    per day) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    calcium (20",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    per day) daily for five days, followed one month later by RT (45 Gy in daily 1.8 Gy fractions) given with concurrent FU and leucovorin calcium (400",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    and 20",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     ,",
"    </span>",
"    respectively) on days 1 through 4, and on the last three days of RT. Radiation treatment volumes were subject to centralized pretreatment review. Two more five-day cycles of chemotherapy (FU 425",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    per day and leucovorin calcium 20",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    per day) were given at monthly intervals beginning one month after completion of chemoradiotherapy.",
"   </p>",
"   <p>",
"    The majority of tumors were",
"    <span class=\"nowrap\">",
"     T3/T4",
"    </span>",
"    (68 and 69 percent of the treated and control groups, respectively), and 85 percent had nodal metastases. Three-year disease-free (48 versus 31 percent) and overall survival rates (50 versus 41 percent) were significantly better with combined modality therapy, and median survival was significantly longer (36 versus 27 months). Benefits were maintained with longer followup (five-year overall survival 43 versus 28 percent, hazard ratio [HR] for survival 1.32 (95% CI 1.10-1.60) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/38/11882/abstract/14\">",
"     14",
"    </a>",
"    ]).",
"   </p>",
"   <p>",
"    In the chemoradiotherapy group, grade 3 and grade 4 acute toxic effects occurred in 41 and 32 percent of patients, respectively, while three (1 percent) died from treatment-related toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?11/38/11882/abstract/4\">",
"     4",
"    </a>",
"    ]. The most frequent grade 3 or worse adverse effects were hematologic (54 percent), gastrointestinal (33 percent), infectious (6 percent), and neurologic (4 percent).",
"   </p>",
"   <p>",
"    A later patterns of failure analysis disclosed a similar frequency of distant metastasis (16 versus 18 percent in the chemoradiotherapy and control groups, respectively), but fewer local (2 versus 8 percent) and regional (22 versus 39 percent) recurrences with chemoradiotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?11/38/11882/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The initial report of this study changed the standard of care in the US following potentially curative resection of gastric cancer from observation alone to surgery followed by adjuvant combined chemoradiotherapy. The impact of these results on the management of patients with EGJ tumors is addressed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/51/39738?source=see_link&amp;anchor=H1035777#H1035777\">",
"     \"Multimodality approaches to potentially resectable esophagogastric junction and gastric cardia adenocarcinomas\", section on 'Adjuvant chemoradiotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A criticism of this trial was the limited extent of the surgical procedure in most cases. Although D2 lymph node dissection (removal of nodes along the hepatic, left gastric, celiac and splenic arteries, and in the splenic hilum) was recommended, it was only performed in 10 percent of cases, and 54 percent did not even have clearance of the D1 (perigastric) nodal regions. This noncompliance likely contributed to inferior survival and a 64 percent relapse rate in the surgery alone arm. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/15/33018?source=see_link&amp;anchor=H12#H12\">",
"     \"Invasive gastric cancer: Surgery and prognosis\", section on 'Extent of lymph node dissection'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23495516\">",
"    <span class=\"h2\">",
"     CALGB 80101",
"    </span>",
"    &nbsp;&mdash;&nbsp;As will be discussed below, the MAGIC trial demonstrated a significant survival benefit for the use of perioperative chemotherapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/27/4536?source=see_link\">",
"     epirubicin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    , and infusional FU (ECF, (",
"    <a class=\"graphic graphic_table graphicRef62502 \" href=\"UTD.htm?35/44/36558\">",
"     table 3",
"    </a>",
"    )) versus surgery alone in patients with resectable gastric and EGJ cancer. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'MAGIC trial'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/23/43378?source=see_link\">",
"     \"Treatment protocols for esophagogastric cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    CALGB 80101, a US Intergroup study, compared the INT0116 protocol regimen (bolus FU and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    with FU plus concurrent RT) versus postoperative ECF before and after FU plus concurrent RT in 546 patients with completely resected gastric or EGJ tumors that extended beyond the muscularis propria or were node positive [",
"    <a class=\"abstract\" href=\"UTD.htm?11/38/11882/abstract/15\">",
"     15",
"    </a>",
"    ]. The fraction of enrolled patients with EGJ versus gastric primary tumors was not reported.",
"   </p>",
"   <p>",
"    In a preliminary report presented at the 2011 meeting of the American Society of Clinical Oncology (ASCO), patients receiving ECF had lower rates of diarrhea, mucositis, and grade 4 or worse neutropenia. Overall survival, the primary endpoint, was not significantly better with ECF (at three years, 52 versus 50 percent for ECF and",
"    <span class=\"nowrap\">",
"     FU/LV,",
"    </span>",
"    respectively). The trial was not adequately powered to assess non-inferiority. The location of the primary tumor (EGJ versus proximal versus distal stomach) did not have any effect on treatment outcome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7097668\">",
"    <span class=\"h2\">",
"     ARTIST trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;Additional evidence in favor of chemoradiotherapy is provided by the ARTIST trial, which directly compared adjuvant chemoradiotherapy to adjuvant chemotherapy in 458 patients with completely resected gastric cancer and a D2 lymph node dissection [",
"    <a class=\"abstract\" href=\"UTD.htm?11/38/11882/abstract/16\">",
"     16",
"    </a>",
"    ]. Disease-free survival was similar in both arms, although there was a suggestion of better outcomes with chemoradiotherapy in those with node-positive disease. This trial is described in more detail below. (See",
"    <a class=\"local\" href=\"#H23495808\">",
"     'Chemotherapy versus chemoradiotherapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25275186\">",
"    <span class=\"h2\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal selection of patients for postoperative adjuvant chemoradiotherapy is debated. In particular, there is controversy surrounding patients with T2N0 disease. While these patients were included in the INT 0116 trial, the TNM staging system in use at that time (the 3",
"    <sup>",
"     rd",
"    </sup>",
"    edition) defined T2 disease as invading muscularis propria or subserosa. It was not clearly specified in the paper whether the enrolled T2N0 patients were limited to patients with subserosal invasion or also included those with invasion limited to the muscularis propria. A subsequent nonrandomized trial that reportedly used the same eligibility criteria as the INT 0116 trial excluded patients with T2aN0 disease (which, according to the 5",
"    <sup>",
"     th",
"    </sup>",
"    edition of the AJCC staging system, which was in use at that time, reflected invasion into the muscularis propria but not beyond; invasion into the subserosa was T2b disease) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/38/11882/abstract/17\">",
"     17",
"    </a>",
"    ]. Thus, it could be that while patients with stage IB disease were included in INT 0116, they may have really been patients with subserosal involvement, and those with T2aN0 disease (in AJCC 5",
"    <sup>",
"     th",
"    </sup>",
"    edition terminology) were observed. &nbsp;",
"   </p>",
"   <p>",
"    The newest TNM staging system (as of January 2010) classifies subserosal invasion is T3 disease; while T2N0 is still stage IB, T3N0 is IIA. A subset of patients with nodal positivity (T1N1) are also classified as stage IB disease (",
"    <a class=\"graphic graphic_table graphicRef57916 \" href=\"UTD.htm?11/6/11374\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Using the definitions from the 7",
"    <sup>",
"     th",
"    </sup>",
"    edition of the AJCC staging system, we consider that observation is appropriate for T2N0 stage IB patients, but treatment would be recommended for any T stage with N1 disease (which would include T1N1 stage IB) and for patients with T3N0 (stage IIA) disease and above.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3744529\">",
"    <span class=\"h2\">",
"     Choice of regimen",
"    </span>",
"    &nbsp;&mdash;&nbsp;The INT0116 study established postoperative chemoradiotherapy as a standard approach for completely resected gastric cancer; however, the optimal regimen has not yet been established. In INT0116, the chemoradiotherapy component was given with bolus IV FU and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    calcium on days 1 through 4 and on the last three days of RT, an approach that has fallen out of favor given the better tolerability and comparable efficacy of daily low-dose infusional FU in other gastrointestinal sites such as rectal cancer. Most clinicians utilize continuous infusion FU (200",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    daily) during RT instead of bolus FU plus leucovorin. Another acceptable option, as was tested in the ARTIST trial, is daily oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    (825",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    twice daily five days per week on radiation days) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/38/11882/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H23495808\">",
"     'Chemotherapy versus chemoradiotherapy'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/51/4922?source=see_link&amp;anchor=H9#H9\">",
"     \"Adjuvant therapy for resected rectal cancer\", section on 'Infusional versus bolus 5-FU'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/51/4922?source=see_link&amp;anchor=H11#H11\">",
"     \"Adjuvant therapy for resected rectal cancer\", section on 'Orally active fluoropyrimidines'",
"    </a>",
"    .).",
"   </p>",
"   <p>",
"    The chemotherapy alone component of the adjuvant combined modality therapy regimen can be either a single agent fluoropyrimidine such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    with short-term infusional FU (",
"    <a class=\"graphic graphic_table graphicRef65525 \" href=\"UTD.htm?36/17/37149\">",
"     table 4",
"    </a>",
"    ) or ECF (",
"    <a class=\"graphic graphic_table graphicRef62502 \" href=\"UTD.htm?35/44/36558\">",
"     table 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/23/43378?source=see_link\">",
"     \"Treatment protocols for esophagogastric cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     NEOADJUVANT/PERIOPERATIVE CHEMOTHERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to the situation in the US, the standard of care for treatment of gastric cancer in many parts of Europe is neoadjuvant or perioperative (preoperative plus postoperative) chemotherapy. In Japan and Southern Europe, patients routinely receive postoperative chemotherapy alone [",
"    <a class=\"abstract\" href=\"UTD.htm?11/38/11882/abstract/18\">",
"     18",
"    </a>",
"    ], although this practice seems to be changing, given the better tolerability of preoperative chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?11/38/11882/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H23495743\">",
"     'Adjuvant chemotherapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Neoadjuvant chemotherapy may be administered as a means of \"downstaging\" a locally advanced tumor prior to an attempt at curative resection. This approach has been applied to patients thought to have resectable disease as well as those with apparently unresectable but nonmetastatic disease. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Initially locally unresectable nonmetastatic disease'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Another benefit of neoadjuvant chemotherapy is that patients who are at high risk of developing distant metastases (eg, those with bulky",
"    <span class=\"nowrap\">",
"     T3/T4",
"    </span>",
"    tumors, visible perigastric nodes by preoperative imaging studies including endoscopic ultrasound [EUS], a linitis plastica appearance, or positive peritoneal cytology in the absence of visible peritoneal disease) may be spared the morbidity of unnecessary gastrectomy if evidence of distant metastases emerges after chemotherapy.",
"   </p>",
"   <p>",
"    Three large, adequately powered trials have directly compared surgery with or without IV neoadjuvant or perioperative chemotherapy, two of which demonstrate a survival benefit for this approach [",
"    <a class=\"abstract\" href=\"UTD.htm?11/38/11882/abstract/3,20,21\">",
"     3,20,21",
"    </a>",
"    ]. Two other trials which compared preoperative treatment using an oral fluoropyrimidine versus surgery alone failed to show a significant benefit for chemotherapy and are not discussed further here [",
"    <a class=\"abstract\" href=\"UTD.htm?11/38/11882/abstract/22,23\">",
"     22,23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     MAGIC trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The largest and most influential trial is the United Kingdom Medical Research Council MAGIC trial, in which 503 patients with potentially resectable gastric (74 percent), distal esophageal (11 percent), or EGJ adenocarcinomas (15 percent) were randomly assigned to surgery alone or surgery plus perioperative chemotherapy (three preoperative and three postoperative cycles of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/27/4536?source=see_link\">",
"     epirubicin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    and infusional 5-fluorouracil [ECF]) (",
"    <a class=\"graphic graphic_table graphicRef62502 \" href=\"UTD.htm?35/44/36558\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/38/11882/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/23/43378?source=see_link\">",
"     \"Treatment protocols for esophagogastric cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Eligibility criteria included patients of any age with a performance status of 0 or 1 (",
"    <a class=\"graphic graphic_table graphicRef72901 \" href=\"UTD.htm?9/15/9467\">",
"     table 5",
"    </a>",
"    ), a histologically proven adenocarcinoma of the stomach or lower third of the esophagus that was considered to invade through the submucosa (stage T2 or higher, (",
"    <a class=\"graphic graphic_table graphicRef57916 \" href=\"UTD.htm?11/6/11374\">",
"     table 1",
"    </a>",
"    )), with no evidence of distant metastases or locally advanced inoperable disease, as evaluated by CT, ultrasonography or laparoscopy.",
"   </p>",
"   <p>",
"    A higher proportion of chemotherapy-treated patients with gastric cancer who underwent radical surgery had a potentially curative procedure (79 versus 70 percent), and significantly more had",
"    <span class=\"nowrap\">",
"     T1/2",
"    </span>",
"    tumors (52 versus 37 percent) and",
"    <span class=\"nowrap\">",
"     N0/N1",
"    </span>",
"    disease (84 versus 71 percent). Chemotherapy was well tolerated overall; excluding patients with neutropenia (23 percent), fewer than 12 percent of all patients had serious (grade 3 or 4) toxic effects. However, only 104 (42 percent) were able to complete protocol treatment, including surgery and all three cycles of the postoperative chemotherapy. These data underscore one of the major problems with the perioperative approach, which is the difficulty in administering the full number of postoperative chemotherapy cycles.",
"   </p>",
"   <p>",
"    Despite this, overall survival was significantly better in the chemotherapy group (hazard ratio [HR] for death 0.75, 95% CI 0.60-0.93) as was progression-free survival (PFS, HR for progression 0.66). The 25 percent reduction in the risk of death favoring chemotherapy translated into an improvement in five-year survival from 23 to 36 percent. Local failure occurred in 14 percent of the chemotherapy-treated patients compared to 21 percent of those undergoing surgery alone. Distant metastases developed in 24 and 37 percent of patients, respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     French FNLCC/FFCD trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;A similar benefit for perioperative chemotherapy was noted in a French multicenter trial in which 224 patients with potentially resectable stage II or greater adenocarcinoma of the stomach (n = 55), EGJ (n = 144) or distal esophagus (n = 25) were randomly assigned to two to three cycles of preoperative chemotherapy (infusional FU 800",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    daily for five days plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    100",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    on day 1 or 2, every four weeks) or surgery alone [",
"    <a class=\"abstract\" href=\"UTD.htm?11/38/11882/abstract/24\">",
"     24",
"    </a>",
"    ]. Patients in the chemotherapy arm were to receive three to four cycles of postoperative chemotherapy as well.",
"   </p>",
"   <p>",
"    Patients undergoing neoadjuvant chemotherapy were significantly more likely to undergo R0 (microscopically complete) resection (84 versus 73 percent), and there was a statistically insignificant trend toward fewer node-positive tumors (67 versus 80 percent, p=0.054) that favored this group as well. Among the patients who received at least one cycle of preoperative chemotherapy, only one-half received any postoperative chemotherapy. With a median 5.7-year follow-up, perioperative chemotherapy was associated with a significant 35 percent reduction in the risk of disease recurrence (five-year disease-free survival 34 versus 19 percent) and a significant, 31 percent lower risk of death (five-year survival 38 versus 24 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H92241562\">",
"    <span class=\"h2\">",
"     EORTC trial 40954",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to these two trials, a survival benefit for neoadjuvant chemotherapy could not be shown in EORTC trial 40954, in which patients with locally advanced (AJCC stage III or IV [cM0], (",
"    <a class=\"graphic graphic_table graphicRef57916 \" href=\"UTD.htm?11/6/11374\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef52078 \" href=\"UTD.htm?4/24/4494\">",
"     table 2",
"    </a>",
"    )) cancer of the stomach or EGJ (one-half in the upper third or cardia) were randomly assigned to surgery with or without preoperative chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?11/38/11882/abstract/21\">",
"     21",
"    </a>",
"    ]. The chemotherapy consisted of two 48-day cycles of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    on days 1, 15, and 29 plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    and a 24-hour infusion of FU on days 1, 8, 15, 22, 29, and 36. The trial was closed because of poor accrual after only 144 of the planned 360 patients were enrolled. The group receiving neoadjuvant chemotherapy had a significantly higher rate of complete (R0) resections (82 versus 67 percent), but they also had more postoperative complications (27 versus 16 percent), and at a median follow-up of 4.4 years, no significant survival advantage (HR for death 0.84, 95% CI 0.52 to 1.35). However, given the limited accrual, the study was underpowered to demonstrate a survival endpoint.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;The impressive results of the well conducted MAGIC and French trials have led to the adoption of the perioperative chemotherapy approach to treatment of gastric cancer in much of Europe and other parts of the world. The impact of these trials on treatment of patients with EGJ and proximal (cardia) gastric cancer is addressed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/51/39738?source=see_link&amp;anchor=H945003#H945003\">",
"     \"Multimodality approaches to potentially resectable esophagogastric junction and gastric cardia adenocarcinomas\", section on 'Lower GI tract trials'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, whether these results have changed (or should change) practice in the US is more difficult to address. The results of the MAGIC and French trials are not directly comparable to those of INT0116 as patients were randomized prior to surgery; randomization occurred after complete resection in INT0116. However, the magnitude of the survival difference between the surgery alone and the treatment arms of all three studies are similar. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Intergroup 0116'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    A major problem in the US is that patients with gastric cancer are commonly taken to the operating room prior to consultation by medical or radiation oncologists. Multidisciplinary preoperative evaluation is preferable.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23495743\">",
"    <span class=\"h1\">",
"     ADJUVANT CHEMOTHERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;More than 30 randomized trials have compared adjuvant systemic chemotherapy to surgery alone in resectable gastric cancer, with variable, mostly negative results when overall survival is considered as the primary endpoint (",
"    <a class=\"graphic graphic_table graphicRef71898 \" href=\"UTD.htm?16/17/16670\">",
"     table 6",
"    </a>",
"    ). While some of the trials were clearly underpowered to detect a significant survival difference, others utilized inferior surgical techniques, or much of the planned chemotherapy was not given because of prolonged recovery from surgery. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23496094\">",
"    <span class=\"h2\">",
"     Meta-analyses",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the variability in outcomes in these phase III trials, several meta-analyses have been undertaken, all of which support a significant survival benefit for adjuvant chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?11/38/11882/abstract/25-28\">",
"     25-28",
"    </a>",
"    ], including one that was limited to trials from Western (ie, non-Asian) countries [",
"    <a class=\"abstract\" href=\"UTD.htm?11/38/11882/abstract/25\">",
"     25",
"    </a>",
"    ]. Several studies indicate a somewhat better prognosis in Asian as compared to Western populations with gastric cancer. This subject is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/15/33018?source=see_link&amp;anchor=H19#H19\">",
"     \"Invasive gastric cancer: Surgery and prognosis\", section on 'Prognosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The most recent of these analyses evaluated individual patient data from 17 randomized trials comparing adjuvant systemic chemotherapy versus surgery alone, conducted in both Asian and Western populations (but not including the largest Japanese trial evaluating adjuvant S-1 monotherapy (see",
"    <a class=\"local\" href=\"#H23496123\">",
"     'Japanese S-1 trial'",
"    </a>",
"    below) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/38/11882/abstract/29\">",
"     29",
"    </a>",
"    ]), and which required complete (R0) resection prior to enrollment [",
"    <a class=\"abstract\" href=\"UTD.htm?11/38/11882/abstract/28\">",
"     28",
"    </a>",
"    ]. The risk of death in patients receiving an adjuvant chemotherapy regimen that contained a fluoropyrimidine was reduced by 18 percent (HR for death 0.82, 95% CI 0.75 to 0.90).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23496123\">",
"    <span class=\"h2\">",
"     Japanese S-1 trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;S-1 is an oral fluoropyrimidine that includes three different agents: ftorafur, chlorohydroxy dihydropyridine (a potent DPD inhibitor), and oxonic acid (which inhibits phosphorylation of intestinal 5-FU, which is thought responsible for treatment-related diarrhea).",
"   </p>",
"   <p>",
"    The benefit of adjuvant treatment with S-1 was demonstrated in a Japanese ACTS-GC trial in which 1059 patients with stage II or III gastric cancer who had undergone potentially curative surgery with D2 lymphadenectomy were randomly assigned to six months of S1 (80 to 120 mg daily for four weeks, repeated every six weeks for one year) versus surgery alone [",
"    <a class=\"abstract\" href=\"UTD.htm?11/38/11882/abstract/29\">",
"     29",
"    </a>",
"    ]. Five-year overall survival was significantly better with S-1 (72 versus 61 percent), with better than expected survival in both groups. By comparison, the five-year survival rates for the INT0116 and the MAGIC trials were 43 versus 28 percent, and 36 versus 23 percent for the treatment and control groups, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?11/38/11882/abstract/3,14\">",
"     3,14",
"    </a>",
"    ]. &nbsp; &nbsp;",
"   </p>",
"   <p>",
"    These results led to the adoption of one year of postoperative S-1 as a standard adjuvant therapy approach for gastric cancer in East Asian patients. It is difficult to know whether the benefit of adjuvant therapy with S-1, as demonstrated in the ACTS-GC trial, can be extrapolated to other populations, given the markedly better outcomes seen in both the treated and the surgery alone control groups, stage for stage, when compared to outcomes in other non-Japanese populations.",
"   </p>",
"   <p>",
"    S-1 is approved in Japan for adjuvant therapy of gastric cancer and in Europe for treatment of advanced gastric cancer; it is not available in the US.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23496205\">",
"    <span class=\"h2\">",
"     CLASSIC trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The benefit of adjuvant therapy using",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    in combination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    was addressed in the multicenter CLASSIC trial, in which 1035 patients with stage II, IIIA, or IIIB (",
"    <a class=\"graphic graphic_table graphicRef57916 \" href=\"UTD.htm?11/6/11374\">",
"     table 1",
"    </a>",
"    ) gastric cancer were randomly assigned to eight 21-day cycles of capecitabine (1000",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    twice daily in days 1 to 14) plus oxaliplatin (130",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    on day 1) or surgery alone after D2 gastrectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?11/38/11882/abstract/30\">",
"     30",
"    </a>",
"    ]. The study was conducted in South Korea, China, and Taiwan. Only 567 percent of the patients assigned to chemotherapy received all eight cycles of chemotherapy as planned, and adverse events (most commonly neutropenia, nausea, vomiting, thrombocytopenia, and anorexia) led to chemotherapy dose modifications in 90 percent of patients. Despite this, at a median follow-up of 34 months, chemotherapy was associated with a significant improvement in three-year disease-free survival (74 versus 59 percent, HR for death 0.56, 95% CI 0.44-0.72), with only a borderline statistically significant improvement in overall survival (83 versus 78 percent, HR 0.72, 95% CI 0.52-1.00) , which requires further follow up.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23495808\">",
"    <span class=\"h2\">",
"     Chemotherapy versus chemoradiotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adjuvant chemoradiotherapy has been directly compared to adjuvant chemotherapy in at least four trials [",
"    <a class=\"abstract\" href=\"UTD.htm?11/38/11882/abstract/16,31-33\">",
"     16,31-33",
"    </a>",
"    ], only one of which has shown a significant overall survival benefit for the addition of RT to chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?11/38/11882/abstract/31\">",
"     31",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the largest trial, the ARTIST trial, 458 patients with complete resected gastric cancer and a D2 lymph node dissection were randomly assigned to six courses of postoperative",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/0/40967?source=see_link\">",
"       capecitabine",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      (XP) or two courses of postoperative XP followed by chemoradiotherapy (45 Gy RT with concurrent daily capecitabine [825",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      twice daily]) and two additional courses of XP [",
"      <a class=\"abstract\" href=\"UTD.htm?11/38/11882/abstract/16\">",
"       16",
"      </a>",
"      ]. Compared to chemotherapy alone, the addition of RT to XP chemotherapy did not significantly reduce recurrence rates, although in unplanned subgroup analysis, patients with nodal metastases had superior disease-free survival with combined therapy as compared to XP alone. Overall survival, a secondary endpoint, was not analyzed.",
"      <br/>",
"      <br/>",
"      At a median follow-up of 53 months, estimated three-year DFS (the primary endpoint) was not significantly better in patients who received combined modality therapy (78 versus 74 percent, p= 0.0862), although unplanned subset analysis did indicate a significantly better outcome with chemoradiotherapy in those with node-positive disease. Overall survival, a secondary endpoint, was not analyzed.",
"      <br/>",
"      <br/>",
"      In our view, this trial should not be interpreted as disproving the benefit of chemoradiotherapy relative to chemotherapy alone. The hypothesis that adjuvant chemoradiotherapy may represent a better approach than adjuvant chemotherapy for patients with node-positive disease will be tested in a successor trial, the ARTIST-II trial. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Adjuvant chemoradiotherapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A Chinese trial randomly assigned 380 patients undergoing gastrectomy and a D2 lymph node dissection to intensity modulated RT (IMRT) plus chemotherapy (one cycle of bolus FU plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/54/24423?source=see_link\">",
"       leucovorin",
"      </a>",
"      followed by IMRT plus bolus FU and leucovorin on the first four and last three days of RT, and followed by two five-day cycles of bolus",
"      <span class=\"nowrap\">",
"       FU/leucovorin)",
"      </span>",
"      versus chemotherapy alone (the same chemotherapy regimens as the IMRT group but no RT) [",
"      <a class=\"abstract\" href=\"UTD.htm?11/38/11882/abstract/33\">",
"       33",
"      </a>",
"      ]. The addition of IMRT was associated with a significant improvement in median recurrence free survival (50 versus 36 months, HR for recurrence 1.35, 95% CI 1.03-1.78), but the difference in overall survival favoring chemoradiotherapy (58 versus 48 months) was not statistically significant.",
"     </li>",
"     <li>",
"      The only trial to show a significant survival benefit for the addition of RT randomly assigned 68 patients undergoing complete resection with a D1 or D2 lymph node dissection for previously untreated gastric cancer to chemoradiotherapy administered according to the INT 0116 trial (but using intensity modulated RT) or chemotherapy alone (five cycles of FU 425",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      per day and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/54/24423?source=see_link\">",
"       leucovorin",
"      </a>",
"      calcium 25",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      per day given five days in a row, once monthly) [",
"      <a class=\"abstract\" href=\"UTD.htm?11/38/11882/abstract/31\">",
"       31",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Intergroup 0116'",
"      </a>",
"      above.) All patients were followed for at least three years. Three-year disease-free survival rate was significantly higher in the chemoradiotherapy group (56 versus 29 percent) as was overall survival (68 versus 44 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Taken together, these data leave some question as to the benefit contributed by adjuvant RT; however, they have not yet led to the abandonment of RT for postoperative treatment in North America.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5490918\">",
"    <span class=\"h2\">",
"     Intraperitoneal chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The observation that resected gastric cancer tends to recur within the peritoneum has provided the rationale for the evaluation of adjuvant intraperitoneal (IP) chemotherapy. Although preliminary reports demonstrated feasibility and safety, the results of randomized studies have been mixed. Several meta-analyses have been conducted, all of which have found a survival benefit for hyperthermic (but not normothermic) intraperitoneal chemotherapy (HIPEC) in this setting. However, the methodologic quality of the analyzed studies has been generally low [",
"    <a class=\"abstract\" href=\"UTD.htm?11/38/11882/abstract/34-36\">",
"     34-36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The latest of these included 10 randomized controlled trials totaling 1062 patients (518 who underwent HIPEC and 544 controls) with gastric cancer and macroscopic serosal invasion without distant metastases or peritoneal carcinomatosis [",
"    <a class=\"abstract\" href=\"UTD.htm?11/38/11882/abstract/36\">",
"     36",
"    </a>",
"    ]. Three trials were described as low quality, although seven failed to provide specific details about the process of randomization. The largest trial enrolled 212 patients, and the smallest 40 patients. Four trials utilized systemic chemotherapy after surgery in both the HIPEC and control groups; the use of HIPEC was associated with a significant improvement in survival (relative risk for death 0.73, 95% CI 0.64-0.83). &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5490761\">",
"    <span class=\"h2\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Meta-analyses provide support for a survival benefit from adjuvant chemotherapy following complete resection of gastric cancer. Adjuvant chemotherapy for one year with S-1 is accepted as routine following resection of gastric cancer in Japan and some parts of Europe [",
"    <a class=\"abstract\" href=\"UTD.htm?11/38/11882/abstract/37\">",
"     37",
"    </a>",
"    ], while in other parts of Europe, a combination of preoperative plus postoperative chemotherapy using ECF (as was used in the MAGIC trial [",
"    <a class=\"abstract\" href=\"UTD.htm?11/38/11882/abstract/3\">",
"     3",
"    </a>",
"    ]) is more commonly recommended.",
"   </p>",
"   <p>",
"    When adjuvant therapy is used, the optimal regimen is not established. Results with adjuvant",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    (CAPOX, XELOX), as was used in the CLASSIC trial, or capecitabine plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    (XP), as was used in the ARTIST trial, are not as mature as those of perioperative ECF (as was used in the MAGIC trial) or S-1 (where available); therefore, these approaches cannot be recommended with the same degree of confidence. Furthermore, it is unclear how the results of adjuvant CAPOX and XP translates to the Western setting. &nbsp;",
"   </p>",
"   <p>",
"    In the US, adjuvant chemotherapy has not replaced chemoradiotherapy as the common standard of care, and adjuvant chemotherapy alone is infrequently used, despite the finding of a lack of survival benefit for the addition of RT compared to adjuvant chemotherapy alone in three of four randomized trials. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Adjuvant chemoradiotherapy'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H23495808\">",
"     'Chemotherapy versus chemoradiotherapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    There is insufficient evidence from randomized trials to recommend intraperitoneal chemotherapy as an acceptable adjuvant treatment after resection of gastric cancer. Higher quality randomized trials are needed. In our view and that of others [",
"    <a class=\"abstract\" href=\"UTD.htm?11/38/11882/abstract/38\">",
"     38",
"    </a>",
"    ], this technique remains investigational and should only be considered in the context of a clinical trial.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     NEOADJUVANT CHEMORADIOTHERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preoperative combined chemotherapy and RT is more commonly used for esophageal, EGJ, and gastric cardia cancers than for potentially resectable non-cardia gastric adenocarcinomas. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/31/39418?source=see_link\">",
"     \"Radiation therapy, chemoradiotherapy, neoadjuvant approaches, and postoperative adjuvant therapy for localized cancers of the esophagus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/51/39738?source=see_link\">",
"     \"Multimodality approaches to potentially resectable esophagogastric junction and gastric cardia adenocarcinomas\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Neoadjuvant chemoradiotherapy was compared to induction chemotherapy alone in the multicenter German POET (PreOperative chemotherapy or radiochemotherapy in Esophagogastric adenocarcinoma Trial) trial that was limited to patients with EGJ adenocarcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?11/38/11882/abstract/39\">",
"     39",
"    </a>",
"    ]. Although there were potentially clinically meaningful survival differences that favored chemoradiotherapy, they were not statistically significant. Furthermore, whether the results can be extrapolated to patients with true non-cardia gastric cancer is uncertain. These data are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/51/39738?source=see_link&amp;anchor=H3447368#H3447368\">",
"     \"Multimodality approaches to potentially resectable esophagogastric junction and gastric cardia adenocarcinomas\", section on 'German POET trial'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are no randomized trials addressing the benefit of preoperative chemoradiotherapy for non-cardia gastric cancers. In three separate phase II studies using different chemoradiotherapy protocols, the pathologic complete response rates ranged from 20 to 30 percent, and 70 to 78 percent were able to undergo a complete (R0) resection after chemoradiotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?11/38/11882/abstract/40-42\">",
"     40-42",
"    </a>",
"    ]. Whether these results are better than could be achieved with surgery alone, neoadjuvant chemotherapy, or surgery followed by adjuvant chemoradiotherapy is unclear.",
"   </p>",
"   <p>",
"    The use of induction chemoradiotherapy for patients with initially unresectable gastric cancer is discussed below. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Initially locally unresectable nonmetastatic disease'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     INITIALLY LOCALLY UNRESECTABLE NONMETASTATIC DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal management of patients with locally advanced unresectable but nonmetastatic gastric cancer is uncertain, and there is no standard approach. Palliative methods for control of local symptoms are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/56/19333?source=see_link\">",
"     \"Local palliation for advanced gastric cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Options for anticancer therapy include chemotherapy alone or chemoradiotherapy:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Unresectable locally advanced gastric cancer is often treated primarily with chemotherapy, using regimens for metastatic disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/10/44202?source=see_link\">",
"       \"Chemotherapy for locally advanced unresectable and metastatic esophageal and gastric cancer\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Initial chemotherapy treatment may render some patients resectable. However, the benefit of neoadjuvant chemotherapy in patients who are deemed initially unresectable but without distant metastatic disease is uncertain. No randomized trials have been completed.",
"      <br/>",
"      <br/>",
"      Several uncontrolled studies have explored the use of preoperative chemotherapy for patients with locally advanced gastric cancer without distant metastases [",
"      <a class=\"abstract\" href=\"UTD.htm?11/38/11882/abstract/43-46\">",
"       43-46",
"      </a>",
"      ]. All have shown that some patients initially thought to be unresectable respond to chemotherapy sufficiently that they are able to undergo potentially curative surgery. However, pathological complete response rates are low, between 5 and 15 percent, and treatment-related toxicity may be prominent [",
"      <a class=\"abstract\" href=\"UTD.htm?11/38/11882/abstract/46\">",
"       46",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Preliminary uncontrolled data suggest that with preoperative combined modality therapy (chemoradiotherapy with or without induction chemotherapy), approximately 70 percent of patients with localized but initially unresectable gastric cancer can undergo potentially curative resection, with pathologically complete response rates as high as 30 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?11/38/11882/abstract/40-42,47-49\">",
"       40-42,47-49",
"      </a>",
"      ]. Although these early data seem encouraging, the studies have been conducted in highly selected patients, and randomized trials will ultimately be necessary to confirm benefit from any of these approaches over chemotherapy alone.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5491664\">",
"    <span class=\"h2\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of induction therapy in patients with locally advanced initially unresectable but nonmetastatic disease is unclear. Data from single arm studies can address the question of increasing resectability, but not its impact on survival. An initial attempt at downstaging with chemotherapy, chemoradiotherapy, or a combination followed by careful restaging and surgical exploration in responders who have no evidence of metastatic disease is a reasonable approach for a fit patient who initially had locally unresectable but nonmetastatic disease. Whenever possible, such patients should be encouraged to enroll on clinical trials testing new approaches.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     ONGOING RESEARCH",
"    </span>",
"    &nbsp;&mdash;&nbsp;The focus of future research is on optimizing the chemotherapy regimen, defining the role of RT, and exploring the effect of treatment timing (preoperative, postoperative or both). The following are examples of ongoing trials:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      As described above, CALGB 80101 compared the INT-0116 protocol regimen (bolus FU and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/54/24423?source=see_link\">",
"       leucovorin",
"      </a>",
"      with FU plus concurrent RT) versus postoperative ECF (the MAGIC trial perioperative chemotherapy regimen) before and after FU plus concurrent RT in patients with gastric or EGJ tumors. Unfortunately, this trial failed to show a survival advantage for ECF. A similarly designed study is also being undertaken in Australia and New Zealand (TROG 03.02). (See",
"      <a class=\"local\" href=\"#H3744529\">",
"       'Choice of regimen'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Neoadjuvant therapy is under study in a European trial comparing preoperative FU and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      versus surgery alone [",
"      <a class=\"abstract\" href=\"UTD.htm?11/38/11882/abstract/50\">",
"       50",
"      </a>",
"      ] and a joint",
"      <span class=\"nowrap\">",
"       Swiss/Italian",
"      </span>",
"      trial of preoperative",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/59/41913?source=see_link\">",
"       docetaxel",
"      </a>",
"      , cisplatin and FU compared to surgery alone. Similarly, a Japanese study is evaluating preoperative cisplatin plus S-1 (an oral fluoropyrimidine) followed by surgery and postoperative S-1 versus surgery and postoperative S-1 alone (KYUH-UHA-GC04-03).",
"     </li>",
"     <li>",
"      In the Dutch CRITICS (ChemoRadiotherapy after Induction chemoTherapy In Cancer of the Stomach) trial, all patients receive induction chemotherapy followed by surgery and randomization to postoperative chemotherapy versus chemoradiotherapy [",
"      <a class=\"abstract\" href=\"UTD.htm?11/38/11882/abstract/51\">",
"       51",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A randomized trial, the TOPGEAR trial, is underway in Europe and Canada to directly compare preoperative chemotherapy alone (ECF) versus chemoradiotherapy (two cycles of ECF followed by concurrent fluoropyrimidine-based chemoradiotherapy) in patients with resectable adenocarcinoma of the stomach and esophagogastric junction; both groups will receive three further cycles of ECF postoperatively [",
"      <a class=\"abstract\" href=\"UTD.htm?11/38/11882/abstract/52\">",
"       52",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     POSTTREATMENT CANCER SURVEILLANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no randomized trials to guide the postoperative surveillance strategy. Consensus-based guidelines from the",
"    <a class=\"external\" href=\"file://www.nccn.org/professionals/physician_gls/f_guidelines.asp\">",
"     National Comprehensive Cancer Network",
"    </a>",
"    suggest the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      History and physical examination every three to six months for one to three years, then every six months for years 4 and 5, then as clinically indicated",
"     </li>",
"     <li>",
"      CBC and chemistry profile, as clinically indicated",
"     </li>",
"     <li>",
"      Radiologic imaging or endoscopy, as clinically indicated",
"     </li>",
"     <li>",
"      Monitor for nutritional deficiency in surgically treated patients and treat as indicated.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?31/28/32195?source=see_link\">",
"       \"Patient information: Stomach cancer (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The poor long-term survival rates after surgery alone for patients with gastric and esophagogastric junction (EGJ) cancer have led to the exploration of a variety of adjuvant (postoperative) and neoadjuvant (preoperative) treatment strategies incorporating chemotherapy with or without radiation therapy (RT). The survival benefit from combined modality therapy has become clearer over time. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Most clinicians now treat EGJ and proximal gastric (ie, cardia, (",
"      <a class=\"graphic graphic_figure graphicRef56689 \" href=\"UTD.htm?40/59/41907\">",
"       figure 1",
"      </a>",
"      )) cancers as esophageal cancers, using preoperative chemoradiotherapy. However, these tumors have been included in many of the trials examining the benefit of adjuvant and neoadjuvant chemotherapy for gastric cancer, and institutional practice varies. The therapeutic approach to tumors of the EGJ and gastric cardia is addressed in detail elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/51/39738?source=see_link\">",
"       \"Multimodality approaches to potentially resectable esophagogastric junction and gastric cardia adenocarcinomas\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients with non-cardia gastric cancer, randomized trials and meta-analyses provide support for a number of approaches including adjuvant chemoradiotherapy, perioperative (preoperative plus postoperative) chemotherapy, as was used in the MAGIC trial [",
"      <a class=\"abstract\" href=\"UTD.htm?11/38/11882/abstract/3\">",
"       3",
"      </a>",
"      ], and adjuvant chemotherapy. Few studies have compared these approaches, and the optimal way to integrate combined modality therapy has not been definitively established. The decision often is based upon institutional",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      patient preference. A major problem, at least in the US, is that patients with gastric cancer are commonly taken to the operating room prior to consultation by medical or radiation oncologists. Multidisciplinary preoperative evaluation is preferable, as is participation in clinical trials when possible.",
"     </li>",
"     <li>",
"      For patients in whom protocol participation is not feasible and who have already undergone potentially curative gastric resection, we suggest adjuvant chemoradiotherapy rather than surgery alone for patients with N1 disease (which would include T1N1 stage IB), and for patients with T3N0 (stage IIA) disease and above (",
"      <a class=\"graphic graphic_table graphicRef57916 \" href=\"UTD.htm?11/6/11374\">",
"       table 1",
"      </a>",
"      ), based upon the results of US Intergroup trial INT0116 [",
"      <a class=\"abstract\" href=\"UTD.htm?11/38/11882/abstract/4\">",
"       4",
"      </a>",
"      ]&nbsp;(",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). For the subgroup of patients with T2N0 disease, either observation or adjuvant treatment is acceptable, and the decision can be based upon individualized patient (such as age, performance status, and motivation for treatment) and disease risk factor (eg, histologic grade or the presence of lymphovascular or perineural invasion) considerations.",
"      <br/>",
"      <br/>",
"      Although the optimal regimen has not been established, the treatment arm of INT-0116 could be considered a standard protocol. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Adjuvant chemoradiotherapy'",
"      </a>",
"      above.):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      One cycle of 5-FU (425",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      per day) and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/54/24423?source=see_link\">",
"       leucovorin",
"      </a>",
"      calcium (20",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      per day) daily for five days.",
"     </li>",
"     <li>",
"      This is followed one month later by 45 Gy (1.8",
"      <span class=\"nowrap\">",
"       Gy/day)",
"      </span>",
"      of RT given with FU (400",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      per day) and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/54/24423?source=see_link\">",
"       leucovorin",
"      </a>",
"      calcium (20",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      per day) on days 1 through 4 and the last three days of RT. As an alternative, current randomized trials are using continuous infusion FU at a dose of 200",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       /day",
"      </span>",
"      during RT, or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/0/40967?source=see_link\">",
"       capecitabine",
"      </a>",
"      (825",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      twice daily during RT).",
"     </li>",
"     <li>",
"      Two more five-day cycles of chemotherapy (FU 425",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      per day and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/54/24423?source=see_link\">",
"       leucovorin",
"      </a>",
"      calcium 20",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      per day) are given at monthly intervals beginning one month after completion of radiation.",
"      <br/>",
"      <br/>",
"      An acceptable fluoropyrimidine alternative for concurrent chemoradiotherapy is continuous infusion FU (200",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      daily) or, as used in the ARTIST trial, daily oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/0/40967?source=see_link\">",
"       capecitabine",
"      </a>",
"      (850",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      twice daily). (See",
"      <a class=\"local\" href=\"#H23495808\">",
"       'Chemotherapy versus chemoradiotherapy'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      For the chemotherapy alone component, other acceptable options include two months of weekly 5-FU plus leucovorin (the Roswell Park regimen), short-term infusional 5-FU plus leucovorin (the de Gramont regimen (",
"      <a class=\"graphic graphic_table graphicRef65525 \" href=\"UTD.htm?36/17/37149\">",
"       table 4",
"      </a>",
"      )), or ECF, as was used in CALGB 80101 (",
"      <a class=\"graphic graphic_table graphicRef62502 \" href=\"UTD.htm?35/44/36558\">",
"       table 3",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/44/34506?source=see_link&amp;anchor=H5#H5\">",
"       \"Adjuvant therapy for resected stage III (node-positive) colon cancer\", section on 'Bolus 5-FU plus LV'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/44/34506?source=see_link&amp;anchor=H9#H9\">",
"       \"Adjuvant therapy for resected stage III (node-positive) colon cancer\", section on 'Short-term infusional 5-FU/LV'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/44/34506?source=see_link&amp;anchor=H11#H11\">",
"       \"Adjuvant therapy for resected stage III (node-positive) colon cancer\", section on 'Capecitabine'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/23/43378?source=see_link\">",
"       \"Treatment protocols for esophagogastric cancer\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An acceptable alternative approach for patients who are seen prior to resection is perioperative (combined preoperative and postoperative) chemotherapy alone (ECF, (",
"      <a class=\"graphic graphic_table graphicRef62502 \" href=\"UTD.htm?35/44/36558\">",
"       table 3",
"      </a>",
"      )). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/23/43378?source=see_link\">",
"       \"Treatment protocols for esophagogastric cancer\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      In terms of patient selection for this approach, it is reasonable to utilize the eligibility criteria for the MAGIC trial (patients of any age with a performance status of 0 or 1 (",
"      <a class=\"graphic graphic_table graphicRef72901 \" href=\"UTD.htm?9/15/9467\">",
"       table 5",
"      </a>",
"      ), a histologically proven adenocarcinoma of the stomach that was considered to invade through the submucosa [stage T2 or higher, (",
"      <a class=\"graphic graphic_table graphicRef57916 \" href=\"UTD.htm?11/6/11374\">",
"       table 1",
"      </a>",
"      )], with no evidence of distant metastases or locally advanced inoperable disease, as evaluated by CT, ultrasonography or laparoscopy) [",
"      <a class=\"abstract\" href=\"UTD.htm?11/38/11882/abstract/3\">",
"       3",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'MAGIC trial'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Since this regimen has not been compared head-to-head with postoperative chemoradiotherapy, it is not known whether this approach is superior to postoperative chemoradiotherapy. However, this approach may be preferred over initial surgery for patients with a high likelihood of developing distant metastases (ie, those with bulky",
"      <span class=\"nowrap\">",
"       T3/T4",
"      </span>",
"      tumors, visible perigastric nodes by preoperative imaging studies, a linitis plastica appearance, or positive peritoneal cytology in the absence of visible peritoneal disease). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Neoadjuvant/perioperative chemotherapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      East Asian patients may take one year of postoperative S-1 chemotherapy as an alternative to combined preoperative plus postoperative chemotherapy with ECF. It is difficult to know whether the benefit of adjuvant therapy with S-1, as demonstrated in the Japanese ACTS-GC trial [",
"      <a class=\"abstract\" href=\"UTD.htm?11/38/11882/abstract/29\">",
"       29",
"      </a>",
"      ], can be extrapolated to other populations, given the markedly better outcomes seen in both the treated and the surgery alone control groups, stage for stage, when compared to outcomes in other non-Japanese populations [",
"      <a class=\"abstract\" href=\"UTD.htm?11/38/11882/abstract/53\">",
"       53",
"      </a>",
"      ]. Until further information becomes available, we suggest that this approach be limited to East Asian patients (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H23496123\">",
"       'Japanese S-1 trial'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Other alternative chemotherapy regimens for adjuvant therapy include",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/0/40967?source=see_link\">",
"       capecitabine",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/11/2233?source=see_link\">",
"       oxaliplatin",
"      </a>",
"      , as was used in the CLASSIC trial [",
"      <a class=\"abstract\" href=\"UTD.htm?11/38/11882/abstract/30\">",
"       30",
"      </a>",
"      ], or capecitabine plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      , as was used in the ARTIST trial [",
"      <a class=\"abstract\" href=\"UTD.htm?11/38/11882/abstract/16\">",
"       16",
"      </a>",
"      ]. However, results from these trials are not as mature as they are for the MAGIC (perioperative chemotherapy) and INT0116 (postoperative chemoradiotherapy) trials, and, as with S-1, it is unclear if the results can be extrapolated to Western populations. (See",
"      <a class=\"local\" href=\"#H23496205\">",
"       'CLASSIC trial'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H23495808\">",
"       'Chemotherapy versus chemoradiotherapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is insufficient evidence from randomized trials to support the use of intraperitoneal chemotherapy, and we recommend against its use unless in the context of a clinical trial (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5490918\">",
"       'Intraperitoneal chemotherapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The optimal approach to patients with locally advanced, unresectable but nonmetastatic disease is uncertain. An initial attempt at downstaging with chemotherapy, chemoradiotherapy, or a combination followed by careful restaging and surgical exploration in responders who have no evidence of metastatic disease is a reasonable approach for a fit patient with a good performance status. Whenever possible, such patients should be encouraged to enroll on clinical trials testing new approaches. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Initially locally unresectable nonmetastatic disease'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11882/abstract/1\">",
"      Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11882/abstract/2\">",
"      Agboola O. Adjuvant treatment in gastric cancer. Cancer Treat Rev 1994; 20:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11882/abstract/3\">",
"      Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006; 355:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11882/abstract/4\">",
"      Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001; 345:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11882/abstract/5\">",
"      R&uuml;diger Siewert J, Feith M, Werner M, Stein HJ. Adenocarcinoma of the esophagogastric junction: results of surgical therapy based on anatomical/topographic classification in 1,002 consecutive patients. Ann Surg 2000; 232:353.",
"     </a>",
"    </li>",
"    <li>",
"     American Joint Committee on Cancer Staging Manual, 7th, Edge SB, Byrd DR, Compton CC, et al (Eds), Springer, New York 2010. p.117.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11882/abstract/7\">",
"      Gunderson LL, Sosin H. Adenocarcinoma of the stomach: areas of failure in a re-operation series (second or symptomatic look) clinicopathologic correlation and implications for adjuvant therapy. Int J Radiat Oncol Biol Phys 1982; 8:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11882/abstract/8\">",
"      Allum WH, Hallissey MT, Ward LC, Hockey MS. A controlled, prospective, randomised trial of adjuvant chemotherapy or radiotherapy in resectable gastric cancer: interim report. British Stomach Cancer Group. Br J Cancer 1989; 60:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11882/abstract/9\">",
"      Drognitz O, Henne K, Weissenberger C, et al. Long-term results after intraoperative radiation therapy for gastric cancer. Int J Radiat Oncol Biol Phys 2008; 70:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11882/abstract/10\">",
"      Kr&auml;mling HJ, Wilkowski R, D&uuml;hmke E, et al. [Adjuvant intraoperative radiotherapy of stomach carcinoma]. Langenbecks Arch Chir Suppl Kongressbd 1996; 113:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11882/abstract/11\">",
"      Shridhar R, Dombi GW, Weber J, et al. Adjuvant radiation therapy increases overall survival in node-positive gastric cancer patients with aggressive surgical resection and lymph node dissection: a SEER database analysis. Am J Clin Oncol 2012; 35:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11882/abstract/12\">",
"      Dent DM, Werner ID, Novis B, et al. Prospective randomized trial of combined oncological therapy for gastric carcinoma. Cancer 1979; 44:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11882/abstract/13\">",
"      Moertel CG, Childs DS, O'Fallon JR, et al. Combined 5-fluorouracil and radiation therapy as a surgical adjuvant for poor prognosis gastric carcinoma. J Clin Oncol 1984; 2:1249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11882/abstract/14\">",
"      Smalley SR, Benedetti JK, Haller DG, et al. Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. J Clin Oncol 2012; 30:2327.",
"     </a>",
"    </li>",
"    <li>",
"     Fuchs CS, Tepper JE, Niedzwiecke D, et al. Postoperative adjuvant chemoradiation for gastric or gastroesophageal junction (GEJ) adenocarcinoma using epirubicin, cisplatin, and infusional (CI) 5-FU (ECF) before and after CI 5-FU and radiotherapy (CRT) compared with bolus 5-FU/LV before and after CRT: Intergroup trial CALGB 80101 (abstract 4003). J Clin Oncol 2011; 29:256s. Abstract available online at file://www.asco.org/ASCOv2/Meetings/Abstracts?&amp;vmview=abst_detail_view&amp;confID=102&amp;abstractID=82318 (Accessed on June 29, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11882/abstract/16\">",
"      Lee J, Lim do H, Kim S, et al. Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial. J Clin Oncol 2012; 30:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11882/abstract/17\">",
"      Kim S, Lim DH, Lee J, et al. An observational study suggesting clinical benefit for adjuvant postoperative chemoradiation in a population of over 500 cases after gastric resection with D2 nodal dissection for adenocarcinoma of the stomach. Int J Radiat Oncol Biol Phys 2005; 63:1279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11882/abstract/18\">",
"      van de Velde CJ, Peeters KC. The gastric cancer treatment controversy. J Clin Oncol 2003; 21:2234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11882/abstract/19\">",
"      Cascinu S, Labianca R, Barone C, et al. Adjuvant treatment of high-risk, radically resected gastric cancer patients with 5-fluorouracil, leucovorin, cisplatin, and epidoxorubicin in a randomized controlled trial. J Natl Cancer Inst 2007; 99:601.",
"     </a>",
"    </li>",
"    <li>",
"     Boige V, Pignon J, Saint-Aubert B, et al. Final results of a randomized trial comparing preoperative 5-fluorouracil/cisplatin to surgery alone in adenocarcinoma of stomach and lower esophagus (ASLE): FNLCC ACCORD07-FFCD 9703 trial (abstract). J Clin Oncol 2007; 25:200s.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11882/abstract/21\">",
"      Schuhmacher C, Gretschel S, Lordick F, et al. Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954. J Clin Oncol 2010; 28:5210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11882/abstract/22\">",
"      Kobayashi T, Kimura T. [Long-term outcome of preoperative chemotherapy with 5'-deoxy-5-fluorouridine (5'-DFUR) for gastric cancer]. Gan To Kagaku Ryoho 2000; 27:1521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11882/abstract/23\">",
"      Nio Y, Koike M, Omori H, et al. A randomized consent design trial of neoadjuvant chemotherapy with tegafur plus uracil (UFT) for gastric cancer--a single institute study. Anticancer Res 2004; 24:1879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11882/abstract/24\">",
"      Ychou M, Boige V, Pignon JP, et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol 2011; 29:1715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11882/abstract/25\">",
"      Earle CC, Maroun JA. Adjuvant chemotherapy after curative resection for gastric cancer in non-Asian patients: revisiting a meta-analysis of randomised trials. Eur J Cancer 1999; 35:1059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11882/abstract/26\">",
"      Mari E, Floriani I, Tinazzi A, et al. Efficacy of adjuvant chemotherapy after curative resection for gastric cancer: a meta-analysis of published randomised trials. A study of the GISCAD (Gruppo Italiano per lo Studio dei Carcinomi dell'Apparato Digerente). Ann Oncol 2000; 11:837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11882/abstract/27\">",
"      Sun P, Xiang JB, Chen ZY. Meta-analysis of adjuvant chemotherapy after radical surgery for advanced gastric cancer. Br J Surg 2009; 96:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11882/abstract/28\">",
"      GASTRIC (Global Advanced/Adjuvant Stomach Tumor Research International Collaboration) Group, Paoletti X, Oba K, et al. Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. JAMA 2010; 303:1729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11882/abstract/29\">",
"      Sasako M, Sakuramoto S, Katai H, et al. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol 2011; 29:4387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11882/abstract/30\">",
"      Bang YJ, Kim YW, Yang HK, et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet 2012; 379:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11882/abstract/31\">",
"      Yu C, Yu R, Zhu W, et al. Intensity-modulated radiotherapy combined with chemotherapy for the treatment of gastric cancer patients after standard D1/D2 surgery. J Cancer Res Clin Oncol 2012; 138:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11882/abstract/32\">",
"      Kim TH, Park SR, Ryu KW, et al. Phase 3 trial of postoperative chemotherapy alone versus chemoradiation therapy in stage III-IV gastric cancer treated with R0 gastrectomy and D2 lymph node dissection. Int J Radiat Oncol Biol Phys 2012; 84:e585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11882/abstract/33\">",
"      Zhu WG, Xua DF, Pu J, et al. A randomized, controlled, multicenter study comparing intensity-modulated radiotherapy plus concurrent chemotherapy with chemotherapy alone in gastric cancer patients with D2 resection. Radiother Oncol 2012; 104:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11882/abstract/34\">",
"      Xu DZ, Zhan YQ, Sun XW, et al. Meta-analysis of intraperitoneal chemotherapy for gastric cancer. World J Gastroenterol 2004; 10:2727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11882/abstract/35\">",
"      Yan TD, Black D, Sugarbaker PH, et al. A systematic review and meta-analysis of the randomized controlled trials on adjuvant intraperitoneal chemotherapy for resectable gastric cancer. Ann Surg Oncol 2007; 14:2702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11882/abstract/36\">",
"      Sun J, Song Y, Wang Z, et al. Benefits of hyperthermic intraperitoneal chemotherapy for patients with serosal invasion in gastric cancer: a meta-analysis of the randomized controlled trials. BMC Cancer 2012; 12:526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11882/abstract/37\">",
"      Grau JJ, Mart&iacute;n M, Fuster J, et al. Impact of adjuvant chemotherapy in the long-term outcome of patients with resected gastric cancer. J Surg Oncol 2003; 82:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11882/abstract/38\">",
"      Glehen O, Mohamed F, Gilly FN. Peritoneal carcinomatosis from digestive tract cancer: new management by cytoreductive surgery and intraperitoneal chemohyperthermia. Lancet Oncol 2004; 5:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11882/abstract/39\">",
"      Stahl M, Walz MK, Stuschke M, et al. Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol 2009; 27:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11882/abstract/40\">",
"      Ajani JA, Winter K, Okawara GS, et al. Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): quality of combined modality therapy and pathologic response. J Clin Oncol 2006; 24:3953.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11882/abstract/41\">",
"      Ajani JA, Mansfield PF, Janjan N, et al. Multi-institutional trial of preoperative chemoradiotherapy in patients with potentially resectable gastric carcinoma. J Clin Oncol 2004; 22:2774.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11882/abstract/42\">",
"      Ajani JA, Mansfield PF, Crane CH, et al. Paclitaxel-based chemoradiotherapy in localized gastric carcinoma: degree of pathologic response and not clinical parameters dictated patient outcome. J Clin Oncol 2005; 23:1237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11882/abstract/43\">",
"      Cascinu S, Scartozzi M, Labianca R, et al. High curative resection rate with weekly cisplatin, 5-fluorouracil, epidoxorubicin, 6S-leucovorin, glutathione, and filgastrim in patients with locally advanced, unresectable gastric cancer: a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). Br J Cancer 2004; 90:1521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11882/abstract/44\">",
"      Gallardo-Rinc&oacute;n D, O&ntilde;ate-Oca&ntilde;a LF, Calderillo-Ruiz G. Neoadjuvant chemotherapy with P-ELF (cisplatin, etoposide, leucovorin, 5-fluorouracil) followed by radical resection in patients with initially unresectable gastric adenocarcinoma: a phase II study. Ann Surg Oncol 2000; 7:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11882/abstract/45\">",
"      Nakajima T, Ota K, Ishihara S, et al. Combined intensive chemotherapy and radical surgery for incurable gastric cancer. Ann Surg Oncol 1997; 4:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11882/abstract/46\">",
"      Yoshikawa T, Sasako M, Yamamoto S, et al. Phase II study of neoadjuvant chemotherapy and extended surgery for locally advanced gastric cancer. Br J Surg 2009; 96:1015.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11882/abstract/47\">",
"      Lowy AM, Feig BW, Janjan N, et al. A pilot study of preoperative chemoradiotherapy for resectable gastric cancer. Ann Surg Oncol 2001; 8:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11882/abstract/48\">",
"      Ajani JA, Komaki R, Putnam JB, et al. A three-step strategy of induction chemotherapy then chemoradiation followed by surgery in patients with potentially resectable carcinoma of the esophagus or gastroesophageal junction. Cancer 2001; 92:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11882/abstract/49\">",
"      Saikawa Y, Kubota T, Kumagai K, et al. Phase II study of chemoradiotherapy with S-1 and low-dose cisplatin for inoperable advanced gastric cancer. Int J Radiat Oncol Biol Phys 2008; 71:173.",
"     </a>",
"    </li>",
"    <li>",
"     Ychou M, Pignon JP, Lasser P, et al. Phase III preliminary results of preoperative fluorouracil (F) and cisplatin (P) versus surgery alone in adenocarcinoma of the stomach and lower esophagus (ASLE): FNLCC 94012-FFCD 9703 trial (abstract). J Clin Oncol 2006; 24:185s.",
"    </li>",
"    <li>",
"     Information on the Dutch CRITICS trial is available online at file://clinicaltrials.gov/ct2/show/NCT00407186 (Accessed on December 14, 2010).",
"    </li>",
"    <li>",
"     Leong T, et al. TOPGEAR: an international randomized phase III trial of preoperative chemoradiotherapy versus preoperative chemotherapy for resectable gastric cancer (AGITG/TROG/EORTC/NCIC CTG). J clin Oncol 30, 2012 (suppl; abstr TPS4141). Abstract available online at file://www.asco.org/ASCOv2/Meetings/Abstracts?&amp;vmview=abst_detail_view&amp;confID=114&amp;abstractID=99024 (Accessed on June 14, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/38/11882/abstract/53\">",
"      Macdonald JS. Gastric cancer: Nagoya is not New York. J Clin Oncol 2011; 29:4348.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2523 Version 23.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-91.202.164.29-B6FAD70B64-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_38_11882=[""].join("\n");
var outline_f11_38_11882=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ADJUVANT CHEMORADIOTHERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Intergroup 0116",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23495516\">",
"      CALGB 80101",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7097668\">",
"      ARTIST trial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25275186\">",
"      Indications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3744529\">",
"      Choice of regimen",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      NEOADJUVANT/PERIOPERATIVE CHEMOTHERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      MAGIC trial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      French FNLCC/FFCD trial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H92241562\">",
"      EORTC trial 40954",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23495743\">",
"      ADJUVANT CHEMOTHERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23496094\">",
"      Meta-analyses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23496123\">",
"      Japanese S-1 trial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23496205\">",
"      CLASSIC trial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23495808\">",
"      Chemotherapy versus chemoradiotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5490918\">",
"      Intraperitoneal chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5490761\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      NEOADJUVANT CHEMORADIOTHERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      INITIALLY LOCALLY UNRESECTABLE NONMETASTATIC DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5491664\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      ONGOING RESEARCH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      POSTTREATMENT CANCER SURVEILLANCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/2523\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2523|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?40/59/41907\" title=\"figure 1\">",
"      Anatomy of the stomach",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2523|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/6/11374\" title=\"table 1\">",
"      2010 TNM staging stomach CA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/24/4494\" title=\"table 2\">",
"      TNM staging esoph adenoCA including EGJ",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?35/44/36558\" title=\"table 3\">",
"      ECF for advanced esophagogastric cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?36/17/37149\" title=\"table 4\">",
"      Modified de Gramont schedule for gastrointestinal cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/15/9467\" title=\"table 5\">",
"      ECOG performance scale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/17/16670\" title=\"table 6\">",
"      Rand trials adjuv chemo gast CA",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/51/4922?source=related_link\">",
"      Adjuvant therapy for resected rectal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/44/34506?source=related_link\">",
"      Adjuvant therapy for resected stage III (node-positive) colon cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/10/44202?source=related_link\">",
"      Chemotherapy for locally advanced unresectable and metastatic esophageal and gastric cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/36/11850?source=related_link\">",
"      Clinical features, diagnosis, and staging of gastric cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/45/7898?source=related_link\">",
"      Diagnosis and staging of esophageal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/35/4661?source=related_link\">",
"      Epidemiology of gastric cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/15/33018?source=related_link\">",
"      Invasive gastric cancer: Surgery and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/56/19333?source=related_link\">",
"      Local palliation for advanced gastric cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/51/39738?source=related_link\">",
"      Multimodality approaches to potentially resectable esophagogastric junction and gastric cardia adenocarcinomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?31/28/32195?source=related_link\">",
"      Patient information: Stomach cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/31/39418?source=related_link\">",
"      Radiation therapy, chemoradiotherapy, neoadjuvant approaches, and postoperative adjuvant therapy for localized cancers of the esophagus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/23/43378?source=related_link\">",
"      Treatment protocols for esophagogastric cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_38_11883="Differential dx appendagitis";
var content_f11_38_11883=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F57034&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F57034&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Differential diagnosis in patients with epiploic appendagitis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Abscess",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Appendicitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Colon cancer or metastasis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Crohn's ileitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ectopic pregnancy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gallbladder disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ileitis caused by infection with Yersinia, Campylobacter or Salmonella",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Left- or right-sided diverticulitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mesenteric adenitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mesenteric panniculitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Metastases to the omentum",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ovarian torsion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ruptured or hemorrhagic ovarian cyst",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Segmental omental infarction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Urachal cyst",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_38_11883=[""].join("\n");
var outline_f11_38_11883=null;
var title_f11_38_11884="Breast cancer genes";
var content_f11_38_11884=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F66808&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F66808&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Major genes associated with breast cancer",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"3\" width=\"15%\">",
"     </colgroup>",
"     <colgroup width=\"55%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Gene",
"       </td>",
"       <td class=\"subtitle1\">",
"        Associated syndrome",
"       </td>",
"       <td class=\"subtitle1\">",
"        Gene frequency",
"       </td>",
"       <td class=\"subtitle1\">",
"        Other cancers",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        BRCA1",
"       </td>",
"       <td>",
"        HBOC",
"       </td>",
"       <td>",
"        Rare",
"       </td>",
"       <td>",
"        Ovary, fallopian tube, male breast, pancreas, prostate*, possibly cervix and uterus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        BRCA2",
"       </td>",
"       <td>",
"        HBOC",
"       </td>",
"       <td>",
"        Rare",
"       </td>",
"       <td>",
"        Ovary, fallopian tube, male breast, pancreas, prostate*, possibly biliary tract, stomach, and melanoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        p53",
"       </td>",
"       <td>",
"        Li-Fraumeni",
"       </td>",
"       <td>",
"        Very rare",
"       </td>",
"       <td>",
"        Soft tissue and bone sarcomas, leukemia, brain, adrenocortical malignancies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        PTEN",
"       </td>",
"       <td>",
"        Cowden",
"       </td>",
"       <td>",
"        Very rare",
"       </td>",
"       <td>",
"        Hamartomas (papillomas of the lips and mucous membranes, acral skin keratoses, trichillemmomas of skin), uterus, non-medullary thyroid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CDH1",
"       </td>",
"       <td>",
"        Hereditary Diffuse Gastric Cancer Syndrome",
"       </td>",
"       <td>",
"        Rare",
"       </td>",
"       <td>",
"        Lobular breast cancer, diffuse gastric cancer",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        STK11",
"       </td>",
"       <td>",
"        Peutz-Jeghers",
"       </td>",
"       <td>",
"        Very rare",
"       </td>",
"       <td>",
"        Hamartomatous gastrointestinal tract polyps, small bowel, stomach, colorectal, pancreas, lung, uterus, ovary",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        PALB2",
"       </td>",
"       <td>",
"        Hereditary pancreatic cancer",
"       </td>",
"       <td>",
"        Rare",
"       </td>",
"       <td>",
"        Pancreatic cancer, Fanconi anemia",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     GI: gastrointestinal; HBOC: hereditary breast ovarian cancer syndrome.",
"     <br/>",
"     * Men with BRAC2 mutations have a five- to sevenfold increased risk of prostate cancer; magnitude of risk is less clear with BRAC1.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_38_11884=[""].join("\n");
var outline_f11_38_11884=null;
var title_f11_38_11885="Gram stain CSF 6B with answer";
var content_f11_38_11885=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F52295&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F52295&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cryptococcus neoformans in an india ink preparation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 240px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    India ink preparation of cerebrospinal fluid (x400) shows a prominent clear zone around individual yeasts, consistent with the capsule of Cryptococcus neoformans. The yeast in the center of the slide is budding.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Harriet Provine.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_38_11885=[""].join("\n");
var outline_f11_38_11885=null;
var title_f11_38_11886="Rate late onset GBS";
var content_f11_38_11886=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F62741&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F62741&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 537px\">",
"   <div class=\"ttl\">",
"    Rate* of late-onset",
"    <sup>",
"     &bull;",
"    </sup>",
"    invasive group B streptococcal disease, by race and year - Active Bacterial Core surveillance system, United States,",
"    <sup>",
"     &Delta;",
"    </sup>",
"    2000-2006",
"    <sup>",
"     &loz;",
"    </sup>",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 517px; height: 327px; background-image: url(data:image/gif;base64,R0lGODlhBQJHAeYAAP///wAAAP8AAIiIiAAzmTMzM0RERLu7u+7u7kBAQGZmZt3d3YCZzMDAwJmZmYCAgBERESIiIszMzEBms8DN5nd3d6qqqlVVVf9gYP/g4P/AwP+AgKCz2eDm89DZ7P/w8P/Q0P+goP8gIGBgYJCQkDAwMP8QEP9AQPDw8HCNxlBQUNDQ0CAgIODg4P8wMKCgoBAQELCwsHBwcP+QkP+wsP9QUP9wcFBzubDA37/M5WCAvyBNpvDz+ZCm0zBZrBBAn/+/v7+/vwAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAAAFAkcBAAf/gACCg4SFhoeIiYqLjI2Oj5CRkpOUlZaXmJmam5ydnp+goaKjpKWmp6ipqqusra6vsLGys7S1tre4ubq7vL2+v8DBwsPExcbHyMnKy8zNzs/Q0dLT1NXW19jZ2tvc3d7f4OHi4+Tl5ufo6err7O3u7/Dx8vP09fb3+MMB+/z9/v8AAwocSLCgwYMIEypcKDCfQ28BHt6KKLHiNYoWZWHMyPHZxo6tPoIceUwkSVQmT6r8lXLlqJYuY07sdQCmoAEGItUMcEBTAQWpFkSwgMimzKOxjKrauW8AgJqMcBbtaaiA00Y8FzkooMkAxgUQqAqqkFPQAQgIDilFynbVWlQ1/xcAGADhqVGpkMI6yqpoaCYF+27uE7uvrKACDtS2XUzr7am4ACpcsAvAAT+gCwrsuyDVQQSxAHjW1AxBAuAAERbwK4BgdIDSpwNI8PqakOq0AAxoDgCUUOx9iQlVsLqR703DkScbcsy4OaiPAqJLjw7k0PTp1Q1dl57dEFPerTdaRnDBMM6tcgmJzmoAqHEAqi3U7Nk+dM+auAkdiDDIQE7IjgyQmmXqgYaXIA4gNwhzzjW4CXTbCdAdIRFKaF2EE+oXgFwIRFABVFvxI1Rwc0EQAFGFrCeIAu71NBs/DkAFAIv2jfXaVWbxJ4gBTqmW3or+kAhABP4saCByCSrm4P+SpzBICmQdDgCVhwBYsGF5gwyA2Hv2yUhjVgpwhUAAMVL0JYqCSLDhILft2OOakRBoJCEHJqckk3iK4uQo310Q3lz7ELlAZpt1RmaBXrb4lIlElrkiUKdZtk9vg/iV25s/PiLnAJcJ0k96iN2Z56id7HnOVquclZ96pLbKiann/BSUpcu5aismsLqa66268jrJrr6OCqywwRa7l7GPDItsg8ri2eyyjD27pLTQskUts9Vm66m2iVzL7UreziIVj4WAJSQrBlTwSbjfcmPlIZwGwJom7FJywG4FSHDJuDiuqC4m75rFqL6EHjokPzkhoFep7UpEmyFq6lvAv7jaAlb/bwZEsKok/NoWwMaTPCwIBE4NB8AFk1mZVgTnVkDpgw1LJCOdXM2lYCX1clzzyBYooFy6BQOFE6eS8mbzpYSg6ulu5/5msIZpfkwZBChmRaS86VlQF8MxOzRzlmUJaEgCDH1UdtlBIKIAcizHpeYCF2BWmoCgjddxlpQG4JTYOlEkY1x8PY1AAcqp5snZiCeu+OKMN+744wft8vVNNdepiE1mQy5Q2vDuDADVl7p8MIx4hbjPAnfflHdPnhXi9LmUAaBmWlCBXiPYghjOdde85GzJzGvLLhsAEx97ucVG56ZxZRDoFTedZVFpJeo5kTuI0jW23vcgJEfGFcpVfnyA/wEIDH6V1ofz3ovvlNB2aPCAygtyUYuwD8m9++RbaVkFb4hXvIJKHXyklj0dPcJ9iTkLagjGNPjshnxjeRm91Ne7i9TPGwqgmCsUBpoJUlAX9nsF5rxhLlika10fBKEFj6e+EKYQEi4MyQVb+EJcxJAVI6RhDW1xQ7fMkHc9XEcGqBHEVOQQiEzKAAYEoIFpFBElP+zaE8mhROnMwIkr7BYFpxiOKkYHA0PEojWOKMXm0EA6YBxjFun3i8llQih684kES3HCFDXnAyZI4xrFqMVaSOYwyrHK5FS0COsVgix76aAhsFeJqwXAMFaxTQTKwkE73lEbXCwFGWWBPoXVZf9MEnBj7CbBmUQuglaNFNJOcDS4Rw5CdKyylQ0+0IxMkmKTsQClBS6QL/S5pjT2uRp/LpC/VZFLXsApmmqK+UvT8ONFtWETAXUzqUIUrZqEuFoBfmTIn8CvSltbkEuUKAJJ2EAALqjlHmtFCAK4MweCcCcB4AkAedLTnvF8Zz7nuU96IoIzFRhAQP84n9y0SEZaSksk++OUOIrNkAOUD3sUhR/vGNA/dsmUIwanHKTlJiff1J04T+JFJkYCBCYQgA2YYcuXRLGe+oQpP2V6z5jik6b9VMQAeCmBXRaAKInqkpn68bJjso4/5IImmYLKlwrcSD8XxVTS/DHH4zB0gP3/4J/ZSFLSE4BgEmcUQAiW0VI9vVQWEmgeABQmNaYeoKIJPYRRK4NUp4RprUs1k3vQJLwftQlpPnrE+Mq3UI8O4pvoi2VHNiCdEzSxEow1wVeTUdZQ4FIWEAhkzdzaymHCiBBzbR25FNiooEaqU9lEEbkC64iCQZApBpyRYWA50o6EQACOzUQNBCACWiKjspggG0DOeg9GnqKSiu3IZDPxARcIoAaUXaclJSKrVNQxubYCgQuWawzgopCFSMyHEjcAD++mD7xlvIcXTVBe6WK3YeblRUn16I74voq437JvLpb4xTC2V43ojZl+cSECAdCXFb4VxoAzcdn81kMD/m0F/w1MMFYFu3dBmsuwhjfM4chB65yStTCAdygPJUa4FifgbYJ9seCKkRgeXsRALj5QYOgCo8WXwPGLW/EB/uKWu7YAQXTIy5IL71gcH9hASnH72F3c1qQsNvKRwaGB6OT2F0tcaZRHPOVz2KDJv/gADW4s5S6b2RQ6xtmZvzFmpJg3XvMiBDHlpS+srHkbGVAylGXi3YgRT4Nak0t1GZHmO1dCAz4WAZhd4l0tWVWaToFogA0NjRkU2MoVjsYMVlyLRocttifj5TaNR2lpgPjA0FiijWeCC0cfLUuV85wghPuPUk8jA5mmhpAFQGQe5sLPxQseXeRyVzvb2hhixkBvwf/x5DZ3WhdwTgv8aKM/Yx87GBrYgHOlk+tuLDHEz+bytXtxHRd8eRzOXXZjyjxuWpxABBigAafDQePnhrsahSYxCGagbC3HQ7tAhkW+JTFwCmZgBjVYspUdLO52q2IG0jFBDWaw6GoVHIYON0XFAQACDMwg4Ny6eLIyHopsp1gAJ36hyEkNCxBo4OXzBsAGZk7zmaccACc4gQ02sPG2bODk0hEByD+4cmtz4uXZrvnNK7Rxpl8o4hgYukyW7AIMhODmI9GA0EXIbkHkPOfb3jOFItRtQVyat18vu8xrTvObv3wDGFB4zzMi5o2HQN5t2a26cdh1AIR9Or0mhA1yvnP/ms99FIgu50jEbINtyxhP9V61DxueCJcjXRkZwHo8QvB3dF4xT7sOvBH7/owlumAGmm8HxNFpA7y36smHNyvlr+Fjz6f+G7gWvSAy4Hpeffv2zyH9Mz4Qgt1ym4ohULZ0gH+r5vJ68vhGcvFRLo4MnN3KG4g5snDN99mX4wNSl0ZKT8Bzkkei6IRux21FYIPwDyPbNXA2IZhvflEtg9ZFYgdjg95+Y5h8Oo9XfwwmfN5AA3GHRsRgfNEBbyHgfgI4ct6XDgZIYcRgaVZHfyQmf7IXfRIRexr3c4ongCmmgcEXgfIgZHnUex8IdNGBgXcGYg7oYhzoEDRwfTUQAtrX/wm7toAX+ICC4FwukIMeNIMPAQKNF3SmUHVX54OFgEcG5lImaA8HZ26acHAJp3ZMWHnR8XklSIQuEQIeyHH8dn0BmIWNsHphSAnoh18kER15dHgK+FwfZ4aRoGwxqIYEKF7Kt4AzoHbFV350OAkfIIQySERt0XFLFoKBWGRReBLFV4aLuD55GIl3toaTRonmZ4l9hIkUhGj31YicuCxOqHtqBoqhiCzNNoS3EG3lQhuKxEanyDu/N4C4AGwaNCRxxnKxGDNASIhGVwuuVidaMz+XuIvckgEpBYm/kgv/E1t0sQ8Lk37GyDtVJgAkeH7MWDnIgRcVAGoAgH/9MI3qE/8CXFiKt2CLsiU7wGQyvyiOtvZmxZSO8VNt0uiO16aJsGiP7ziJ+kh0/NiPt+KC22KKABksH3ACQYiNBFmQvOKEysiGkLAAFoAAE5kL+MiQ31CN5ViPlRAvFjBovoaRMQNx7AWBlhABBTAU7MhqItkwG+CCuTImH9kzsrZuLXlmuxIBYVIBEFBVGnGTOIkJRQMBGmWTQDllwHIAAVWURnmUO7YrB5AeUWmRTomUmFA83kOVVfmUv1MAEICSXlmTs3CRW5kOsGIl/QABsDOWZfliMakAA1A+u0CWbWkOw1I+xPiTdVlDu/KM+RML4MgPe8mXmBABROKVHRWSg+mPljD/JpyCAD6jlYu5RZcgkxPDS5I5meFlCYTjVMnDkpqZXpkwAP2imKEpYJ1Qmk15mu2SK8OhLpkhlnrJmvBlCUVjACZyM2xJm7VZCd3YM5OSlwLHm71JCcNBkXojnMNJnAxnnP8gm0nBnM05CZ7ZD9C5nNKZLTGJl3KZmdm5LHT5Xt9ZLOFZW+OJLOU5kOeJnv+4nosBj/IjV2+Rnu7pDH02PFjpG4Ghi/V5K42mjYdEHCbZn7ziaTfhjAMynwQaLP/5aILgSPtJCIEZoQtqK/cpMeryTZWhoBXqn9AWjxoqJ+1IoCjQAA+gAgmQACrwACzKog3woi+KAjFBn/RZQyaq/wIsgDglkKIpOgIt+gAkAKMvWg806p4NQAIjUAL/UAIj8AIv+gI/KgM8mgBKujg7yqM+2qJBCqMrAA5FKp0rgKRV2g9MGqSWIKRH+qMjMKVjmjhTmgAywKIv0ALR8KWnuQIvIKX/wAIqYKavgKYk8KMoyqM5ehAwsKINoE6mKKdC6o4tkKeByacP0AAyegwlKqQtmgAw4A9wGgN0WhJd1wIEwQJTGqcsuqUxmnEtEAMPoKn+AAMJ8AAxUKnWEKYjUKj8wAIjQAJdqg+hyqJs6qZY+qMxwKUphAKs6qr9AKuy+qnfgKx6uqyxSqmM6IWVsAKY2qJryqOJc6Up+qNOCv+jtlKiJ4qr/ACnc7oON7qpZCoD6apCC7kJl/qigcqiUkqoZ1MCiOqsbXGkOPoP6Nqr8vCoSfqqfZqopslHvCCkUNqig0qlApEAPtoA/AoSR1qw/lCmAusQ5BqYsTqrs2mIzlCiJCCl7Mqpu0qtDoGnGEumKbsSYfqv/aCrL7CxqmCn0kCuawoQsCoDQUqr7YCn0TqziAq0R7GqMtCmAXCok3qz7UkMLWCiO/sPzOqk5tAAMTC0uVq0o7KuGSsDnqpJT5sMq3qiSrsPpPoAVlsN2MqqrZoA5soPzBq2wcKyccunvGpZY+sMK8CqKnC2ASCpMWCzwXCpgbqtBbGjzfr/LcjaqgA7qUabY3s7DXjaqnG7D/oqq4QbC9jasCl6ua/6rWrbAJvLO/4at0z6rpaAs+/QAFAKtwDBpJNasaJwqSy6poCbsRLroipraI+atAbbtMsYr+ZAsiYLELtLsZjwpMCqrAJBqrEqq6TLhB17svuQACSgkM0woTVqCsbrvHILpz+LCFFroicKsQTRo0Caqrtoq4WqAtorsiARtQ8wtaErA/dqvQBBqisqvaXbj8iKsAOqsCpBv/aLvHC6vgJcn6x7FH3LosVKu/igAxMwARwgCB4QLZPblj0wAT/AAIIwAe7UA4LgAwTwAxcMAB6QwYzWdRTAAD3AwnXZwR8c/8LupAOCwAEUQAE8IAg74E44IAg/4E4prMMdABINjAgM4E4TIAhLTABNDAAccAMMkMIdsMPGyAETsAM4DAA6wMSCsMNHrAge0MMA4MEEQAH7pMYAUMU8/BBJfAgvfAMp4MRg3MZ3/MRRrMUTUMcA8MIUIMMORwFbHMV6HMY4IMiXcAMinME8IE9sTMU9YMbcwMIdwAAgjHHEewgd0ANVnMMT4AOGnMekTABdzAGYbMVj/EIUcAOibMcEsAOIrMihcMmh3MMeIE8Z3AE70MerbAxXTAFB/MeM7MeHjMcEQMvF6BGmEMwsTAEp0MewPMpQPM05rAOfDAAd8MvB0so+IP/LUixPgtABOiwLPIDKNxDG4vzHJxzFPIDFrfDOz5zKOfzD1HzPsHzKKcAA3AyRijoLLOwB9IzM6ezFd5wCdzzF2dwByowUHUDBBKDO7jTO5ewLO5zJFLDOGT3RKrzPKYwJV5zNfGzMpYzPUlzBGK3DDY2HmwwLHuDJbJwCQ+zHImzKgnAD7lTQDDAB2ewBbJwRDy3CEk0AR9zJb6wMV4zBofwDgoADGt3LBf3OgRzGDEDH1ozMJr3E0vzHA83QTtvSu/DSDBDTP5zJNW3W7pTJ0TzWGPzT7NAB0fwDRQ3JgtADR50Nl8wAXfzE4MwBpewDV63FOmDFO7zS0QnWxuD/Aagc0yaM1gTg2GrN02zs094Q12xM121MAf0sDj49zHwcxQJt1yy1wczgATjA1gCQAo1tw4/N2pGdApM91azg00eNyfzsxJg8xrat27kdwlt82UTsxJrdbnHMDqaN2qrd2mec1q4tCNE8AZ6NybE93CosxmFMARyg29HMxjU9zPKUwkOcxms83jKVwj+s3ByQyAJY3Pdw3GxMwT9AwgBw3pDd3Mut3CaM38x935nMyBacw73dxgG+27iN2j5t2BnH3iCxwzgwxqiM3BWcws8t4RXMxqjc4Bi82WUJn7m4VtSmnObZoaRyoX9mG+QTJfwp4s6SjQ5aCIXlzyreHAY6/xfeOBdiyb0x3ioN+mq+0eEwnuNtQeLBlhOZ4ZObCORMwuHSlhPXVOP2h+TYgthQzhEKPuVHUeVWPqOkneX3gOVcrhJe/uUkEeZijsRbXubyQOZonhFqvuYV0eZuDsdnHuftAOd0jg92fuf2kOd6Tg983udpPueAfg5/PujvoIk4buhjLuiKPg6F3ujr8OiQbpaMPunfIOmWbpeVnuncgOmc7uib/unZ4Omi7qWhXupSXq2o3uWnvuoELA3d6+rfZa2yHg+kXuuj3uq4bp/FQBtGPl27buvEICAIABZ8deTBfujEcAH/Imn5mOz1RQzWUx8cCe11vuzNXprc22Hc3v/t3v7t4B7u4j7u5K44w64xxn5eqi6J615BZPbu1ODrs75l7Q6v9W7v9L7nwYBjLcbv+/7veA7w925DAp/v7M7q8G7wc1nwB6/w8+DvCe/uA0/wEe/nDC/xDZ/xGK/x85AAweDxwADyviDyI//xJm/tKJ/yKr/yLN/yLv/yMB/zMj/zu+CZEcBAwCEY8UladXZcH+5AOZ8b2BQ+q4AAP8/zQH8oRh+PqCABu9EbrFgwCYQwquAAJmIwrIj0ZhFHqWD1QS/v85gW1/SKomDzOI/1TH8aqskNF6Av4AM+KoOO3bOSprAAJx4BTgH3H0Ps6S4yQXH3TjH335MyH2P35YP/912vLhGDjnqfH+mOChWQGHQhPBj6OSVTM2nF9ZAv+XXB91SDjtqzCm0faqQf9/iZoTd/Dn9kOzwRjAYwO6OkCpHE+gfA7G6y9a9gFbBfO1UDGi+OCqDk+p/T+4PwNqyAPq6/+xFhLoh//HVh+5ci/EWz9qaw+r3v+mNC9t9wFnIROA7QjH8DJ6ngat4/7b0hSqfgaOGvGlTxNK62CifUjLdjMERC/aQgFEQB/n6zIYgPCBEDAISFhoeIiYqKCxEWAAaDkAoDBoQDEYYOARKLnp+gAAcQCwABB4QBDpWXEQcBEAEBkqG1tre4uZoRnQAQj6YHAwWXBhIBCKIBusyG/woFyb7ApxcVhJGEr83bhM/Jx8nav6moAN7czAgFCpfEAKzjwYUIEQ7ouRIQ9u/uleDKm2TJonWvVr591a4NGFbs0KmCtxzwIhTvFMN3xpYBsBCgFMSPIEEZgFbowoWNyI51KmANwqAK7kIuWrDOkEmUCDAhWBBPm8xPNNkVcgkAJoCbHHfW/Plp1D4AKgGwPHoyKSUAPAkyNYSpF1ROUlu+jAlA0FZFXQvp5Gkh6tQL9hxAiHbW0Ei6SFOCnaoPZ92/3BYIlLWApqx9A2SRHBVgImBCAWVlMqzqmiyhBgQ+BRy5sahYEynHHZzpsbnB7BIHICkagERZJ02XHWxP9f9i0F7Lav0bgTaky5cUJ1Pd17TgwYULHA6+Olzv4rKjS59Ovbr169iza9/Ovbv37+DDix9Pvrz58+jTq1/Pvr379/Djy59Pv779+/jz69/Pv7///wAGKOCABBZo4IEIJqjgggw26OCDEEYo4YQUVmjhhRhmqOGGHHbo4YcghijiiCSWaOKJKKao4oostujiizDGKOOMNNZo44045qjjjjz26OOPQAYp5JBEFmnkkUgmqeSSTDbp5JNQRqlLZtYcQ4qUWDbJEyeZ7Zbll0UmFos7rwVw0jECDaLcBQEAA+abMyr30DHEKFAZIVZKJZCbcPbp4iaxqSZQBQuwKZA6YPlOqaiLHMVGp02z+IKMcrktaumJjRZS5iz5rBYLopVeKuqopJZq6qmopqrqqqy26uqrsMYq66y01mrrrbjmquuuvPbq66/ABivssMQW60kgADs=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Per 1000 live births.",
"     <br>",
"      <font class=\"bullet\">",
"       &bull;",
"      </font>",
"      Occurring in infants aged 7 to 89 days.",
"      <br>",
"       &Delta; Includes selected counties in California, Colorado, Connecticut, Georgia, Maryland, Minnesota, New Mexico, New York, Oregon, and Tennessee. Additional information available at file://www.cdc.gov/ncidod/dbmd/abcs.",
"       <br>",
"        <font class=\"lozenge\">",
"         &loz;",
"        </font>",
"        Rates for 2000 to 2006 include surveillance areas participating since 2000, with the addition of Colorado in 2001. New Mexico, where surveillance began in 2004, is not included in comparison of incidence over time.",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     From: Centers for Disease Control and Prevention. Trends in Perinatal Group B Streptococcal Disease - United States, 2000-2006. MMWR 2009; 58:111.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_38_11886=[""].join("\n");
var outline_f11_38_11886=null;
var title_f11_38_11887="Gram stain stool 1";
var content_f11_38_11887=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F82723&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F82723&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Gram stain stool 1",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 368px; height: 240px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCADwAXADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDzZke2tzKzHy++eKyf7Rniv/tNs+5V7Gte9aO9RgGIT07Gs02ipt2gbB1FcSlbfc9GnGLXvI0IPFNwu5o7fc5HGTUYXUNUcyXQ2hj8q5pmmxwtfZxlUH3cd66Jrj7OiFFB5wOKE7O0VqZVeWnqkYsMLWlzskJXPYVtxvFEI1RssRyKj1xBHbxXcij5qrafPnLCPeegpLXUzl78bmqFMiY79qqTpKyiJiCp796tBJGY8445FSyQ5UYNNnPF2ZmR2si5G7P93NPYtGQG6H0q7tIb5gQq9M45prshUnGT6mp1ZpzXK2SpztBz6/pU3mSrjcMN2HaiQrhQ6KQeQDjk0vLklhgDNGwN3HI7xMWnYZduPapo0aWQh2IB6VWb94ArA/L0q1D2JOSfTtTJZeto3SPygQe+TSRSLJcMjjLxDINOglIyGH40oKKCVxvbvVIwZOxVsN6+9KwDDj86gZgIkLHnOSKl3LI2UzgDpQZ2sBIXAx170pBSM7Pwofj+lR7ig69e1MSEXeYyJAAPaoLhfk2McL3xVgzr5Z3HmqU0u9+BkE1LNIK+5GpTzsqpC097cM+UYkGp1gjaESiRFTGckgKB65ottl5DvtZMqPlLAfjQUxqDMfyqSV4AzSGJnwJDgVNJF5aDaSWzyaG3PxjA9RzTIuQX2mWt3F5UqtsPB2muTvNI1PTZSdOTz7VTnBPOK7WPJbacnHengkZAFK7W2ppTrOGhzmjyJqKtIrbJF++hPOa17aJI0LFcsepPNRf2baNefaQhSY9dvGatHcjFCMp/e9KTs9ipzTehl6nOkEaoqKzsSBmszybksXaPAPAArpPIiDb5ArN29qRhnkYC/wAqVkVGrZWRiwWzMM3I2v2wauLA6kGLkE455q4EQ8g5NNU7Scn6U7oiUm2IsOCC+ScetLKEIAXAxTJJwFI3UqyB4gfQc0bke8iqQ6N2NCysr88jsM4pJ58E1WGWPB596Rai2tTVU71IzgfWn24IfOKz4mZAOeTV62lbOB1NUrkSjYnu1laFzaxo02PlDuVXPucEj8jUZg2pyvOeDVjzCh2v370pcZAHPrVLyM9diugUtwOaSWJCq56+tO35f5U98Gm3LSMpAXFLzGlqMkQDB4+pqIwWtzAyXEccgPZlBpoZ0TbNyaZu2sGUYHvSuVY5EWrRQNMHJRRkqAf89qGDLA3nBQSTt2nnHb8amgZowIpc4Jp0sCuyZP8AFjmpWr1PX5rDtHUw3PzfOCuelbVs0fmMWX8DUUEMcXK9duKt2kCugeReOgpp31OWtO+5U1Q/bgQ+RCg6etSaSkaNuUL5e3jnpWheRYsysSjLcc1lGD7EYvNbKscGm9rERacbGvBlssMjmonl2yMjZJ7VTur+e3dLSzSIzSg7GdjhBx8xAByBkdxzgd+HySpBIiBSSF2j6AUr9TJQd7FmUNsHbPeqr5LL6DsKS2vYndwxIYdjVrygy8Hg96epduXci8sSyKTnKipfMLHaMYHWonZo8BATnvjpTlUp0796VtBMC/LFc/lT9gePaw3A9QR1pY2ch8xg4pY432BicE9hRYLk8UgXJfpinxyfPweCMjiq7KABuOW56U0y/Pjpj0oQmrl5YDIMkkZpI5GhkXJDLnBINSQTApgnmpCqE5bt1qrmOuzBp1Ayckt0px2/KXIyec+lUJmQ4PoeKax3xqVPJpXGoDrgh5Dt6VLBGChLDJqsjbOo9qvR4+Ucc0ki5aIxr263iS3VTtzj0p+kMYMJAvlwhiTjuT1J961riygMMoKku/f0NS28SQWiQBeAOfrVpq2gpTTQ2Q71xkYJ5NNjUIm0HAprxmI5UnGaGG5QwIYHuOlFjLQTzGRyVBI71LGwfJHBx0oXIQ9ASe9V53ZG+Xgjg0mPckbCOXJpryKiNuPGOKheViMHtVIpPJJ87AKOwqb3NIw7k7TFxjsKA7AYJ70RRqvU1O8abC2efSkN2RDJJhfl6iq9y5dWw3zU+4TYFAPFVH+8GHWkzSCRHDKZFIf76nH1omvNjLFDGzuepxwPwpC20kuOKVHG3MbZU9cDr9aLlyjfYZeE7CSD9QaIjjG7P1p8kfmRenPNLsAXDfnSK0sWLRlJAPHPHFaUVvGigqcHrWVaRlmJA+laiA7QWPPtWiOWroxzRZHLEgHNNEhzleoPepgxA+nanHG3OBkdKq+hlchGfMLDHPaiWUBefypgbJIz0OajeQN82M0rjsEzeaygcH1pGjBjK9D61FvAOeaGkV3w2ce9FkDuYVxZNGWyDvHTtiqVyksYXKkD1A6V0rQ723EnHof61I6xyxtGwBGMUr21OuNd9TKs4ZXtY5RuYk4NbUaYVVB4x0rK0lpLW5kt2UmI8jPar8rMk48s/L3qtU7GdV8zHzpmMtuJK8/Wq96VezwwG49M0t1K6wOFyZGGABVHT7CRgftk/wA5/h9KN9bhG0VdkMTfZmXdKGcjqetPklM8yqMszjGR2rWtre2Db/LyRxk1J5MaMGjCgn0qdLlusjPhso7ZRnLN3JrRWQC36dPbFAUEfOM0xowWC7uOlP1MnLm3I/MwCFHWnKp3YIIOPwpZIwgLE8KMmprZ2a2R2XbuB4o8wGqhA254PWpYskY9OKYAWPWpQo4wce9ICJQCGJNQyBcjB5HWrDAgEe/WomQOScfjmkUmMWfB5qR5225BxVaSL5uOfrUTgqMKCKVy7Jl1JQF+cA1LFsZVKnHtWSCxBHNP3SRqCvJ7CgTgau1SM56VKUJAIOAOlY9vdyPJsdce/atNGfb97GeRVpWM5qxZEjHAY96skHOQe1UYVZm+ckmpy5Ubc8079jJobO2QysfbAqrblm/dgkjPenorNISw4PXNMR/KwxGPWlctR0L0jbVIHBFUC5djnNK85OQep/Go0y3OMe9S3cqMLCsWCnHJqIDaDtGMkk/XvVLVtS+xy7E+Zj0rHTXZQzKy9c9T61PvPY6oYeUlc6PzCDzyO9NkkxjBP41irrSZAkU47GrhuN8SuisQfaldrcHQaepblnBX5jjAqm9yBnBBFPaLfgzN8p7dqy5UZI3WbaPmGMY6d+n6UJXFZR0LUUhdny4fJyAew9P51JZKyyyBnGGIKrjGBjpVW027QU4xwDV23iJk2THk8qRTsWmiZjt49aHUsvvUwtSAAxz6GntAwXg80JGTkkMsJFikG8ZzWkWyAV6Vz8wkSQMOma17OXzIV5wcVqlpc5au9y3GdxAJAz1J7VDZ3kN6khgLYU4O4Y69DRgg8mnQKiKUSNEXJJ2qBk+tBiPWMB2zzVZl2lhyB71JKHDkoevNRl9yZ5zUvuaxdiJWXo+KR5Id3y4PbNMDLkkiqMtzCpA2rwecevWnFXHKVi15xZeRz0qSJwiZ6HNV7aFvLIc5Oan8oNwOg68UabFkmFmzISFQDiojE72ziM4Y9CacIiYsEnGc1MowMDp7U0K423Xy4AC26TGN3vUSxIp3F2JBzj3qwxCqFxjPNMbAwB+dPqTuPXKpnH0BpyBGHoetIrtIQBkD1phDh23EEZ4x196S0DcnEmQcgAdKWRk4Ixx1OaiTkYyR6cdaSRFRPmbrQwsMngFwmJDhDwMU6SAuiwbyEUDB68D1pofMiwqOepPYCrTuMkccUr2KsQGUQSRqOQcLk024uGhuE3ECNuOe1OnjWSJsjkDII7VUldkiiWVd6n5Tn1qdGaximXjIG6HI9c0wsVyF6e9QRIUAXJxUkgkKgR8E9TSKsh9vIkpIBww7GntEWJ+UAVFFEqtu53Dv603c0cjNuZsn7uaOomrbDvJ5245qC4j2ZA9KteaDwFwe/NMZS5bcOB6igV2U7ZXBJbv+tXxk455quiBQeDTjIRgmm2FrkiyMJAd/QYwamFyMZLbjnHU1nySksdpqtBLJ5zIwOw8gipbuaKkmbLXDN8ykYFMkkDKCRVNpmRchS3tT4JWkPzAqetAuSxZQbwTwTTwwRCOtMQEpzxUNxcpBEZJeFFFxKN2YurW80t0zwrurnp0dWYFSpziuon1hMZgiJ3dTnpWIzC4kcs4IDZwKIt9UenRbS1KSg7EUq+8nCmtbUJ59OhigbKgjOT3qfTYFMqByNq8/MOlWNcjF1tLnzBjqKJO7SsKU05WOeTWLi3YLKMoT1q+s0d6UVWyCfXOKzrqwfJUI+z1PaqEKSwSN5THCHrmr0e25nUoqp8J3dpZqq8dqvKoUKCORXOaPrqjalwPxro45I5/nicFal3TszhlSlDckZ+hNP3jb7VBs3OVzj1pGyo7/AJ000ZMcyox5x6fSqsoaN8pxinAsSxz06VIHUAEpvIHT1qluS1Ymgk3gFl+YDGM9qmDA9D9RTFj3MshBXjpmkeDJcjIJ5OOM09DFkjOUJBHI96btIiJI4NNTiML0wMDJzTt7bCpOaT2LRVMAYNhgKy5rWMybS5z3rYUMZACPl71KLaF28xQBnjkUlcJWvqZXnsq7T3qzC5MfykZ9DRJGCuSQG6DIz+lVt2GIJH4UWNC7JK6RKUTce4otJnZiWRk/2T1qOFl2AgnFTK3OVPXrTXYGtAa4VnC4wccUEBRuYZpWgDHdkj1pk0qQozyH5FHJ/If1p37CsToORxgHrUyBTkkCqcE5khWWPmNhkH8cf0pWl28k5J7UmK1y24DDIAIHeomwWyen51F5/AAGARSEnbk8GgaQ+OII7kck9/amSxndtD4J71Imdue9OEZJ3HGR0ouMg+zSbsecdvcUstqCAC5ODkZq2qqMHALdPpUZVt3QkZo1K5xAgC80uzcMKKfHHuJJOF9qmACocdamwc5VVWHBXrUcp28kY+lTSXixSgSDAboSOKW4XzBkcjFJq2rLT1KBkweSPwqL7W24g9PWlmUhiccjmqXzSNxSSvudCimaAkU4PJ+lRSzopAbgZ70/To1aTy2brTb+zaGQkglCeDVW1sRomMJRydhB5xUiR9CB+lU2h2kEcHsRV2DcQO9JxtqU2uhLsA464pRwxxnnin7Mg+pFIqjGSfyqSGyOW72fKo+cdu1ZupSu1i7Sqchs+1aGP3udue1Q6pEbiyeOP72fzoa2NKckpHJ3N+ZUREQqAOfepdOdAy4XgHp61am0udlDmMkKMU22tzGiqqEOW5q0layPQc4tFk3AE0axDcWOGAFbsdpIipvXcmOg7Gqen2rxXG7Z8p/M1dlnkSMqrbnJwPah7JI8+rK8vdMy4hzDIYy2Qec1z91bKLkfMdjda6y6wjkDliOTWK0PmxMwxiMk5qU9bnRRloZl/bRWewRdTg1r6JM6TgA/KyjIrHupjcMokHC8Zrd8P2+yIynndwAfStFF8vvDxM4qBsQlnmO3k1YaF0XAFTQIkYBUcmnSSZNNI8SVTXQzJAybsrgA5HFRWckZkdwW3d+K02G8Ej8aqTmNJMMAuR371PU0jLmRY8ySRNy/cqyoYDOM+tRWW3GwZUdqsAiM4YhvcVT0Rk97IY8ZYHAGT0NV2hZQAuPxFXDINuVGTTGDOueh9KFoCZWIIYrnGKnUYUbehqMxAqS/Uimpujg7ccUdBsz3ffj19zzSBVJbPNQv04z6c0+I4Gd34VPQ6LEq7hwvAHapUYY4OarFyQDipN4UEg/N2pBYnMoX7zYHuaY+2SGaJuUlQrn0z0P4HBqrPALlAHJBHof0qzGFACjoB3oK5dCOxhe1tVh3A7SSOfXHH55/OpgGOd1DEK2MnP1pd7ErtYYzzmi5NhwjwKXZuHWm7jv+8Kdkg4B61RNiaJcDB9KfuC9TmoslahkZiRt2ge9LcRf3AY54NBkByV4qhHJxlqkMrEDac9qdiWXEUsNw5FKVPvyaSGfEYUcmniUFnBz8voKA1EWJcfOob61HJLgkKParBOQQRgVAYVA3iotctPuUZoiUJOC1ZhXb0Jz3rekgGxmz1qjPbcnnPpSWh005ozbYv9sjGQDnIGeorpJpPMt2QrncMVlR2375ZMfOOhz+Fa9uy7Pm7etOT0Cau7oyDEqY3cY7GnRSL0XHHpSXZ8+eRs8AVXtoyVOCCw9KHruaKOheWYM2MUrtgg54NV4QysQatFQY1BGDQ0YzViuCM89fWnlgDwfalRF3H+VO8rByOtGhN2NQ5XDHg+9LO0IVG2phTzjrTzCrnkYBqJ9PikhMYBAPU5oSV7lKXcv5QcpjAH6VzOr3yJdAxYDZ6g8fSr98Z7HTiVJcqcA47Vyjs0shZlxzkNQotu/Q3oU09WbjPNcuqxOAWHX0rRgsYoo1RuSfvfWsfQ2c3iMmWAGK15S81xwpRF689aduX3SazalZDm0yzVxKUXP0qdNu3EYGB6VDOTgZbgcYHepLcqAcnj6015s46km1qSbyh+alRyw6HFOk8vHygGo0Of8AV5HsRiqMLD43WRioJAB54qi1lK2prJM26BfmAFaccKIxZVAZuWIHWlaItzuwKOt0VGXLsShh5WUAIqNs/eGee1NB2fID8velL4IAxiglIJN20471FbysuUkbvVvaW5zxUDxhSSw5PehAvMc5DMOeKc6q0eP61FsXHBOTUdpOks0sLRENHj5z3ot2B9zMOFQHBY1Va3dJfMhJyT90nirRBAAoXk8546VKdjsQ9GwoyOcc0nBOe3tQp3dj+NKPQjNIBC+1fWmeYxfCjAp0gJI5yKVBtYEDjvSKXmBLBeadATk46CpNgI5xu9Kjb5ZhgdqZDZLsyAcnmpY0bcpBGO+aYkqltrEZzUeo3kdhbl3+92ApOXYIwcnZFybaFyxx2qhcXkSEZkTBrl7/AFx5mbc+0D+EGqtxcebAGVyxx0NFpdTqWEtudWl+kkgCMGA7iplu4zNgMp/GvPTcTDcYi4Xvin2txIG3F2J+tX7NrqS8MmenwFTjGavwEZI6f1rjtD1MyERSsdx6HNdZbOCeenfNF+jOOpScGWimfunOOtR9Q2RwKnXHl5HQ1AwITgYPrSsQmIEJHSopFLAluKspnYCetQ5yx3DoOtJouLZEEVVyTwRUm0GIgHtQu09Rx0FOkXHKjilYvmdzEniJZhyPoaS0RYWzlsZzzWrLEHOehpkMKMeo/pTvob+00K4IlmyRgDpVopx0zQIlRgBUzKSOBR6GUpXKjqR1GBSxtg/Wp54GZ/MzxjG3Ht/k0gUbuB09aRN7oaVIORikBzn2qdHUAqcHFRyKe34Ugv3FVlkRlIBU8EGsy5062SNtyfJn+H1NWWYxZPpSPOhX5nXB7Gi3Yaco7EVvBBBCvkDAIznvVfy5mdpHztB+Va0gqsmcgj0ph29PSqQudmakkjbt6bcHj3qZELIexqV0yegx/KmhivTH0ovrcl6k0SBEGevvUyxgLnNQhw+NtTKfwFO5m4kpcYwTTA5zimgEk8Zz2pCGU4IouKw/bxnqKIdr7getM35GATUbvtPBwc0kx8uhaabylxnOKryXSZA6nvUE8owAhJb1pltbmQgkGqV2KySuzQhzjJ5+tOOBnoCaeke1AvpxVOeYJKM52g9qqxktTOZiCAP1oPTt9aiuXSNGd2CRoMlmPAFPi2yKHVg6MMgqcg1md4biv1xinSHgc9R+dJJuC4QDf0pILQ7leVifbNHmMUK24bcbOc565qYISBkfkKcNofGKmGRgcbcdc0IhshQEtx1pkkZLHPGeMirBQbs1E/MwznGcjHegkbDapEwcHJ681zHiSeSe73DPlJ8uMVv3N0Vm2RgnHrRf2kc9lJLIvzAZpXs+ZnXQfJLU4NnRwVEYJJ7inuD5qqBggYIFXo9jxPhAuGwPemG2drgHop6VpezPSk00PskXBAAyfaqs9o4nYouEq7b2bpdPhWx610FgAkI3qpI9RRezujinPkOasplRxyd2eMCuz0O7knbDJlSPvUv9kWd4A7xbWHQitG3tlsoxHEp2+1Ds9lqc9StGasXDNtQKMU6OQSdAOtQyL5bAuQM0+JcfMvAz+FQcrRJIWAAQj6Ux1JODxx1qK3eaRpTInlhDgHn/ADn6VMZFPGcsKGCRH5ZAyRmpVO4EHtTQ/HUZpokC8rjrzRdDabHyAtG3FU1gkFwmF/dkctjvV0SCQegp2wOQKEF2tCHy+Oaeqv5qqq/L1JqSQFdoHQU9GCsGPPNMRXll8tW3dMVHtWROWwPan3S+exUD5TVS5WSOLZbjLcAfTvSSuytEixFDGkYMY4z1pkgOeO1SDd5CKxwwAzj1qF5FUbTgnvmm9SExjDCgk/8A16rskbSbmQFj0pZHOD1wKarbm2jHrmp2NE2SAhFwcLnoBUc8mBwOlRtmYHHQVEysG56D3oCxOhJXIxg00oxJwBUqDEYzz+FBIABpXBCRoVOfWp3yE461EpCuSOaa0pJHAx3PvTbFbUhlupUIWGPv17Uq3Mh/13HHXHFKTgc+lVbnLAA56+lK5aSY9rxM7QxJzgYFOikZmIzkVUjRRlm2qigkljjApui3tvqD3D2Vwk0cRCsV4wf6imu6HKKsbCxjbnvV+2ZPL4HTviqCSFQRipopDtwBVx2OSoi0zjBxWfIGLOSBtFLcTTYxCoLE85x/WgFiGUDkgFvSm7kJWMy4CeWVlUFW4IPeljVY40WMIiKOAowBSTQG4cYyAKilXfIqRscr1NZnoJIn34O4ZpbW5WRirZU5zzVZBIFIfqOnvUCSSJcrIF78inZsrlRtIVZs5GadMxAHPQ/hTLZI3AdmySafcxqI8cHJoRi1ZlV7lcld2DnAphkdJA3Vm4ANSS2xcZ+UEdDikEYVg0nLrxTHoLHab5N8rZJ9Kg8QyJp9nhXJaQbcE1pWboXyxAB5xWV44tftMNtJbkb42/SjRyUZFUpe/qYEKLuRShAwCCanlZIcORuQc1UhM9vclLp8qBwM0XkgkchSdmOlL7R7DhdaGza3UUjYBxkdavRROTiNWc+1c/p8qrJyh3AfpWsFbUNMaK3mMBZgxJzggZ+Xjnrg/hRs/I4KtNo6uBAIQD1xzSTOUKoVJ3Hlx0Xjqf8A63+NZ+nXMcMccAMkjooUserHHJ9smppJHdQzjaCeh9Kcm0cSp6il0UF5ST6AmpLe+SeNkTCsD93NZdy2ZCAw/Gq1mwExK4z0BrPmTOn2GlzWlvXMojTeM/Lk9B/n+lSLLDBBJmQM6j8/pULLJKMBcgjGazLuxNrGGMu7LdD2oeugoU4t2L+m3akMZckH9K0otk3zIcj0rnS3lwkr1qxZ3MsBQuCFPqOtNXeqLqUVujoYkAGAOKniwoO4ZOO9U7e4SaMMDz1PNTFuAyVUX1OOaadmXYBH5bGU84+WqFwQTx09qeWZlAx+FQyggk96p6kp2ERiG4p6t8/zDOKE+VSeuPWo3JGM/lS6ibuRXbGMM65bHIA6mqscnnsHKleT3qS5O7B6EVWinDOQxoKS0FuJ41UgDPY1DCN6KQSpNSGNZDnAGTT4XVXaMg4WhpLYpbEjAJFwecVAIyxzzU24MOKf0THpUhsRkYUD26VNGisgzULrnAJ4PapI8hcA0CY+SAEjaciq0sTKc5x7Va3EDIz+VMZsg7qBJlXGV549qgcAtjNXJFwBt4quY/nz+VJlxYyS2hubaWCYExyoVbHFQ6Bo1po9vJDYo2JWy7ucs2Ogq3EuDx1FXYFVevBqo32JnIQoq444pQqoxOSQR0ptyf4QTUIkwQpxiqiYNtlqPZktnB7A0kh3cZwTTlj2/MD29KYVywIOSKpkXMiC6V0VEB3DqcdKsBI1QHkHOc1mWE/lzmNgOe5rWj2lP3hB9Kzsk7HoT02CMKDkckiomTcSNuD2xTg6FyQOB0xVhTEUzxx0ptIjmaKsA8osRjrVgSkg7k47VBJLDEWLuOO2ajF5Gi7zyG4FJj5Wyx5+SUxgrTyAwBP54rJXcbh9mSucls1rxSRugA4PSi1iZq2xWuEKkbVyaFXzgQ+M4xir7xK6jJPNQ21vEjuUOSe570PVCjLqcpf6VLFcFnz5R5z6VUFpkCQE+WeBmu/aONhhuRUHkwhjtiX6Yp82h2QxbSszkbXEeAcnnGMVtQafdbUkjChPStLy4VbiJAc9cVctnCwlm5QU3JJXsZVMRKWxTtliwXciN16npWTqGsNK2y2CttyKzfE2qrc36x2LkRBcMy9Cap2SMuSpyCOTWfLpzS+46qNGy5mWXuZXlbzuT3xSRTNE6uowAeagG6GUll3ZFPQFhub06CqsdSs1ZnV/aw9ojQuM45x2qMKk8TGd+V6VzKm5tmRikiL1Ge4rdi/fIjrnB61HK1pc5ZQUdUQxu6zAMMqOlX7i4aeFUYAMOQQKT7OxAK/eoiszFbKGdnKjlj1Y07J6kuaIYLh7d8jBVjyPWujspUlRWXlPSsKPYVywyo9alsbvyJymMI36U+pjWjzrQ3yVRyf4T0qKaaOR2jU/MBk00OGQYOQeaNq7SQoye9VvqcNrA2DF16VE3zYNOdtsBJX8v8+9QfNsDDODQBBM/wA+ce1UwpZ2GMe9W/ODPtApZAAwZVGTTWhexHCJMlAuQepqQrtyWppd0w3PI5xUcshbhjjND1GiRDukIxwOlBc7iKSFWjUng57VBIx8zpgGpe4XJZHBXg59Kkhk4ANVSxxTRMQ3WpuNI0fMAXFIx39BVeJ9x55/rU5yUI5oExVTP3j7imycemB3p0e1cLye+aV8EUNgiFeDmra4MXyjJqCFMtg//qq8gGMKuBVpaGVR6mfKpH3iR70LCqAMSS2KsXkaSLsYdTxSy4jCgdQKaslcjV6DDIwUjHXjOKfAhCksc571Xj3OCdvTvU0bskWCKYmuiMCO2Ta5fBZe4p6nC+YpIHvVNL0SLtBAU9ST1pxuiECkjBPFZ3Z6TgW45xtO8bffvVOW6dYSyOBlsAEU4oHUNK5HpxSXUEYgLqSGU5HvQn3ElFEMTtK0oZQ2RjJFEKTTIuR+7XpRaO80wVVCg/erZtxGg9+9O9mVKXKiAExptAxnsO9EbMQCSCOtWGw0gJG38aeEBDsRnHP1prQ53K5ZhkLR5YflTcYPGPelt5UVOenvQJV835SSKV+xNtRYWPIf8KfgMM5I4qndvKIiyDGDTwJ54VkLKoPQDmldl8g2WZVL+YjADkH1qjqep7NLlGxk3cAN3q/DHJIrJPgr24rE8SQPJIkYfhQMZptJuzNqEU5HPxQgW4weSc89qu2zFQRG2Nw5qGJsqYiu7HerttCqgHAyelOV3uek2loPKKYhvyzdBxVmEW9sjSzEGRTlUqEIyMEPJzUt3bIYgT8zg81D7XIumV9U1G41LYdoEadMDpVnTrwwBVfDJnk9SKz5EaNNsRyOpqxYNE0Tb/vHpRZJWS0Lmly2OgeaQuvkISD0xV+OVks2EicgcCqOjwfZkMsjfL2BNPubkDqdsZPU9xRbSyPNnq9Cj9p2KyleWPeqkkzB+BuYjA+lWZY1nkBj79Kvx6fFFGGkG5/c9Kei1Zq5qKsXdJO62/ecEL0NWgyrwM81QhVlx82AOg9asBhu5PNO5xTSbuPIwSD3pAflJOfShjtGSRmhDlTj+dFyLERt0C7lHNLFExwGxQzlE+XB+tAl3kBR9fSncmwGJB94GmS2+85Xip2YMQGIH41BMXCfumXPHU0r3Y9SF0Knk/Sq7kM4GOh9KvSAhcNy54NVGUbwc809BXIZcDPp61B94+1Wp1DjOOfSoEQqcnBJqWaxZPCxT3xVmNxsyetVR15pS+PrUlWuS5y5J70/cOc1FG4Yjrn6U9cYyc5NFwsWYWGP8anZwBxyaqocDuKtRgZ3EHArRaowmtSnL58sgAABFSz5dkGO3XNWE2szMoPtUcyGRcLwRVWRnfUbbJgMDTmBwcgAZ4qJC8YZXGffNKNzgFsDvxQSzjYbIkFmOMkkClhtJnLMSdo6ZqfftfaTu9CPSrVncRYZHbvS5mepKOhD5cp+VuuOtNmiYxEOePfvV+SZHcLH1HTFVrnaUKthmJxjFK72M4x1uU9IlRYn2kF93X1rSSbYASMYODUE9ogVfJTaScse5pYYgeBk44zUuSbuW4XLMk29cjr7dqeJhHGcvz6VUigIyxb5T2FWYoiEwqBvqKaszNxsSWzPL823anoauxkKRnrUFsZMtvCj09qnSBc7i2SP0oZm2PZAUIPIPb1psI8tdmMrngelKz8EHGemKaCd53HOelIaHxj96c8Z96qa5aJdRAK22UDjjrVptwDFep6GlsnD26tIBuBxVX6lJuPvI5u2shbzKCC59AOKvQabI0ckj4RQSQMdRWx5abCfl6+lJPKViYAZQjn3pSfY09rJswGv4hEwkjAbs1ZlzeCQlYT8vc07V9PupwxgUCMnPXpVGwt3jxvUFV5OaXJH4rnpUrWLsW14WPf0qxYxeYyfKQSMHHaq9vGCuVbljkKB0roNMtBaw+acl2HNFrGdaokrEhZo0CklVHr3NSmITbRL0qFoRJKrSk46haluWcR/ugpY8CltscL1YlsgSRscqOmKuO4bAOCR2rItDdx3BVwNhHUetaIwCTg5A5OKbTuTJEnmENikcgybuSQaruec9M0IxA5PFIVi28+44wMe3SljIwcE9apNJ279aA5J/nQvIlxJRMWvHjbhQufrU5XCfKc96qjaJWY9TUyscY9expkvTYiwzudxO6rMW9FLAngdKgQfvGLVYil+Ur/Sm9gepVkuCwY7Hb0x0NRwpIyZkG0n86utMBx/SgENyR1PpQmiWVwm3AxTpIcL0q4ApAJHTvQQsp+Rc49RRYnmKCRHGeaikt/mLAnpWnLGVAyOtMVRj5hxS5WUqiRQRD0Gal8tsfKT+NXBGn405kwAFPNPlD2hHDGSxx+lXYwFHPNOhRAi7evvS7Rk56Z4qjCcrsqGTBIU45pm/Zu5Jqaa3yBjOfpUQjAOwDJ9adhXRXEhZxx1q0B8p4NMmhEfzAc1HHKe4/8ArUgavqc3aW3nRvITtA7VUjjJufL4AJ49a1hYmHbKkp2nqKpyutveecVzg0uazdtT1I+8Wri3a2RGwQ54ye9QJAIi0rNmQ8gGp7q5eYB2GE7VVacuwGcACpUnYagTyyNgbpBnHNOifdHgEAfzrNvZi23ymCYPPON1bmh2ef30qjB+6CMU0tLsVRKEbklpbO65cYHYetXVj28AcVZRSHPGTikkKxYDDlv0q7WPPlNyZX8rnjnNM28kA/rUyupU7z2qCN/MmYAfKKVrlJ9xNgYkHoaV9kbIrModzhASASQCePXgE/hVxbcsueg9aUW5IwT0o5Q9okZzMyuQT0pkBEO/BJVjn6VoSW+3LMOvSqjRAdulTymkaiZFZv5sryMf3Y4AqS5ePyn2nOBxUYhC/dFRCItIwZiVPbmhmmjYltG8sWd341m6hp0sPywfOHq7NNcJdJHAPkxzUkLuk4WRySRSV07m8ZuC0YaXYeRal3UFmGB7VdOMqpb7uAaFuGQEAgjH5VWhlMZxJlhjGT1+pp6vUybcnqWSASFyPSoJtyOAMFc4zU6SowLZ2qegNRM2xgD0zmkldiJVj2gEdM55FKeFz1qxJgx4X06VDJwoCml0uSndlbDEZ4PvTCvX3qRsqAO31prkAnHGaC0QMwB69KFc5IHXNDHLDoMcUmMNnOKAZIZSOeOOKkjkJXnuaq4PJJx9KUSYXGaCHG5ciYlsLmpc9ARyaq28uG5NWQ4K5HOKozkmhpUljzxVq3XKB+vFQx8gn3rQt3UxLgU0jOcgSPKA8fnSm5hh3Rs6q6jJDHFSKwAGMD6VwPjyZW1qG0Gd8u3OwnK+g+v9KN3YKNNVG0zufMSQAqytkdqjK8nPQ1xMLTWDRxW1y0oRQuc5z6/rmui0LVDfrKk+Flj9D1oi+vQuthnTV0XnQllIbaM8/wD1qpm4mWRtq7znGKvnBOc8VTnVUbKZB71okcykW0nMaBm7dasLOW2gYweaymkBXHUe9LFKRwxpMm9zb8xRy5xk4qtdErnHGaoXVy4iCwtmQ+laEBH2fMh3MRzU20uWtCBpDIgVATtHNNVW8rJGDUyuAdoAWoppAV2dxzQBzB1AXEIjjYBQe/Ws7VHGBhvmz25qaKxsxGxLuZB79auh7Vbc7YlDqMN65x3qE0npc9myjsX9N0641PT4XDLDFt4yMk1DP4XvEEkn2pWA7YrV8L3QudIj2kZjJBA7c1pSEE4DEr35rWDaukedUrTjMxrDSLf7PCs8IZ05z71rbBjKjAHSnREAnnAHSllYKmQT9KOpjOpKW4x7hYsO59jVWe6F24SEbVX171Uvl8xw3O3vzU1paswDJnjgmjl6scbJBGjMWDYweAKvx26RDKqOnNUQyWcpa8baueNq7v0FaZkiaEOrDaec1TIkyXOBkjtmohKGPTKnvQrbkznIquZkBCD5QOc1IlEsXBxHz3IFV5bffGdoySOQak4UhmfHpThKqk45PejQE2jPZGUfPj6UvkggMB15qa4Yuu4HrxVa4lljjzHy/TGKT8jaLuE0KqN4PzDjOaqDIlDY5HGcU24ugh8uZsSAZIHaoU1GOUqkKMzHg8cdu4PFZ69TrimkaMiL8vAyaY48ptgGQajl4OR1FVorwm/EfBcjO2kkHK3qi5Lb/MCzc9hT5VRoAf4ycLVe4uGZ1WTAJOBzVyGCRifLXIA59q0V2ZTbjuSQlli/edaArP06GpFwFCkZOetKoaMkBck0WvsZcxVgHnSyxOm10OTn06U6W22/Nj86e8MplEsRKyDqMkZ/Grk6SyIMgUOIvaGJLCACwqBzyBWtcqojIxhh2FZzQspORUtG0ZleRgMcZJprkrjGeeOBUrAE85Hfio+/HBNSaEZG5wNxGOfrVq3kwwXPtUDKTgn9KjywO/jg4FF0DjdG5H8vTG01Pbn5XUcAVlw3W0qHwfatCzmWQkqRgmrizkqQaLGJChEL7ZP4W9K53V9AKwfbEfzb0HJYjgDPIHvjvXToV3HtmnbgQQe/aqfkRTqOnK6PM1uysxYAI3oRWh4daWbVmcDOV59K6u70nT7tszW6k+o60sFhb2Ee21TaD1Jqo8sbtI7KuLVSHLYaxOAD1qvI3rVl8Kck81l3cz79qLnNWux5rWtx7nIyP1qPztvc4qFNxcbjillPy8849KmSWw1cuW77ZAUHWr0dxtyrDjr1rGst5yc8VowoRtc8kCoZa8y1xzjv0poTIORikVskLjBppd/uMMnqTSKRyjheeMDrzSnkjJOPQ0jneSdueOTio5plSInJwOuATx+FQe2iTSbiTTtZ8tZMQTdRnjNdxhnZEx+5YfM2PXPft9O9ec30Ui263IGFV+CK7/Tnd7KKRxyyitL7S+X3HBjYJaosCEMhKsTj+dSIEaAIRn+dIckkdqa2ImGfxxV2PPuxoRDlSoITk+9Ldy+UA6jAzyBSK2GJweeeKbKvm8ZAA65pWKuxrTW1xhZkjfHOJF3VMiRsBjGzHAUVWtbNAvmXLgtjBxwM1J5ghdTy6kZBAOMfXp+FO1tguugrHyCeuD0qIAOCT949KmmxLtZ8Y60ibPNHHyjr70rXKT0EBG3a3IFSrsAG08HpRKwXGcEdqryEsh8vAx0zQTuOEZKyBgRg8GnorEAsBxSkkxp8w3Y5HrT3ZVAQkBj3pbju0ZmraWlx+/gbbMOoHesu2KrbvmIeeh5JUA/yrXvLh4LZ3U8duOpqlEv9pQExlIpwOuetRJO2ux20amlmJBKblA2frU1tYoLlpyu2QjAPfFUrWN7WQK+SM84HFWb6/wDKQeSru3ThaajLaPUuTT0RBMjx6mgdSyqCc+9bEF9FvMbEKw96yYJZt2brgY4BHNLPcW8E+XUGQjinJ2WqMpR53Y3VMbv8hBqdFAkBHI9xXEJq8ltdO8JyvdT6V1ukXiXtss0fbgj3oTZnWoSpq5oIQSeMe5p3XuPwqB3fHzDA7YoyN2R1qrHKQ3iBW3dRUccccq/dGasXAZkwBx3qBdsagZHPWk0aJ6GfcQYcgdBVNV5OR04rfWOMR5PJNZEyhJG+tQ1Y6KU76FWbPy7VGScHnGB6+9VLwTHakGVOeWzirsuAQB6elRsCTz0rO50JEADqF3Ek+vrVi2maMjaDj0pCpJBPapY48sOOtUiJ2NBLo/LjJNTLMGYg/LVQxhCp6rSzRvsBUgH164rRWOSUV0LuGXkNkHpTGkYtsPT1qEXJ2KCOe/FO38ZAp79DNKxHcQsdpJIGeR7VGUSRdwXGKtRlpdwNP8pVUBRz3xVLYJGTJbnO7k5qvK7R5GzdmtiQrjcQcDnpVeSJHK42nnrU3EkZ6FtoAGCe1aNs4DBTTJIwP4PyqKeB5IMxOUcEEHFK99x2RpEKnPU+tQupHz5HNOjLNEN/JAxmklkUqQBge9N6iV0f/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_38_11887=[""].join("\n");
var outline_f11_38_11887=null;
